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Abstract 
Autoimmune disease, such as multiple sclerosis, results from the breakdown of 
immune tolerance to self. The goal of therapy is to restore this state of tolerance, and 
understanding how this may occur physiologically is important for improving 
intervention strategies. Experimental autoimmune encephalomyelitis (EAE) is a 
mouse model of multiple sclerosis in which disease is induced by immunisation with 
antigenic components of myelin. In B6 mice, disease course is monophasic and mice 
spontaneously enter remission, providing an ideal scenario to study the natural 
restoration of tolerance. IL-10-deficient mice fail to recover from EAE, and it is 
thought that production of IL-10 within the CNS is particularly important for 
recovery. Previous work from the Anderton lab had also shown B cell production of 
the immunoregulatory cytokine IL-10 to be vital for recovery. 
The aim of this PhD was to further investigate the role of IL-10 producing B cells 
and CD4 T cells during remission from EAE. While B cells clearly play an 
important role in recovery, and post-recovery B cells can transfer protection to naïve 
recipients, B cells do not localise to the CNS. Instead, IL-10 producing CD4 cells 
having phenotypic markers and functional characteristics of regulatory T cells were 
found to accumulate in the CNS during recovery. Depletion of CD25 cells in vivo 
resulted in impaired recovery, and transfer of CD4
+  CD25+  cells from recovering 
mice protected recipients, further confirming a role for these cells. Thus, regulation 
through IL-10 production appears to be mediated by both B cells and CD4CD25 T 
cells in this model. 
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1. INTRODUCTION 
1.1. Part 1: Immune tolerance 
The immune system cannot predict which foreign antigens (Ag) it will encounter 
during a lifetime, yet is required to produce a highly specific and rapid response to 
invading pathogens. The adaptive immune system consists of a multitude of B cells 
and T cells, each bearing a randomly generated Ag receptor and capable of rapidly 
expanding and acquiring effector functions upon receptor engagement. The random 
generation of receptors with such a varied repertoire of specificities, while beneficial 
in terms of ability to recognise many pathogenic Ag, inevitably generates cells with 
reactivity against the body's own tissues, or for innocuous Ag such as proteins 
ingested as food. If these cells become activated they may cause harmful tissue 
damage. For this reason, stringent safeguards to prevent autoreactive cells entering 
the periphery, and to prevent initiation of inappropriate responses, have evolved in 
tandem with the adaptive immune system. However, these do occasionally fail 
resulting in autoimmune diseases (such as multiple sclerosis (MS) and type-I 
diabetes) or allergic reactions (such as coeliac disease and asthma). 
1.2. Central T cell Tolerance 
During their development, precursor T cells leave the bone marrow and enter the 
thymus. As they move through the thymus they are "educated" through the processes 
of positive and negative selection (reviewed in (1) and (2)). T cell receptors (TCR) 
recognise Ag indirectly, binding processed peptides presented in the context of MHC 
molecules on the surface of other cells. The first checkpoint in T cell development is 
recognition of MHC on cortical thymic epithelial cells, and only those T cells 
bearing TCRs capable of binding self-MHC survive; in this way the mature T cell 
repertoire becomes MHC-restricted. At this point T cells also change their expression 
of the CD4 and CD8 coreceptor molecules, going from double positive to single 
positive expression (3). CD8 cells are restricted to MHC class I molecules, which 
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are found on the surface of most cells. CD4 T cells are restricted to MHC class II 
molecules, which are usually only present on the surface of professional Ag 
presenting cells (APC) including dendritic cells (DC) and B cells (4, 5). 
As the developing T cells move into the thymic medulla they are exposed to myriad 
self-antigens presented by epithelial cells. Thymic medullary epithelial cells possess 
the ability to express a variety of proteins that are otherwise highly tissue-specific 
(6). The transcription factor AIRE is vital for expression of some of these proteins, 
such as the pancreatic islet 13  cell Ag preproinsulin II, in the medullary epithelial cells 
of the thymus (7). People or mice with a mutation in AIRE develop a syndrome of 
spontaneous autoimmune diseases against organs including the parathyroid gland, 
adrenal glands, ovaries, liver, pancreas (J3 cells) and skin (melanin) (7). Transcripts 
of the myelin Ag myelin basic protein (MBP) and proteolipid protein (PLP) are also 
expressed in the thymus (6). Many T cells bearing TCRs with high affinity for these 
self peptide-MHC complexes are deleted in the thymus through apoptosis (1, 8). An 
alternative fate of T cells recognising self peptide with high affinity may be 
differentiation into regulatory T cells (9), and this will be discussed in section 1.5 
Some potentially autoreactive cells escape deletion by virtue of low avidity 
interactions with self peptide-MHC (8, 10), and some self peptides may not be 
presented in the thymus (11, 12). Also, cells recognising innocuous non-self Ag 
(such as food Ag) are obviously also not deleted in the thymus. Therefore, central 
tolerance is incomplete, and peripheral mechanisms to control the activation of T 
cells must be implemented to avoid harmful responses. 
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1.3. Peripheral T cell tolerance 
1.3.1. Clonal Ignorance 
Some autoreactive T cells never become activated simply because they never come 
into contact with their cognate Ag (clonal ignorance). Sites such as the testes, eye 
and CNS have tight endothelial junctions that act as a physical barrier and do not 
usually allow naïve lymphocyte entry (13). Therefore, T cells specific for Ag in these 
tissues are not normally activated, or effector cells cannot gain entry to initiate 
pathology, unless the barrier is broken down by inflammation (14, 15). APC in these 
so-called "immune privileged sites" may also actively delete T cells or induce 
tolerance in cells entering these sites (16). 
Another form of clonal ignorance is the failure of APC to present certain epitopes of 
a protein Ag. During normal Ag processing, proteins are cleaved at specific 
enzymatic sites, so that common immunodominant epitopes tend to be presented to T 
cells, either for deletion in the thymus or for activation in the periphery (17). Thus, 
even if T cells specific for cryptic self epitopes (which are not normally generated 
during Ag processing) are allowed into the periphery, they will not normally be 
activated. 
1.3.2. Deletion 
The most obvious solution for dealing with autoreactive T cells in the periphery 
would be to delete them. T cells that bind peptide-MHC complexes with very high 
avidity are deleted through activation induced cell death (AICD) (18). AICD is 
mediated by upregulation of the pro-apoptotic molecule Fas on the surface of highly 
activated T cells, and Fas-deficient mice are prone to 
lymphoproliferative/autoimmune disease (19). Deletion of cells with high affinity 
TCRs may also lead to "tuning" of the T cell response, such that pathogenic cells are 
deleted but those with too low affinity for self to induce autoimmune disease remain 
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unaffected (20). While this may seem potentially dangerous, it probably also 
maintains TCR repertoire diversity, which is important for protection against 
pathogens. 
1.3.3. Anergy 
Not all self-reactive T cells in the periphery are deleted after their encounter with Ag. 
Mature T cells leave the thymus and circulate through the lymphoid system, 
surveying DC for cognate antigen. In order to become fully activated, naïve T cells 
must not only receive signals through TCR binding of peptide-MHC complexes 
("signal 1"), they also require interaction with costimulatory molecules such as B7 
presented on the surface of APC ("signal 2") (21, 22). Full activation results in 
production of interleukin (IL)-2 which acts in an autocrine fashion to allow T cell 
proliferation and differentiation into effector cells (23). Without the appropriate 
costimulation, the T cell undergoes abortive activation, leading to a state of 
unresponsiveness in which further TCR ligation, even in the presence of 
costimulation, is unable to induce proliferation (24-26). This is termed anergy. 
MHC and costimulatory molecules are upregulated on the surface of APC in 
response to innate "danger" signals (21, 22, 27). These signals may be from host 
factors such as IL-6 and TNFa released during tissue damage, or through the binding 
of common pathogen-associated molecular patterns (PAMPs) to pattern recognition 
receptors on APC, for example bacterial lipopolysaccharide (LPS) binding to Toll-
like receptor(TLR)-4 on DC (28). These receptors form a safeguard within the innate 
system by upregulating T cell activating molecules only under appropriate conditions 
i.e. when cell damage has occurred or foreign organisms are detected. It is thought 
that the continuous presentation of self-Ag in the absence of costimulation (i.e. when 
no danger signals have been received) is utilised by DC draining healthy tissue as an 
active mechanism of inducing anergy of self-reactive T cells (29, 30). Then, when 
these same self Ag are inevitably presented along with foreign Ag in "danger" mode, 
only naïve T cells recognising the foreign Ag are activated and the resultant immune 
response is focused on the "dangerous" Ag rather than self. 
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It seems counter-intuitive for the immune system to keep cells that are potentially 
autoreactive. Why not delete them? It may be that these anergic cells now contribute 
to maintaining tolerance through blocking access of naïve T cells to the same Ag, or 
inducing anergy or deletion in autoreactive B cells (31). 
1.3.4. Immune Deviation 
Polarisation of the T cell effector response may be related to the activation signals 
initially received by APC, and is important in determining the overall outcome of a 
response (32, 33). Thi cells mainly produce IFNy, which activates macrophages to 
increase killing of phagocytosed or intracellular organisms and also slows pathogen 
growth through its cytostatic effects . Th2 cells produce cytokines such as IL-4, IL-5, 
IL-10 and IL-13 to aid B cell maturation and antibody (Ab) production, and 
activation/recruitment of innate inflammatory cells such as eosinophils and mast 
cells, for the combat of extracellular pathogens. Both phenotypes cross-regulate the 
expansion and differentiation of the other (32, 34). Skewing of the response can be a 
useful mechanism of preventing or alleviating damaging responses to innocuous Ag, 
particularly when switching Thi to Th2 responses,(35, 36), although both Thi and 
Th2 responses can initiate autoimmune disease of different types. Immune deviation 
could therefore be considered a rather simplistic tolerance mechanism. 
1.3.5. Regulatory T cells 
It has now become clear that in addition to the above mechanisms of peripheral 
tolerance, harmful responses against self-Ag are actively prevented by a population 
of regulatory T cells (Tregs). The concept of a population of suppressor cells that 
prevent autoimmunity was first proposed over 30 years ago by RK Gershon (37). 
Two important findings in the 60s and 70s pointed towards the co-existence of 
suppressor cells and self-reactive (potentially pathogenic) cells in healthy animals, 
and that removal of the suppressor population would allow the initiation of 
autoimmune disease. First, it was observed that mice that were thymectomised on 
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day three of life (d3Tx) developed a spectrum of autoimmune diseases, and disease 
could be prevented by transferring normal adult CD4 cells before day 14 (38, 39). 
Second, thymectomy of adult rats followed by sublethal doses of irradiation (to 
deplete some peripheral lymphoid cells) induced autoimmune thyroiditis that could 
again be prevented by transfer of normal adult CD4 cells after irradiation (40). The 
field of suppressor T cell research boomed in the 70s and 80s, with some convincing 
evidence for the existence of both CD4 and CD8 suppressor cells, but fell out of 
favour due to a failure to identify the elusive "suppressor factors" thought to be 
required for function of suppressor cells (reviewed in (41)). 
With the development of more sophisticated methods for identifying and sorting cell 
populations, the evidence for the existence of suppressor T cells became 
overwhelmingly convincing, and the field was rejuvenated under the title of 
regulatory T cells in the 1990s. Sakaguchi initially narrowed down the cell 
population able to prevent autoimmune disease in d3Tx mice to those CD4 cells 
expressing CD5 at high levels (42). They also showed that autoimmune/wasting 
disease could be induced in T cell-deficient mice by transfer of splenocytes depleted 
of CD5h1  cells (43). Mason and colleagues further refined this regulatory function to 
be contained within the CD45RBI0  populations, using a similar approach of cell 
transfer into lymphopaenic recipients to induce autoimmune/wasting disease (44). 
Finally, Sakaguchi and colleagues showed that the CD4 population able to suppress 
autoimmune cells, and lacking in d3Tx mice, constitutively expressed CD25 (IL-
2Ra) and make up 5-15% of total CD4 cells in the peripheral lymphoid system of 
normal mammals(45). While CD25 expression is not limited to regulatory T cells, 
and not all CD4 regulatory cells express CD25 (46, 47), the identification of CD25 
as a marker for Tregs was a great step forward. 
The ability of CD4CD25 cells to regulate autoimmune responses has now been 
demonstrated in several models including autoimmune gastritis (45), Type-I diabetes 
(46, 48) and EAE(49, 50). The role of CD4CD25 cells in preventing responses to 
tumour Ag (51), infectious pathogenic Ag - a role in memory maintenance has been 
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suggested (52), transplant Ag (53) and allergic responses (54) has also been well 
documented in mice, and data on roles in human disease are now emerging. 
Prevention and control of autoimmune responses will be focussed on in this 
introduction. 
Since the demonstration of CD4CD25 regulatory cells, several other types of 
regulatory cells, including CD4 Trl and Th3 cells(55, 56), CD8 T cells(57), NKT 
cells(58), and even B cells(59, 60), have been described. It could be argued that 
many cells have regulatory function within the context of the activation and control 
of normal immune responses, but how many of these cells have truly dedicated 
regulatory function is debatable. For example, Th2 cells prevent the differentiation of 
Thi cells (34), and in some autoimmune settings such as EAE, where disease is 
induced by Thi cells, Th2 cells could therefore have a beneficial effect simply by 
"regulating" Thi activation (61). Also, some regulatory cell types can be induced by 
treatment of DC or altering priming conditions in vitro or in vivo (55, 62, 63). 
Whether these conditions occur naturally is doubtful, however these artificial 
manipulations can point towards the development of new therapies. 
1.4. B cell tolerance 
The B cell receptor (BCR) directly recognises conformational epitopes of native 
proteins. During development in the bone marrow, B cells are positively selected 
based on surface BCR expression(64), although the exact mechanisms of this 
selection are unclear. Immature B cells have a lower threshold for BCR signalling, 
and cells binding Ag with high affinity tend to be deleted at this stage (65), but this 
process is probably even less thorough than T cell thymic selection. Also, during the 
activation and differentiation of mature B cells in response to Ag, uniquely, 
developmental genes are reactivated to initiate genetic rearrangement of the BCR 
(66). The aim of this process of somatic hypermutation is to generate BCRs of 
increasing affinity for the Ag, but the potentially harmful consequence is the 
generation of BCRs (and Ab) specific for self. Therefore, stringent peripheral checks 
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are required to ensure B cells remain specific for the initiating Ag and that B cells 
specific for self Ag are not allowed to differentiate into Ab-producing cells. 
In the periphery, crosslinking of the BCR by multimeric Ag generates activation 
signals, and BCR-bound Ag is internalised for rapid processing and presentation on 
MHC class II molecules (67). B cells also have receptors for "danger" signals such as 
LPS (28). For complete activation and maturation of the B cell response to take place 
(germinal centre formation, affinity maturation, class switching), CD4 T cell help is 
required through the interactions of MHC-peptide:TCR, CD40:CD40L, and possibly 
Fas:FasL (68, 69). 
B cells unable to elicit T cell help undergo apoptosis or become anergic (64). Failure 
to receive T cell signals is likely to occur when B cells are specific for autoAg, and 
the corresponding T cells have therefore been deleted or anergised. In a BCR tg 
model in which B cells develop in the presence of their specific soluble Ag, B cells 
that had not received BCR signals (due to lack of crosslinking) but presented peptide 
MHC complexes to T cells and therefore received signals through ligation of CD40 
and Fas, underwent apoptosis (68). This is the likely outcome whenever B cells 
present abundant soluble self-Ag, taken up via the BCR in the absence of 
crosslinking, or by pinocytosis. 
B cells receiving chronic stimulation via the BCR are also induced to apoptose when 
CD40 and Fas are ligated by ItD401, and FasL on interacting T cells (68). This not 
only ensures downregulation of ongoing responses, but also deletes any cells 
responding to self Ag (i.e. Ag that is constantly present). It has also been reported 
that B cells specific for self Ag are excluded from B cell follicles when the Ag is 
chronically present, leading to their death in T cell zones (70). 
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It has been found that autoreactive B cell anergy may be overcome by provision of 
sufficient "help" from activated CD4
+  T cells, in a model using B cells with 
transgenic TCRs specific for anti-dsDNA (71). Interestingly, in this model, addition 
of CD4CD25 regulatory T cells allowed only abortive B cell activation after Ag 
binding, and prevented secretion of autoAb, suggesting a role for Tregs in 
maintenance of autoreactive B cell anergy. In support of this, the initial reports of the 
effects of CD4CD25 cell depletion by d3Tx included B cell autoimmunity (45), 
and Bystry et al have reported the ability of CD4CD25 cells to inhibit B cell 
blasting in response to Ag in vitro, and to inhibit in vivo B cell autoAb production 
(72). However, in these studies additional effects of CD4CD25 cells on helper 
CD4 cells may also act to prevent autoimmune B cell Ab production in vivo. 
Overall then, the maintenance of B cell tolerance relies heavily on signals (or lack 
thereof) from CD4 T cells. Therefore, efficient maintenance of CD4 T cell 
tolerance is perhaps even more important than direct effects on B cells. 
1.5. The Biology of Regulatory T cells 
Over the last ten years or so, a wealth of information regarding regulatory T cell 
biology and functions in various immune settings has been uncovered, although 
many questions still remain. A more detailed description of what is currently known 
about these cells is therefore merited. 
1.5.1. Origins and specificity of CD4CD25 regulatory T cells 
As well as its role in deletion of self-reactive cells, the thymus has been shown to be 
the major generator of CD4CD25 cells (73, 74). Thymectomy of mice on day 3 of 
life (d3Tx) results in a reduction of CD4CD25 cells in peripheral lymphoid organs 
of adult mice (45, 73), demonstrating that the thymus is required for their generation, 
and that generation of CD4CD25 cells occurs fairly late in development. The 
autoimmune disease that develops in d3Tx mice can be prevented by transfer of 
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CD4CD25 cells from normal adult mice (73, 74), demonstrating the importance of 
these cells for maintenance of peripheral self tolerance. 
Thymic selection of CD4CD25 cells is thought to be based on recognition of self 
Ag presented on thymic epithelial cells (75). It has been observed in mice with 
transgenic TCR specific for non-self Ag that CD4CD25 cells tend not to be 
generated when they are crossed onto a RAG-deficient background (74, 76). A high 
proportion of CD4CD25 cells in transgenic mice possess an endogenously 
rearranged TCR, suggesting that this is required for self-reactivity and differentiation 
into a regulatory cell in the thymus (74, 76). This has been confirmed by crossing 
mice expressing neo-self Ag, such as RIP-OVA mice (which express OVA in 
pancreatic 13 cells and also in thymus under the control of the rat insulin promoter) 
with mice bearing transgenic T cell receptors specific for OVA (DO 11.10 mice). The 
offspring of these mice were found to have higher than normal proportions of 
CD4CD25 regulatory cells in both thymus and peripheral lymphoid organs (around 
50% of peripheral CD4 cells expressed CD25 and were specific for OVA)(77). 
Several pieces of evidence suggest that selection to become a regulatory cell may be 
based on avidity for Ag(9, 76, 78). Work from Caton's group has demonstrated that 
different outcomes of T cell selection could be driven by TCR affinity or level of 
self-Ag expression. In these studies, HA28 transgenic mice, which express the 
influenza virus haemaglutinnin (HA) protein as a neo-self Ag in the thymus and 
periphery, were crossed with mouse strains having transgenic TCRs of varying 
affinity for the Si epitope of HA(9). Conversely, mice bearing a single HA-specific 
transgenic TCR were crossed with mouse strains expressing HA under the control of 
different promoters leading to different levels of HA expression (79) Overall, these 
studies have shown that as peptideMHC:TCR avidity is increased, a combination of 
increased deletion of HA-specific cells and selection of a higher proportion of 
CD4CD25 regulatory cells occurs, and this process is mediated by radio-resistant 
thymic epithelial elements. Therefore, this model proposes that some of the CD4 
cells bearing TCRs with high affinity for self Ag are not deleted, but are programmed 
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to become regulatory cells and released into the periphery as a crossover mechanism 
of central tolerance policing peripheral tolerance. This proposal has been further 
supported by findings in a model crossing DO 11.10 mice with mice generated to 
express ovalbumin in all nucleated cells(76). 
Whether cells selected to become CD4CD25 regulatory cells in the thymus differ 
in their TCR repertoire and specificity from CD4CD25 cells is unclear. It would 
seem intuitive that they should differ to some extent, since high affinity for self may 
determine the cell fate, and combined usage of certain TCR-a and -13 chains may 
predispose to self-recognition. The models described above show that a different fate 
for clonally-related cells is possible, depending on avidity for and level of expression 
of cognate Ag (9, 76). However, these studies are far from physiological. Like the 
naïve T cell repertoire, the TCR repertoires of peripheral CD4CD25 cells appears 
diverse (80). Recent work from Rudensky's lab has suggested that while there is 
some overlap in TCR alpha and beta chain usage, certain Vet chains are dominantly 
expressed by CD4 +  CD25+  i cells n contrast to CD4
+  CD25 cells, and that this may be 
related to differences in affinity for self (78). Thus some T cells may be predestined 
to become regulatory cells. 
Certain tolerance protocols, specifically low dose oral Ag administration (81, 82), 
intravenous injection of a low dose of soluble peptide (81), or continuous 
subcutaneous infusion of peptide (83) can lead to de novo induction of CD4CD25 
cells from naïve CD4CD25 T cells. These cells appear very similar to thymically-
generated CD4CD25 cells in phenotype and function. Exposure to TGF13 during 
naïve T cell activation may also induce their differentiation into regulatory T cells 
with the phenotype of thymically-generated CD4CD25 cells(84, 85). It is therefore 
difficult to determine the true frequencies of thymically-generated versus 
peripherally-induced Tregs. 
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1 .5.2. IL-1 0 producing T regulatory Type-1 cells (Tn s) 
A further population of inducible CD4 regulators have been termed T regulatory 
type 1 (Tr) cells (55, 86). Trl cells were initially shown to be generated by in vitro 
culture with Ag in the presence of IL-b, but other mechanisms of producing cells 
with similar characteristics have been demonstrated, including activation of naïve 
CD4 cells in the presence of the active form of Vitamin D3 and dexamethasone 
(62), or nasal administration of peptide in vivo (63). The main defining characteristic 
of this group (or groups) of cells is the production of high levels of IL- 10 in response 
to Ag Analagous with CD4CD25 Tregs, Tr I cells have been shown to inhibit 
colitis when cotransfened with CD45RBhi cells into Severe Combined 
ImmunoDeficiency (SCID) mice(86), and also to inhibit the proliferation of 
responder cells in vitro (although this may not require IL-10)(87). 
Trl cells may be induced by IL-10-producing DC in vivo: work from the Mills' 
group showed that DC induced to produce IL-10 by binding of filamentous 
haemaglutinnin from Bordetella Pertussis, generated Bordetella-specific TrI cells 
(88). Natural induction of Trl cells by DC in vivo as a mechanism of self tolerance, 
although expected to occur, has not yet been definitively shown. It is thought that 
immature DC may induce Tr Is in vivo (55, 89). 
Tn-type (IL-10 producing) cells specific for nickel have been cloned from the blood 
of healthy individuals as well as skin and blood of Nickel-allergic patients(90). Non-
allergic individuals appeared to have higher levels of these cells suggesting a role in 
prevention of allergy. Likewise, host-specific IL-10 producing cells have been 
observed in SCID patients that have received allogeneic bone marrow (91), and are 
thought to contribute to prevention of graft-versus-host disease in these patients. 
Veldmann et al have recently identified desmoglein 3-specific TrI cells in healthy 
people (92). Skin desmoglein 3 is the auto-Ab target in pemphigus vulgaris, and 
patients with this condition were found to have a relative deficiency of desmoglein 3-
specific Trl cells (92). Low dose peptide therapy for cat dander allergy has also been 
associated with an increase in Ag-specific IL-10 concomitant with decresed Thl and 
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Th2 cytokine production (93). Thus, Trl cells may play an important role in 
preventing certain autoimmune/allergic responses in humans. 
1 .5.3. Distinguishing Markers of Tregs 
Thymically generated Tregs constitutively express markers such as CD25, CTLA-4 
and GITR (94, 95), but these molecules are also upregulated during the activation of 
naïve or memory T cells. Therefore, when attempting to investigate their role in 
disease or inflammatory settings great care must be taken to distinguish cells that are 
regulatory in function from recently activated effector cells that have a similar 
phenotypic appearance. 
One distinguishing feature is cytokine production: CD4CD25 cells do not produce 
IL-2 or classic Th1/Th2 cytokines such as IFNy/IL-4 upon restimulation (94, 95) 
(production of IL-10 and/or TGF3 is controversial and is discussed in section 1.5.4. 
CD4CD25 cells are also classically anergic in vitro, in that they do not proliferate 
in response to cognate Ag in the absence of exogenous IL-2, in contrast to activated 
T cells which produce IL-2 and proliferate in response to cognate Ag in vitro. 
+ + CD4 CD25 cells can inhibit IL-2 production by activated T cells(96, 97), thereby 
preventing their in vitro proliferation - another functional characteristic to 
distinguish them from activated T cells. 
Very few molecules have been described that are specifically and uniquely expressed 
by regulatory T cells. Neuropilin-1, a receptor involved in T cell activation, was 
recently shown to be constitutively expressed on CD4CD25 cells(98). It appears to 
be a distinguishing marker since expression of neuropilin-1 is not upregulated upon 
activation of naïve T cells(98) However, expression levels (as measured by flow 
cytometry) were not very high, so it remains to be established whether this will be a 
useful marker for identifying and sorting regulatory T cells. 
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Recently, the transcription factor FoxP3 was described to be required for the 
regulatory function of CD4CD25 cells (99-101) (see section 1.5.4). In humans 
there has been some doubt as to whether FoxP3 is also upregulated upon activation 
in naïve cells (102). In mice, FoxP3 expression does appear to be restricted to 
regulatory cells, although this included both CD4CD25 and CD4+CD25CD45RBI0 
cells (101). However, FoxP3 expression does not appear to be restricted to 
thymically-generated regulatory cells: stimulation of naïve CD4CD25 cells with 
TGFI3 has been reported to induce CD4CD25 regulatory cells expressing 
FoxP3(84, 85). Interestingly though, Trl cells, induced in vivo by intranasal peptide 
administration or by in vitro stimulation of cells with Ag in the presence of Vitamin 
D3 and dexamethasone, do not appear to express FoxP3(87), suggesting that TrI and 
CD4CD25 cells are indeed separate lineages of regulatory cells. Production of anti-
FoxP3 mAb for use in mice, and GFP-FoxP3 mice will no doubt allow further rapid 
advances in the understanding of the biology of CD4CD25 cells and their 
clarification of their relationship to other cell lineages. 
1 .5.4. Regulatory Cell Functions in vivo 
Intuitively, regulatory T cells cannot simply downregulate all responses, they must 
somehow distinguish between responses that should be prevented or stopped and 
those that should continue. How this is achieved is still somewhat of an enigma, but 
there are clues. The mechanisms of suppression by Tregs are still unclear, although 
several have been proposed and these are often related to molecules constitutively 
expressed by these cells. Some of the molecules initially thought to bmportant for 
the effector functions of Tregs are more likely to be involved in the decision whether 
or not to prevent a particular immune response. Therefore the factors involved in 
turning regulatory functions on or off as well as those mediating regulation will be 
discussed together. 
1.5.4.1. Cellular Targets and Antigen Specificity of 
Suppression 
CD4CD25 cells have been shown to regulate CD4 T cells(103), CD8 T 
cells(104), B cells(71, 72), and innate immune cells(105). The central role of CD4 
cells in orchestrating immune responses may mean that regulation of CD4 cells is 
likely to be one of the most important functions of Tregs. 
It is known that both CD4CD25 and Trl cells must be stimulated via the TCR for 
activation of suppressor function(55, 96) On the other hand, the Treg and its target 
do not always appear to require recognition of the same Ag, or even share MHC 
restriction, provided that the Treg has been recently (but not necessarily 
concomitantly) activated via its TCR(1 06). This suggests a direct T:T cell interaction 
rather than Treg:APC activity. Contact-mediated suppression has also been 
suggested by in vitro experiments in which suppression was abrogated when the 
Tregs and responder cells were physically separated in a tnanswell(96). Using MHC 
class I tetramers to activate CD8 T cells and recently-activated CD4CD25 cells, 
Shevach et al have shown suppression in the complete absence of APC(104). 
However, CD4+  CD25+ cells can control intestinal inflammation mediated entirely in 
the absence of T cells in vivo(105). Also, CD4CD25 cells can have direct effects 
on DC(107, 108). The main cellular targets of regulation will therefore most likely 
depend on the type of immune response, and is unlikely to be limited to one cell 
type. 
1.5.4.1. FoxP3 
A mutant strain of mice, termed "scurfy", develop a spectrum of autoimmune 
diseases that is remarkably similar to the human immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)( 109) Gene analysis of 
scurfy mice and IPEX patients revealed that a mutation in a common gene encoding 
the forkheadlwinged helix transcription factor FoxP3 resulted in impaired generation 
of CD4CD25 regulatory cells in the thymus(99-101). Furthermore, FoxP3 appears 
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to be important not just for the thymic generation of regulatory T cells but also their 
function. Transfection of naïve CD4CD25 cells with the gene encoding FoxP3 
confers regulatory function on these cells, as well as the acquisition of the 
"regulatory phenotype": upregulation of molecules such as CD25 and CTLA-4 (99-
101). It has since been found that naïve CD4 cells can be induced to become 
CD4CD25 cells with regulatory function by TGF3 in vivo, and this regulatory 
function is associated with upregulation of FoxP3 (84, 85, 110). Thus, FoxP3 
somehow determines the function of Tregs. 
1.5.4.1. 	IL-10 
The role of cytokines in the function of regulatory cells is controversial. Peripherally-
induced IL-10 producing cells (collectively termed Trl cells) were initially 
characterised by their suppression of T cell responses through production of IL-10 
(55, 86). However, in some cases this does not appear to hold true, at least in vitro: 
O'Garra and Wraith have reported that Trl cells induced by their methods 
(VitD3/dexamethasone and intranasal peptide administration) require cell-contact for 
in vitro suppression, not IL- 10 (87). However, IL- 10 production in vivo is still likely 
to be important for the action of these cells (111). 
A similar discrepancy concerning requirements for IL-10 has been observed for 
CD4+  CD25 +  cells. In some studies, and particularly in vitro, IL-10 does not appear to 
play a major part in suppression. Rather, Treg:effector cell contact is crucial (96, 
112). In vivo, the requirement for IL- 10 varies with the model used. For autoimmune 
gastritis induced depletion of CD25 cells by d3Tx, IL-10 is not required for 
prevention of disease (113). However, IL-10 does appear to be important for 
CD4CD25 cell-mediated prevention of T cell-dependent and T cell-independent 
colitis (105, 114, 115), as well as the suppression of EAE (50), anti-Leishmania 
responses (52), and allogeneic transplant rejection (116). 
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1.5.4.1. 	TGF/3 
Another cytokine with downregulatory properties implicated in the action of some 
regulatory T cells is TGFI3. TGFI3 niRNA can be detected in CD4CD25 
populations from naïve mice (73), and it has been suggested that cell-bound TGFI3 is 
involved in the cell-contact-dependent suppression observed in vitro (117). However, 
the importance of TGF P for Treg function, like IL- 10, remains controversial, and the 
observation that surface-bound TGFI3 is involved in suppression in vitro has been 
disputed (118). 
In some models, particularly type-I diabetes and colitis, TGFI3 appears to be 
important for prevention of autoaggressive or inflammatory responses (119-121). 
Green et al use an inducible model of diabetes in which pancreatic P cells express 
CD80 and produce TNFa, thus creating an inflammatory context in which T cells 
may encounter Ag in the pancreas to initiate diabetes. In this model, highly potent 
CD4CD25 regulatory T cells have been observed to accumulate in the pancreatic 
LN before disease onset (122). Low numbers of these pancreatic LN CD4CD25 
cells are able to transfer protection to pre-diabetic mice (122). The regulatory cells 
express cell surface-bound TGF3, and the ability of CD4CD25 cells to suppress 
diabetes was directly dependent on the ability of target CD8 T cells to respond to 
TGF3 {Green, 2003 #5071. 
Inflammatory colitis can be induced in lymphopaenic mice by the transfer of 
CD4CD25 cells (T-dependent), or by infection with Helicobacter hepaticus (T -
independent). In both these models, protection from disease can be provided by 
CD4CD25 cells (105, 123), and in the T-dependent model of colitis CD4CD25 
cells can cure disease that has already been established (121, 123). In these colitis 
models, disease prevention or cure may be mediated, at least in part, through 
production of TGFI3. However, these studies used blocking Ab, which may affect 
many cell types, and TGFI3 is known to be important for normal immune regulation 
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in the gut environment. A more recent study using TGFI3-1-deficient CD4CD25 
cells found that although these could suppress proliferative responses of CD4CD25 
cells in vitro, they could not inhibit induction of colitis in vivo (119), suggesting a 
requirement for TGFj3 production/expression directly by Tregs in this model. 
As already discussed, TGF3 may also contribute to infectious tolerance by 
instructing the development of new regulatory T cells (57, 84, 85). 
1.5.4.1. Requirements for IL-2 and the IL-2R in function and 
maintenance of Tregs 
The constitutive expression of certain markers on Tregs suggests requirements either 
for survival or for effector function. It could be suggested that CD25 on Tregs acts as 
an IL-2 "sink" to absorb IL-2 and thereby reduce proliferation of the IL-2 producing 
T cells. This seems unlikely, since activated T cells expressing high levels of CD25 
are unable to inhibit proliferation of cocultured cells (96). It has also been shown that 
Tregs directly block responder cell synthesis of IL-2 (96, 97). 
While CD4CD25 cells do not produce IL-2 themselves, they are highly dependent 
on IL-2 from other cells for survival: mice deficient in IL-2, CD25 or 1L2R13 are also 
deficient in CD4CD25 regulatory T cells and develop spontaneous autoimmunity 
(124-126). Also, administration of anti-IL-2 or anti-CD25 in vivo leads to rapid 
depletion of CD4CD25 cells (127, 128), and increased susceptibility to 
autoimmune disease (127). Likewise, STAT5 is required for IL-2 signalling and mice 
in which STATS is over-expressed have an increased frequency of CD4CD25 
regulatory cells (129). 
Similarly to the "IL-2 sink" hypothesis, it has been suggested that co-transfer of 
CD4CD25 cells with CD4CD25 cells prevents disease by competing for space in 
a homeostatic manner (130). This is based on studies inducing colitis in mice with 
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CD4CD25 cells into lymphopaenic mice, which found that trasnferring TCR 
transgenic CD45RBh  T cells with the pathogenic CD4CD25- cells gave the same 
protective effect as transferring CD4CD25 cells. Although this may hold some 
truth when using lymphopaenic systems, homeostatic competition is unlikely to 
explain the in vitro effects of CD4CD25 cells or the regulatory functions observed 
in vivo in lymphoid-sufficient hosts. Unlike transfer of CD4CD25 cells into 
BALB/c SCID mice, depletion of CD25 cells in vivo does not lead to spontaneous 
gastritis in lymphoid-sufficient mice (127). However, these mice are more 
susceptible to induction of gastritis by immunisation, suggesting that the homeostatic 
proliferation of CD4CD25 cells after transfer into lymphopaenic mice in some way 
serves to provide the signals necessary to activate the autoreactive cells. 
1.5.4.1. "Killer" Tregs 
Rather surprisingly,, gene profiling of CD4CD25 cells showed granzyme B 
expression in these cells (131). This was largely ignored at the time, since granzymes 
are associated with CD8 +  cytotoxic T cell function. Ley and colleagues have recently 
shown that human CD4CD25 cells upregulate granzyme A upon activation (132). 
These cells killed activated CD4 and CD8 T cells as well as monocytes and DC in 
a perforinlgranzyme-dependent manner, suggesting a novel mechanism of regulation 
by CD4 T cells. This mechanism would obviously be cell-contact dependent, fitting 
with previous in vitro observations, although cell death had not been reported in 
these studies (96). 
1.5.4.1. CD281CTLA-41B7costimulatoiy network 
CTLA-4 is a downregulatory molecule whose expression is elevated on activated T 
cells. CTLA-4 binds B7 molecules with high affinity, outcompeting CD28's ability 
to bind the same molecules, and also signalling negatively to the T cell to inhibit 
further activation (22). CTLA-4 is constitutively expressed on CD4CD25 
regulatory cells (133, 134), and it has been proposed to be necessary for suppressor 
function since blocking anti-CTLA-4 can abrogate suppression in some systems 
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using Fab fragments to block (133, 134), but not when using whole Ab with potential 
cross-linking ability (103). CD4 +  CD25+  cells express several molecules associated 
with negative signalling and limitation of cell division (CTLA-4, PD-i, C135) and it 
has been suggested that this could contribute to their anergic state (135). Blocking 
CTLA-4 could therefore act to overcome this anergy in vitro. 
CD4CD25 cells that are deficient for B7 expression have been found to be resistant 
to suppression in vitro or in vivo, and are inherently more pathogenic than 
CD4CD25 cells from wildtype mice when transferred into lymphopaenic hosts 
(136). This suggests a role for engagement of B7 on activated T cells by CTLA-4 on 
CD4CD25, and may also partly explain the pathology seen in CTLA-4 knockout 
mice, which experience an overwhelming proliferative syndrome resulting in early 
mortality (137). Thus CTLA-4 may provide a mechanism for direct T:T cell 
suppression. 
Conversely, Tregs may act indirectly on T cells via APC. One example of this is the 
downregulation of the costimulatory molecules 137-1/2 (108). A different APC-
directed approach to turning off T cell responses involves tryptophan catabolism by 
DC. It has been known for some time that interferons produced during infection act 
to induce the production of indoleamine 2,3-dioxygenase (IDO), and that IDO then 
catabolises the degradation of tryptophan (138). This deprives the infectious 
organism of an essential growth factor. However, it has now become clear that 
tryptophan catabolism may serve additional immunoregulatory functions. 
Tryptophan is degraded into metabolites termed kynurenines and these induce 
apoptosis of various immune cells (138). Using an allogeneic islet transplantation 
model, Grohmann et al showed that engagement of B7 on DC by CTLA-4-Ig fusion 
protein stimulated IFN production by DC, resulting in synthesis of IDO and 
tryptophan catabolism in those DC (139). Deletional tolerance to the allogeneic 
grafts was thus established. CTLA-4 is constitutively expressed by C64CD25 
Tregs, and it has recently been shown that interactions of Tregs with DC may induce 
tryptophan catabolism in a manner analogous to that described for CTLA-4-Ig (107). 
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However, in this model there appeared to be an additional non-CTLA-4-mediated 
mechanism of IDO induction by activated Tregs (107). 
While CD28 does not appear to be required for the suppressive function of Tregs 
(133), a strong signal through CD28 ligation (along with TCR stimulation) abrogates 
their anergic and suppressive state (96, 112). The CD28/137 costimulatory pathway is 
also important for CD4CD25 Treg development and homeostasis. This was 
revealed by the surprising result that NOD mice crossed onto either a CD28 
background, rather than being resistant to spontaneous autoimmune diabetes, 
developed diabetes with accelerated onset (48). The number of peripheral 
CD4+CD25+ cells was also reduced, and the onset of diabetes in these mice could be 
prevented by transfer of CD4CD25 regulatory T cells (48). 
1.5.4.1. GITR 
Gene profiling and antibody screening studies by the Shevach and Sakaguchi labs, 
respectively, led to the concomitant identification of the glucocorticoid-induced TNF 
receptor (GITR), as a molecule constitutively expressed by CD4CD25 cells (131, 
140). Ligation of GITR abrogated suppressor functions of CD4CD25 cells in vitro, 
suggesting a role for this molecule in suppression (140). However, GITR expression 
is also upregulated upon activation of naïve CD4 T cells, and subsequent studies 
have shown that ligation of GITR has positive costimulatory effects on activated T 
cells (141). The effects of administration of anti-GITR could therefore be attributed 
to increased costimulatory signals to effector cells in some models, as has been 
demonstrated for EAE (142). Furthermore, GITR engagement on CD4CD25 cells 
has been shown to confer resistance to suppression by CD4CD25 cells(143). Thus, 
ligation of GITR on either Tregs or activated effector T cells may act as a switch 
leading to abrogation of suppression. 
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1.5.5. Responses of Regulatory cells to Antigen: in vitro vs in vivo 
The early studies using in vitro assays found CD4CD25 cells to be anergic, in that 
they failed to proliferate in response to Ag unless exogenous IL-2 or additional 
costimulation was provided (96, 112). It was assumed that these cells would likewise 
be anergic in vivo. Indeed, it has been reported that TCR transgenic CD4CD25 did 
not proliferate in vivo in response to immunisation with specific peptide in CFA, but 
did undergo homeostatic proliferation in a lymphopaenic environment (144). 
However, several studies have since shown that CD4CD25 cells do proliferate in 
response to cognate Ag in vivo (145). These studies used transgenic CD4CD25 
cells (of different specificities) and showed that these proliferated in response to 
immunisation with specific Ag in adjuvant (77, 146, 147), immunisation with Ag-
pulsed mature DC (148), or locally in response to Ag draining from the tissues (77, 
149). A proportion of CD4CD25 cells also appear to slowly cycle continuously in 
vivo (149), presumably in response to presentation of self peptides on DC. This 
continual cycling may also partly explain the constitutive expression of activation 
markers such as CD25, and the high dependence of Tregs on IL-2. 
1.5.6. Conclusions - how do Tregs fit into immune responses in vivo? 
A clearer picture of how Tregs fit into the initiation and control of immune responses 
is now emerging. Under inflammatory conditions, such as infection, DC become 
activated through ligation of toll-like receptors and the presence of inflammatory 
cytokines (28). This results in upregulation of costimulatory molecules such as B7 
and GITR-ligand, as well as enhanced expression of peptide-MHC (22, 28, 141). 
Interaction of CD4CD25 cells with these DC results in the temporary abrogation of 
suppressive functions and proliferation of the Tregs (presumably making use of IL-2 
produced by concomitantly activated CD4CD25 cells) (131, 140, 148, 150). At the 
same time, engagement of GITRL on CD4CD25 cells confers resistance to 
suppression (143). Production of IL-6, in addition to some other unidentified 
cytokine(s), by DC in response to engagement of TLRs has also been reported to 
make responder cells resistant to suppression by CD4CD25 1 cells (151). 
CD4CD25 themselves are reported to express TLR- 4,5,7 and 8 (152). TLR-4 
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binds bacterial LPS, and Caramaiho et al found that addition of LPS to cultures of 
+ 	
i 	 i CD4+  CD25 cells induced their proliferation, even n the absence of DC, indicating 
that Tregs may respond directly to inflammation, and may play a more general role 
than suppression of autoimmune responses. 
In contrast, under steady-state conditions, suppressive functions would presumably 
be maintained, and activation of naïve cells would be prevented. Naïve cells 
responding to Ag under these conditions are more likely to recognise self-Ag or non-
harmful Ag such as commensal bacteria or food Ag, and therefore it is beneficial to 
prevent these responses. The one potential flaw in this argument is the finding that 
transferred Ag-specific CD4CD25 cells proliferate in response to Ag draining 
tissues under steady-state conditions (77, 149), and the factors promoting this 
expansion have yet to be identified. 
After expansion in vitro with Ag and IL-2 (with or without additional anti-CD28), 
CD4CD25 cells have been found to regain regulatory functions, and are in fact 
more potent in their suppressive capacities (45, 153, 154). In vitro stimulation of 
CD4CD25 cells for three days with LPS, followed by three days in the presence of 
IL-2, results in a further enhancement of suppressive potency compared to IL-2 alone 
(152). As the source of inflammation is cleared, it is likely that the number of 
activated DC will decrease and the stimuli leading to abrogation of Treg suppression 
will be downregulated. It would be expected that the expanded CD4CD25 cells 
would now be highly potent regulators. Thus the balance of power would shift from 
effector cells to regulatory cells, and the regulatory cells may contribute to the 
downregulation of the effector response, and perhaps more importantly the 
downregulation of any self-reactive cells that may have been activated as a side-
effect of the inflammatory conditions. Indeed, it has been found that depletion of 
CD25 cells in vivo leads to increased numbers of Thi effector cells (155). 
Interestingly, this study used foreign Ag (ovalbumin), indicating that Tregs may 
control the responses to foreign Ag as well as self Ag. It has even been suggested 
that Tregs may prevent the complete elimination of the parasite Leishmania, and that 
this has a beneficial effect by maintaining functional memory to prevent new 
infections (52). 
1.6. Part 2: Experimental Autoimmune Encephalomyelitis as a 
CD4 T cell-driven autoimmune disease 
Experimental autoimmune encephalomyelitis (EAE) is a widely-used murine model 
of multiple sclerosis (MS). The model was developed after an unfortunate side-effect 
of a rabies vaccine: it was observed that some people given the vaccine developed 
acute paralysis, with symptoms similar to MS patients. Further investigation revealed 
that some of the rabbit nervous tissue in which the vaccine virus had been prepared 
was still present in the inoculation, prompting speculation that a myelin-specific 
immune response had been provoked, resulting in the observed CNS inflammation 
and paralysis (156). This was the first suggestion that MS may in fact be an 
autoimmune response, and the animal model EAE was developed as a tool to 
investigate the pathogenesis of MS. 
There is still some debate over the etiology of MS, although it is now mostly agreed 
that it has an autoimmune basis. This is particularly supported by the fact that the 
most successful therapies for MS have immunomodulatory functions (157-160). 
Also, myelin-reactive T cells have been identified in the lesions of MS, although 
these cells have also been identified in the blood of healthy individuals (161), and 
myelin-specific Ab are present in the CNS and blood of MS patients (158, 162). The 
processes that lead to the development of MS are still unclear, however studies on 
the pathogenesis and susceptibility to EAE have given some clues. From an 
immunologist's perspective, EAE provides a model with well-defined self Ags, that 
has proved highly useful for studying various aspects of immune tolerance. 
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1.7. Pathogenesis of EAE - cells types involved 
To induce EAE, animals are immunised with myelin (spinal cord homogenate) or 
myelin components, emulsified in Complete Freund's Adjuvant (CFA). EAE can be 
induced in many animals, but mice provide the bulk of data for this model, due to the 
availability of inbred and genetically manipulated strains of this species. In mice, 
clinical disease manifests itself eight to ten days after immunisation, with the onset 
of ascending paralysis, and this correlates with perivascular infiltration of the brain 
and spinal cord by mononuclear cells. EAE is mediated by myelin-reactive CD4 T 
cells: this has been demonstrated by the ability of purified CD4 cells from mice with 
EAE to induce disease when activated and transferred into naïve mice (163, 164), 
and the failure to induce EAE in mice depleted of CD4 cells (165). The most 
common myelin proteins used to induce disease are proteolipid protein (PLP), 
myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG). 
Immunodominant T cell epitopes have been identified within each protein, and 
peptides containing these can also be used to induce disease (166, 167). 
For this project, EAE was induced in B6 mice (H2b)  by immunising with the major 
encephalitic epitope of MOG: MOG(35-55) (168). MOG constitutes less than 0.1% 
of total myelin, but has been identified as a possible target autoAg for both T cells 
and B cells in MS (169, 170). 
While CD4 T cells are thought to initiate the response, macrophages clearly play a 
central role as effector cells in the pathogenesis of EAE, through production of 
cytokines such as TNFa and lymphotoxin, expression of self peptides on class II to 
reactivate T cells, digestion of myelin and Ab-mediated cytotoxicity (171, 172). In a 
rat model of EAE induced by transfer of activated encephalitogenic T cell lines, 
Flugel and colleagues showed that the severity of disease induced by different cell 
lines correlated with levels of macrophage recruitment into the CNS rather than 
numbers of T cells entering the CNS(173). 
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Activated macrophages and DC, as well as resident macrophage-type cells such as 
microglia, upregulate MHC class II to activate T cells in the CNS during EAE (174). 
This activation of T cells within the CNS is thought to be important for T cell 
maintenance and effector functions in the CNS, since effector cells specific for an 
irrelevant Ag do not accumulate in significant numbers in the CNS (173, 175), and 
mice in which de novo processing of myelin is prevented do not develop EAE (176). 
As well as presentation of myelin Ag, expression of costimulatory molecules by CNS 
APC appears to be important for disease propagation, since mice in which B7 was 
not expressed in the CNS developed mild EAE with a short duration (177). In 
addition to their functions in recruiting and activating T cells, activated DC migrating 
from the inflamed CNS are likely to perpetuate inflammation by activation of fresh T 
cells in draining LN, and in some models this is thought to contribute to relapses by 
inducing epitope spreading of the response (178). 
CD8 T cells are not thought to be absolutely required for induction of EAE, since 
mice depleted of CD8 cells develop EAE after immunisation with encephalitogenic 
peptide, although the disease severity is decreased (179). However, CD8 cells are 
present in EAE and MS lesions (180-182), and transfer of activated MOG-specific or 
MBP-specific CD8 T cell lines into the relevant strain of mice can induce EAE 
(183, 184). Therefore it is likely that CD8 cells are not absolutely required for, but 
can contribute to, pathology. This appears be mediated in part through production of 
IFNy, since administration of blocking Ab against IFNy reduced the severity of 
disease induced by myelin-reactive CD8 cell lines (183). 
The role of B cells and Ab in the pathogenesis of EAE (and MS) is controversial. 
Early work using mice made deficient for B cells by injection of depleting anti-Pt Ab 
from birth suggested that B cells were required for induction of disease (185). 
However, the generation of jiMT mice, genetically deficient for the immunoglobulin 
t heavy chain and therefore lacking mature B cells in the peripheral circulation, 
showed that B cells are actually not required for induction of EAE, since these mice 
develop disease with normal kinetics. As described above, EAE can also be passively 
41 
induced by transfer of activated myelin-reactive CD4 cells alone, further suggesting 
that B cells are not required for initial induction of disease. However, B cells and Ab 
with specificity for epitopes from MBP and MOG have been reported in EAE, and in 
some MS patients (162, 186, 187). In one clinically defined group of patients Ab 
may in fact be a major contributor to demyelinating pathology (187). In mice and rats 
with EAE, Ab against similar epitopes have also been found, and in some cases these 
Ab are pathogenic (188, 189). Myelin-specific Ab may have pathogenic effects 
through enhancement of complement deposition, or opsonisation of myelin for 
uptake by macrophages (187, 190). Therefore, similarly to CD8 T cells, B cells are 
probably not required for EAE initiation, but myelin-reactive Ab may contribute to 
pathology. In the more complex clinical situation of MS, the contributions of these 
cells to disease may become more important in certain groups of patients. 
1.8. Breakdown of tolerance in induction of autoimmune disease 
1.8.1. Central tolerance 
Deletion of self-reactive T cells is vital in preventing autoimmunity, as evidenced by 
the spectrum of autoimmune diseases that occur in people with a mutation in the 
thymic transcription factor AIRE(7) (see section 1.2) Another function of thymic 
selection that may influence an individual's susceptibility to autoimmunity is the 
generation of regulatory T cells(74), see section 1.5.1. 
Similarly to MS, susceptibility to EAE is MHC-dependent, with additional genetic 
factors involved, so different strains of mice respond differently to the various 
peptides/proteins, and not all strains develop disease. This strain-dependence often 
appears to be related to efficiency of central tolerance. In SJL mice, a splice variant 
of proteolipid protein(PLP), DM20, is dominantly expressed in the thymus (11). 
DM20 lacks the PLP(139-151) epitope present in the full transcript of PLP expressed 
in the CNS, and the peripheral repertoire of SJL mice has a remarkably high 
frequency of PLP(139-151)-specific CD4 cells - as many as one in 20,000 CD4 
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cells! (11) Unsurprisingly, these mice are highly susceptible to induction of EAE 
with PLP(139-151), although they do not develop spontaneous EAE. 
Interestingly, a recent report by Reddy et al (191) suggests that SJL mice have a 
relative defect in the generation of PLP(139-15 1)-specific CD4CD25 regulatory T 
cells, fitting with the observations that CD4CD25 cell selection is based on 
recognition of self Ag in the thymus. BlO.S mice, which also have the H-2s 
haplotype, are resistant to EAE induction with PLP(139-151), and in the same study 
these mice were found to have higher frequencies of (PLP139-151)-specific 
CD4CD25 cells in their periphery. Although the authors state that expression of 
PLP is greater in the thymus of B10.S compared to SJL mice, they did not define 
levels of PLP(139-151) expression. 
In B1O.PL mice, EAE is normally induced by immunisation with the MBP peptide 
Ac(1-11). This peptide has extremely poor binding affinity for the H-2u MHC 
molecules present in B1O.PL mice. It is thought that the interactions of Ac(l-ll)-
reactive T cells with Ac(1-1 1) presented in the thymus do not reach sufficient avidity 
for deletion and these cells therefore escape into the periphery (8). 
Expression of MOG mRNA has been shown in medullary thymic epithelial cells (6). 
However, a comparison of the repertoire and the pathogenic potential of MOG-
reactive T cells in the periphery of MOG and wildtype mice on the C57BL/6 
background suggested no differences (192). Therefore central tolerance mechanisms 
appear ineffective for the deletion of MOG-reactive T cells. 
1.8.2. CNS entry - breakdown of clonal ignorance 
Clonal ignorance relies on self-reactive T cells not coming into contact with their 
cognate Ag. The CNS is protected by the blood-brain-barrier (BBB), a physical 
barrier consisting of endothelial cells with tight junctions that are thought to prevent 
access of immune cells into the brain and spinal cord (13). However, naïve T cells 
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have been observed in the CNS, in a model in which T cells are transgenic for MBP-
specific TCRs (16). In this case, the MBP-specific T cells appear to have undergone 
tolerance induction in the CNS, while non-myelin specific cells found in the CNS 
were still able to respond to Ag (16). Additionally, LeFrancois' lab have reported 
the migration of activated/memory (non-myelin-reactive) T cells throughout the 
body, including the CNS, although entry into the brain was delayed in comparison to 
other sites such as the lungs (193). Thus, the BBB does not appear to provide 
complete protection from lymphocyte surveillance. 
In most models of EAE, pertussis toxin (PTx) must be given around the time of 
immunisation for full EAE induction. PTx may serve 2 main purposes in EA-E. First, 
it is thought to break down the blood:brain barrier to allow lymphocyte migration 
into the CNS (194, 195). Secondly, and perhaps more importantly, it may act as an 
adjuvant to activate resident APC within the CNS (196). These would then produce 
chemokines to recruit T cells, and also upregulate expression of MHC and 
costimulatory molecules to induce effector functions and retain T cells once in the 
CNS. 
The requirement for T cell activation and recruitment by innate cells in the CNS has 
been demonstrated by Darabi et al (175). In this study it was shown that an 
intracranial injection of the microbial adjuvant CpG allowed the localised 
recruitment of MOG(35-55)-specific CD4 cells after subcutaneous immunisation 
with MOG(35-55) in CFA, in the absence of PTx. This suggested that localised 
activation of APC by an inflammatory stimulus within the CNS was sufficient to 
recruit and maintain activated myelin-reactive T cells, although in this model the 
inflammation remained localised to the site of the initial CpG innoculation. Once the 
initial inflammation is established, it is likely that the damage caused by T cells and 
mononuclear cells will be sufficient to propagate the response without additional 
adjuvant. 
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Chemokines are small soluble molecules that form gradients along which cells 
bearing appropriate receptors migrate (197). The chemokine monocyte 
chemoattractant protein-1 (MCP-1) is produced by several cell types in response to 
inflammatory stimuli, and MCP-1 mRNA is upregulated in CNS lesions of mice with 
EAE as well as in MS (198). The ligand for MCP-1, CCR2, is expressed by activated 
T cells and monocytes (199). Mice deficient in either MCP-1 or CCR2 are relatively 
resistant to EAE induction by active immunisation with encephalitogenic peptides, or 
by transfer of activated encephalitogenic T cells from wildtype mice (200, 201). This 
resistance is associated with a failure to recruit activated T cells and 
monocytes/macrophages to the CNS despite the "leaky" blood:brain barrier induced 
by administration of PTx. Therapies that target effector cell migration to the CNS, 
such as anti-MCP-1 or anti-VLA4, reduce the severity of EAE (202). Thus, it 
appears that the physical barriers protecting the CNS can be overcome during 
inflammation through increased expression of chemokines and T cell-stimulating 
molecules. 
1 .8.3. Molecular Mimicry and Generation of Cryptic Epitopes by 
Pathogens 
The effects of PTx during the induction of EAE could feasibly be induced by an 
infectious agent in the CNS. Indeed, chronic infection with the murine neurotropic 
pathogen Theiler's virus has been reported to result in the activation of myelin-
reactive CD4 cells in some mice (203, 204). Several human autoimmune disorders, 
including diabetes and MS, are suspected to have an infectious link. However, none 
has been conclusively proved; this may be due to the lag between the activation of 
the response and the onset of disease symptoms and diagnosis (205). Infection 
stimulates strong priming conditions through activation of APCs, and as already 
discussed may lead to presentation of Ag and epitopes not usually encountered. 
Under very strong stimulating conditions the high activation threshold of T cells with 
low affinity receptors can be reached, and tolerance based on low affinity for self 
may thus be overcome (206). 
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Another possible mechanism of tolerance breakdown caused by infectious organisms 
is molecular mimicry. In this case, T cells specific for Ag from the invading 
pathogen also cross-react to self Ag, and when activated during the infection may 
additionally attack the tissue(s) expressing that self Ag (207, 208). Pathogens exploit 
molecular mimicry to survive since cells tolensed against self may not be able to 
respond to homologous Ag on foreign organisms. Again, there is no clear evidence 
for a role for molecular mimicry in the pathogenesis of MS (205). 
While T cells may be able to recognise different epitopes within a protein, expression 
of specific proteases in the thymus may allow dominant expression of one epitope, 
and therefore only T cells recognising this dominant epitope will be deleted. This has 
been shown to be the case for MBP (209, 210). This does not normally lead to 
autoimmunity, since the subdominant epitopes will not be presented by DC. 
However, it has been recently suggested that viruses may alter Ag processing 
enzymes to prevent presentation of their own viral antigenic epitopes, and in so 
doing may also encourage presentation of cryptic self epitopes (17, 206). 
1 .8.4. Defects of regulatory T cells 
There is now much evidence for the ability of CD4CD25 regulatory T cells to 
control spontaneous autoimmune activation in various models. As already described 
(section 1.5.4), the crucial role of CD4CD25 cells has been demonstrated in human 
patients with IPEX, and in scurf' mice, which have a mutation in the gene for FoxP3 
and therefore fail to effectively generate CD4CD25 regulatory T cells. This has 
been one of the most conclusive pieces of evidence for the central role of regulatory 
T cells in preventing peripheral autoimmunity in humans. 
Depletion of peripheral CD25 cells in mice has been shown to increase their 
susceptibility to autoimmunity (127), and mice deficient in CD25 cells due to 
genetic deficiencies in molecules such as IL-2, FoxP3 or CD28 develop spontaneous 
autoimmunity (94). 
In patients with multiple sclerosis and type-I diabetes, a decrease in the proportion 
and/or function of peripheral regulatory T cells has been suggested to contribute to 
disease (211, 212). Likewise, a proportion of NOD mice spontaneously develop 
type-I diabetes and other autoimmune conditions, and this strain has been reported to 
have a defect in thymic generation of Tregs (48, 213), although this is not the only 
immune defect in these mice. 
In a study of juvenile idiopathic arthritis (JIA), the numbers and functional 
characteristics of CD4CD25 cells in the joints of patients was found to inversely 
correlate with severity of disease progression in some patients (214). However, 
another study on different types of rheumatoid arthritis found that while CD4CD25 
cells with reglulatory potential were enriched in inflamed joints of most patients, this 
did not appear to directly correlate with reduction in disease (215). Ehrenstein et al 
have suggested that TNF(x may inhibit the ability of CD4CD25 cells to suppress 
effector cytokine production by T cells and monocytes in arthritis patients (216), 
although these studies compared CD4CD25 cells from patients before and after 
treatment with anti-TNFa, so the effect may be due to general inflammation rather 
than a direct effect of TNFa on Tregs. Defects in regulatory T cell numbers and/or 
function are now widely suspected, if not yet demonstrated in all diseases, to play a 
part in the development or progression of autoimmunity in humans. 
1.9. Natural and therapeutic mechanisms of control of 
autoreactive cells 
1.9.1. Cytokines in EAE 
1.9.1.1. Th11Th2 
The role of various cytokines in EAE induction and resistance has been intensively 
studied. Immunisation with encephalitogenic Ag in CFA induces a Thi response, and 
the cells able to transfer EAE are generally Thi in phenotype (217). Thi cells 
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produce IFNy and TNFa: cytokines that activate macrophages to increase production 
of nitric oxide and other metabolites involved in pathogen killing as well as 
expression of MHC II molecules (33). 
IL-12 has long been thought to be required for Thl polarisation (33). Fitting with a 
Thi-driven disease, IL-12 deficient mice are resistant to EAE induction (218), and 
treatment of mice with Ab against IL-12 ameliorates EAE (219). However, IL-
12p35-/- mice are susceptible to induction of EAE (220), and IL-12RI32 mice 
unexpectedly developed EAE with earlier onset and increased severity (221). Recent 
studies on IL-23 have revealed that some of the results on the importance of IL- 12 in 
EAE may have been misinterpreted. IL-12 and IL-23 both use the IL-12p40 subunit 
in combination with separate second subunits (p35 for IL-12 and p19 for IL-23), and 
the IL-12 and IL-23 receptors also share the IL-12R131 subunit (222). Thus, studies 
finding that mice deficient in IL-12p40 are resistant to EAE induction have not taken 
into account the effects of IL-23 deficiency. Cua et al dissected the roles of IL-12 
and IL-23 in EAE using p19, p35 -/- and p40-/- mice in combination with IL-23-
expressing vectors delivered systemically or into the CNS (223). In this study, IL-12 
did not appear to be required for Thi priming of MOG-reactive T cells in the LN, 
rather IL-23 production in the CNS (most likely by resident microglia and 
infihitrating macrophages) was essential for EAE induction. 
Also surprising was the finding that IFNy-knockout (IFNy) mice develop normal 
EAE after immunisation with myelin Ag (224). It may be that in IFNy-deficient mice 
TNFa can compensate for IFNy in functions such as activation of macrophages. 
Perhaps even more surprisingly, IFNy mice exhibited an impaired recovery, 
suggesting a more important role for IFNy during recovery (224). This was attributed 
to IFNy—mediated induction of macrophage nitric oxide synthetase, and production 
of nitric oxide in the periphery and in the CNS. In vitro nitric oxide was found to 
inhibit lymphocyte proliferation. In support of this hypothesis, a separate study 
reported a correlation between levels of serum nitric oxide intermediates and 
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resistance to reinduction of EAE in Lewis rats that had recovered from EAE (225). 
Induction of apoptosis by IFN'y has also been reported to limit the size or duration of 
immune responses (226), although this has not been directly investigated in ENE 
studies. 
Deviation of the T cell response to a Th2 phenotype has been suggested to be 
responsible for resistance to EAE induction in male SJL mice (227), and injection of 
CNS-specific Th2-type cells (producing IL-4 and IL-b) can prevent EAE induction 
(227). Th2 cells specific for non-myelin Ag (keyhole limpet haemocyanin, KLH) 
were also found to prevent EAE induction if KLH was given at the same time. Also, 
IL-4 treatment ameliorated disease severity by inducing Th2 cells in an MBP-
induced model of EAE(35), and IL-13-producing vector cells decreased EAE 
incidence and severity in a rat model(228), probably by decreasing macrophage 
activation. In a transgenic mouse in which most T cell receptors are specific for MBP 
Ac(l-1l), recovery from EAE induced by Ac(1-11) was associated with a switch 
from a Thi (IFNy, TNF(x) to a Th2/Th3 cytokine profile (IL-b, IL-4, TGFI3) in both 
LN and CNS(229). 
However, MBP-specific Th2 cells can induce EAE when transferred into RAG' 
hosts (230). IL4 mice do not exhibit increased disease severity and undergo normal 
recovery (231). Finally, an attempt to therapeutically deviate the anti-myelin 
response towards Th2 in primates resulted in severe encephalomyelitis (232), so this 
approach as a therapy has to be viewed with caution. 
1.9.1.1. 	IL-10 
IL-10 has pleiotropic downregulatory effects on cells of the immune system. IL-10  
receptor is expressed by all haematopoietic cells, and expression levels may be 
regulated by activation status, with cells such as macrophages upregulating IL-bR 
upon activation (233). Treatment of DC with IL-10, before or during their maturation 
with activation stimuli such as TNIFa or LPS, rapidly decreases Ag processing and 
expression of MHC and costimulatory molecules on the surface of APC, to reduce 
further activation of T cells (234). IL-10 appears to be required for the induction and 
effector stages of some regulatory T cells (TrI cells), although whether the I cells 
are directly affected or the IL-10 acts via the APC (or both) is still unclear (55). IL-
10 can directly turn off cytokine production (e.g. IFN'y) in pre-activated effector T 
cells, as well as inhibiting the proliferation of naïve T cells under what would 
otherwise be priming conditions (233). Macrophage effector functions are also 
silenced by IL- 10 (233). 
IL-10 appears to play a central role in controlling severity and mediating remission 
from EAE, although the exact mechanisms for this remain to be clarified. IL-10 
mice develop EAE of increased severity and fail to recover (231, 235). Both IFNy 
and IL-10 are detectable in the CNS of mice with EAE, and a decrease in IFNy 
concomitant with increasing IL-10 during the acute phase appears to correlate with 
remission (229, 236, 237). 
Various interventions that utilise IL-10 can prevent EAE induction. Transgenic 
expression of IL-10 under control of the class II promoter is sufficient to prevent 
EAE induced by active immunisation or passive transfer of Thi cells, in the absence 
of endogenous IL-10 production (238). In these mice, the prevention of EAE 
appeared to correlate with a suppression of effector T cell function rather than 
inhibition of Thi cell induction. Activation of non-neuroantigen-specific Th2 cells 
during the induction of EAE can also give some protection, and this is likely to be 
mediated through production of IL-10 in the LN (61). Mathisen et al have 
demonstrated that PLP (139-151)-specific memory cells can be transduced to express 
IL-10 under control of the IL-2 promoter, and that this Ag-specific induction of IL-
10 can give protection when attempting to induce EAE with PLP (139-151) (239). 
These cells also accelerated recovery when given after the onset of clinical 
symptoms. IL-10-producing transfected fibroblasts could inhibit EAE when 
inoculated into the brain (240). However, in this study, intracranial delivery of IL-10 
in protein form or expressed by an adenoviral vector were not efficient in inhibiting 
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disease despite producing apparently similar levels of IL-10 to the fibroblasts (240). 
In contrast, Cua et al found that intracranial, but not systemic, administration of 
replication-deficient adenovirus IL-i 0-transfected vectors was effective in preventing 
EAE in a different mouse model of EAE (241). EAE could also be prevented by 
giving OVA-specific Trl cells systemically, but only when OVA was also injected 
intracranially, suggesting that CNS localisation of IL- 10 production is required (62). 
Systemic administration of IL-10 protein has also given conflicting results despite 
apparently similar protocols: two groups have reported suppression of EAE induction 
(242, 243), while two have reported no effect (241, 244). Overall then, there is 
conflicting evidence as to the ability of IL-10 to therapeutically mediate resistance to 
EAE, apparently depending on unidentified factors related to the model used and 
mode of delivery of IL- 10 (245). 
Taken together, the various studies looking at IL-10 in EAE suggest that IL-10  
production increases with, and is required for, recovery. Similarly to other tolerance-
inducing protocols using IL-b, EAE can be prevented by strategies that increase IL-
10 levels during the initial induction period of EAE (61, 238), and these probably 
work by downregulating APC activation as well as preventing Thi effector cytokine 
production. However, for full amelioration of disease, intracranial delivery of the 
exogenous IL- 10 may be required (241), correlating with the increased IL- 10 mRNA 
observed in the CNS during the recovery phase of EAE (236). 
1.9.1.1. TGF/3 
Levels of TGFI3 have also been found to increase in the CNS with recovery(229). 
EAE can be ameliorated by administration of soluble TGFI3, while administration of 
blocking Ab specific for TGFJ3 exacerbated disease(246, 247). Induction of oral 
tolerance using MBP resulted in MBP-specific TGF3-producing cells with the 
capacity to prevent EAE (these cells also produced IL-10)(248). TGFI3 has 
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downregulatory effects on both T cells(249, 250) and macrophages(25 1), but, as is 
the case for IL-b, the specific in vivo targets during EAE have not been identified. 
1.9.2. Regulatory  cells in EAE 
There has been much excitement in recent years over the potential of both naturally 
occurring and experimentally induced regulatory T cells to prevent or treat 
autoimmune diseases. In the mouse model of induced diabetes used by Green et al, 
CD4CD25 cells expand in the pancreatic lymph nodes of mice in the early stages 
of developing diabetes, before onset of disease, and very small numbers of these cells 
are able to delay diabetes onset in naïve recipients (122). CD4CD25 cells with 
regulatory function have been found to be enriched in the joints of arthritis patients 
(214, 215). However, in both these studies, the accumulation of CD4CD25 cells 
did not appear to prevent or cure disease. 
Relatively few studies have investigated the ability of regulatory T cells to 
therapeutically mediate recovery once an autoimmune response has been initiated. 
Two recent studies showed that CD4CD25 cells that had been activated and 
expanded in vitro could halt the progression of diabetes in the NOD mouse model, if 
given at the very onset of clinical signs (153, 154). These studies utilised islet-
specific transgenic T cells, and it has yet to be determined whether the approach of 
expanding Ag-specific Tregs from a polyclonal population can be effective 
therapeutically. Colitis is an inflammatory model with similarities to autoimmune 
inflammation, since the target Ag are commensal bacteria of the gut (252). Using this 
model, two groups have shown that CD4CD25 cells transferred after inflammation 
is established are able to mediate resolution of inflammation and restoration of 
normal intestinal architecture (121, 123). 
Whether Tregs can and do mediate control of established autoimmune responses 
under physiological conditions in vivo remains unclear. Despite the fact that the 
source of Ag cannot normally be cleared in an autoimmune response, many 
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autoimmune conditions show periods of decreased and enhanced disease signs, for 
example, MS patients usually initially experience periods of remission and relapses 
(158). This suggests that there are fairly successful attempts to regain control of the 
autoimmune cells, and regulatory T cells seem prime candidates to be involved. 
Some time ago it was reported by Swanborg and colleagues that TGF3-and IL-4-
producing CD4 "suppressor" cells are induced during recovery from EAE in Lewis 
rats (253, 254), although suppression is likely to be mediated through TGFI3 rather 
than IL-4. These findings are analogous to the report from Weiner's group showing 
enhanced TGFI3 (and IL-10 and IL-4) production in the LN and CNS of MBP TCR 
transgenic mice during recovery (229). In Swanborg's studies, these "suppressor" 
cells appear in the LN and spleen during the recovery phase and can transfer 
protection against active but not passive EAE induction in naive recipients for up to 
four months after recovery. This is in contrast to Ellerman et al, who reported the 
isolation of suppressor CD4+  T cells from LN cells of recovered Lewis rats: in this 
case the cells were able to prevent EAE induction when co-transferred with 
encephalitogenic MBP-specific T cells (255). In Swanborg's studies, the suppressor 
cells were able to inhibit in vitro production of IFN7, in response to MBP, but did not 
affect IL-2 production (256), unlike the cells described in more recent studies on 
regulatory T cells. In vitro inhibition of cytokine production appeared to be TGF-
dependent (253). Interestingly, both CD4 cells and B cells were required for 
protection (257). The characteristics of these cells and how they are induced have yet 
to be further described. 
In the B1O.PL/J mouse strain, EAE is induced by immunisation with MBP Ac(1-1 1). 
Sercarz et al have reported that recovery in these mice is associated with the 
emergence of "regulatory" CD4 and CD8 cells (258, 259). However, the CD4 
cells do not possess the typical characteristics that have been described for 
CD4CD25 or Trl regulatory T cells: they are not anergic and appear to be Thi in 
phenotype (260). They recognise epitopes from the encephalitogenic TCR rather than 
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myelin Ag (258). Thus, it appears that stimulation of an immune response against 
peptides from the dominantly used TCRs (V138.2) in this model of EAE may help 
downregulate the response, possibly through apoptosis of the encephalitogenic cells, 
although this has not been determined. Indeed, "TCR vaccination" with these 
peptides has proved effective in preventing and treating EAE in this model (261). 
Thus, an autoimmune response against TCRs may prove fortunate in some instances 
by downregulating a pathogenic response. 
The high susceptibility to EAE and poor recovery of IL-10 mice (231) suggested 
classical Treg involvement, although this has yet to be shown. Barrat et al have 
shown that IL-10 producing Trl cells are capable of preventing EAE (62). They 
generated ovalbumin (OVA)-specific IL-10-producing TrI cells in vitro by culture of 
transgenic DOl 1.10 T cells with OVA in the presence of the immunosuppressive 
drugs Vitamin D3 and Dexamethasone. These cells were able to prevent onset of 
EAE when transferred into naive mice. The presence of OVA in the CNS, i.e. at the 
site of pathogenic effector cell action, was absolutely required for protection, 
suggesting downregulation of effectors by IL-10 produced in the CNS, rather than 
prevention of priming in the LN. It has also been demonstrated that IL- 10-producing 
Th2 cells specific for keyhole limpet haemocyannin (KLH) could protect naïve mice 
against EAE if KLH was given subcutaneously (61). Thus, IL-10 producing cells are 
capable of affecting EAE, and since IL-10 increases in the CNS during recovery 
(229, 236) it appears likely that this may be a mechanism involved in mediating 
natural recovery. 
Lafaille et al have demonstrated a role for both CD4CD25 and CD4CD25 cells in 
preventing spontaneous autoimmune cell activation using mice with transgenic TCRs 
for the immunodominant epitope of myelin basic protein (MBP), Ac 1-1 1 (47, 262, 
263). These mice develop EAE spontanteously when crossed onto a RAG 
background (100% of T cells have the transgenic receptor on this background). On a 
wildtype (RAG-sufficient background), a limited amount of endogenous TCR 
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rearrangement is known to occur, and these mice do not develop spontaneous disease 
(47, 262, 263). Transfer of CD4CD25 cells from wildtype TCR transgenic mice are 
able to protect RAG -'- TCR transgenic mice from spontaneous disease, if given at an 
early age (264). Analysis of protective CD25 cells showed that only dual-receptor 
cells bearing both the transgenic MBP-specific receptor and an endogenously 
rearranged receptor were capable of preventing disease. It is thought that the 
endogenously rearranged receptor is required for regulatory cell selection in the 
thymus, while the transgenic TCR receptor confers the correct specificity for 
induction of effector function after transfer. 
In two separate reports, high numbers of CD4CD25 cells from naïve syngeneic 
mice could decrease the severity of disease when transferred prior to EAE induction 
(49, 50). This protection required IL-10 production by CD4CD25 cells (50), and 
appeared to be mediated within the LN since transferred cells were not observed in 
the CNS (49). The numbers transferred would lead to a marked increase in the 
frequency of CD4CD25 cells in recipients, and it is assumed that this effectively 
raised the threshold for activation of naïve autoreactive T cells. Conversely, 
depletion of CD25 cells prior to EAE induction resulted in increased disease 
severity in two reports (50, 265), but not a third (142). Taken together, these studies 
demonstrate a role for CD4CD25 cells in regulating the activation of autoreactive 
cells, as has been demonstrated for other autoreactive T cells (266) as well as the 
activation of T cells specific for foreign Ag (155). However, they do not address the 
natural role of CD4CD25 cells once EAE has been established. 
1.9.3. "Regulatory" B cells? 
Studies on the role of B cells in influencing T cell responses have not always given 
clear answers. There is some evidence that B cells may preferentially enhance Th2 
responses through expression of ligands such as 0X40(267). B cells are also capable 
of producing a number of cytokines: B cell production of IL- 10 has been documented 
under Thi- and Th2-activating conditions in vitro (268). Studies using B cell 
deficient mice have generally reported either a decrease in the overall CD4 T cell 
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response or no effect when immunising with nominal Ag or using infectious models 
(269-272). However, findings in EAE suggest the opposite: that B cell deficiency 
results in an enhanced and prolonged Thi response with impaired recovery (59, 273), 
suggesting that B cells act to downregulate rather than enhance the T cell response. 
Fillatreau et al used bone marrow chimaeras to further define the role of B cell IL-10  
in EAE. In these chimaeras deficiency of IL-10 production was restricted to B cells 
by reconstituting lethally irradiated mice with a mixture of VtMT and IL-1 0 -1-  bone 
marrow (59). When EAE was induced in these chimaeras, they developed non-
remitting EAE as observed in p.MT mice. The normal (remitting) disease course 
could be restored by the transfer of wildtype (I L-10-sufficient)B cells prior to 
immunisation. Chimaeras in which B cells were deficient for CD40 also failed to 
recover from EAE, suggesting that B cell activation via CD40 is important for 
induction of IL-b. 
The disparity in the observation on the effects of B cell deficiency may reflect 
differences in the type of model used, and indeed there is further evidence for B cells 
playing a downregulatory role in autoimmune and infla'mmatory disorders. Induction 
of IL-10-producing "regulatory" B cells has been reported in a chronic inflammatory 
gut model (TCRa mice), in which prevention of disease progression was dependent 
on these cells arising during the acute phase of inflammation (274). In this model, the 
B cells expressed CD1d, a non-classical MHC I molecule required for presentation of 
lipid Ag to NKT cells, and it was suggested that interaction with NKT cells 
augmented IL-10 production, leading to downregulation of IL-1. In the EAE model, 
it has been reported that, while NKT cell activation (using aGalCer) could protect 
mice against EAE induced by MOG(35-55) in an IL-b- and IL-4-dependent manner, 
CDld mice did not develop the chronic disease seen in j.iMT mice (275). In a 
mouse model of arthritis Mauri et al have shown that production of IL- 10 by splenic 
B cells from arthritic mice can be induced by stimulation with the immunising Ag, 
type II collagen (CII), and anti-CD40 (60). These in vitro stimulated cells could also 
protect naïve mice from arthritis induction in an IL- 10 dependent manner. Analagous 
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to the findings in EAE (59), CD40 ligation and BCR stimulation were required for 
induction of IL-10, although additional unidentified T cell-mediated signals were 
also required for protection from arthritis (60). Therefore in situations of chronic 
inflammation, or prolonged antigen stimulus, the regulatory role of B cells may 
become important. 
B cells efficiently present specific Ag to CD4 cells, principally to gain survival and 
differentiation signals (69). During this B:T interaction, the opportunity also arises 
for B cells to influence the nature of the T cell response. It is thought that Ag 
presentation by B cells may induce a Th2 phenotype in recently activated T cells, 
through binding of ligands such as ICOS:137h or 0X40:OX40L, and also lack of IL-
12 (267, 276, 277). However, in our experiments, spleen and lymph node in vitro 
cytokine recall responses show decreased Ag-specific IFNy but little upregulation of 
IL-4 in recovered mice compared to mice with EAE ((59) and unpublished 
observations). Since B cells appear to regulate the ongoing response rather than 
preventing induction of Th 1 cells in EAE, it seems more likely that IL-10 produced 
by B cells may directly reduce IFNy production in already polarised Thl cells. The 
targets of B cell IL- 10 have thus far not been identified. 
1.10. Summary 
Regulation of immune responses, whether preventing activation of inappropriate 
responses or controlling the size of useful responses, is vital for avoiding damage to 
host tissues. There are many ways the immune system can regulate responses and a 
better understanding of the specific mechanisms involved in regulating inappropriate 
responses, and why they sometimes fail, will allow us to develop improved 
therapeutic and preventative strategies for autoimmune disease. EAE is a CNS-
targeted autoimmune disease, driven by Thi cells reactive for myelin components. In 
some models of EAE spontaneous remission occurs, indicating successful control of 
pathogenic cells and inflammation. While the EAE model has been used for many 
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years, the mechanisms allowing recovery from CNS-targeted autoimmune disease 
have still not been fully identified. IL-10 clearly plays a major role in the recovery 
process, and B cells appear to be one of the vital sources of IL-10 during recovery, 
although a role for regulatory T cells has also been proposed (231). 
1.11. AIMS of PROJECT 
The aim of this project was to further elucidate the mechanisms behind the natural 
recovery in the MOG(35-55)-induced EAE model, focussing particularly on IL-10  
production, with the following objectives: 
. To further characterise the B cells responsible for mediating recovery via IL-
10 production. 
. To test the ability of lymphoid populations from recovered/recovering mice 
to transfer protection to naïve recipients in the MOG(35-55)-induced EAE 
model. 
To analyse the cell populations producing IL-10 in the CNS during recovery. 
. To identify whether regulatory CD4 cells play an additional role in recovery 
from EAE. 
W. 
2. Materials and Methods 
2.1. General reagents 
2.1.1. Wash Buffer 
RPMI 1640 medium containing 25mM HEPES buffer (Gibco, Life Technologies, 
Paisley, UK), 
2mM L-Glutamine (Gibco), 
100U/ml Penicillin and 100tg/ml streptomycin (Gibco), 
5x10 5M 2-mercaptoethanol (Gibco) 
2.1.2. RPMI-5 tissue culture medium 
Wash Buffer as above, with the addition of 5% heat-inactivated foetal calf serum 
(FCS) (Sigma, Poole, UK) 
2.1.3. MACS buffer 
HANKS Balanced Salt Solution (Sigma) 
2% heat-inactivated FCS (Sigma), 
100U/ml Penicillin and 100tg/ml Streptomycin (Gibco) 
2.1.4. FACS buffer 
PBS, 
2% heat-inactivated FCS (Sigma), 
0.05% sodium azide (Sigma) 
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2.2. Mice 
p.MT (278), IL-10 (279), OT-11 (280) and Ly5.1 congenic mice, all on the C57/136 
(H2b) background, as well as C57/136 mice were bred and maintained under specific 
pathogen free conditions in the Institute of Immunology and Infection Research, 
University of Edinburgh. All mice were sex-matched within experiments, and used at 
6-10 weeks of age. 
2.3. Antigens 
MOG(3 5-55) peptide (MEVGWYRSPFSRVVHLYRNGK) and OVA(323 -339) 
peptide (hereafter referred to as pOVA) were prepared at the Advanced 
Biotechnology Centre, Imperial College, London, UK. Recombinant extracellular 
domain of mouse MOG (rMOG) was provided by Dr S. Anderton (59). 
2.3.1. Production of MOG-biotin conjugate for identifying MOG-
specific B cells by FACS 
rMOG was biotinylated by adding 37.5.ti of 1mg/mi biotin (Pierce, Cheshire, UK) 
(in ddH20) to 500p1 of 1mg/mi rMOG (in PBS), mixing gently, and incubating at 
room temperature for 30 minutes. The protein was then dialysed in PBS at 4 0C, 
changing the PBS buffer three times, to remove any excess biotin. 
2.3.2. Testing of MOG-biotin as a FACS staining reagant 
The MOG-biotin was tested by incubating single cell suspensions, obtained from the 
spleen or LN of mice with EAE or from naïve mice, with anti-B220PE and different 
concentrations of MOG-biotin in FACS buffer for 20-30 minutes, followed by 
washing and staining with SA-APC for 20 minutes. As detailed in figure legends 
(Figure 3-6) and text (section 3.2.4), different approaches were attempted to decrease 
the background staining with this conjugate. 
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2.3.3. Production of HEL-MOG(35-55) conjugate 
The EDC kit (Pierce) was used to couple Hen Egg Lysozyme (HEL) protein (Sigma) 
and MOG(35-55) peptide, following manufacturer's protocol. lOmg/ml HEL and 
4mg/ml MOG(35-55) were prepared in buffer containing 0.1M 2-[N-
morpholino]ethane suifonic acid (MES) (Sigma), made up in ddH 20, pH 4.7. Two-
fold serial dilutions of MOG(35-55) were made, down to 0.25mg/mi, in MES buffer. 
500ti of each peptide concentration was added to 200p1 HEL, i.e. individual 
reactions contained: A: 2mg HEL + 2mg MOG(35-55) 
2mg HEL + ling MOG(35-55) 
2mg HEL + 0.5mg MOG(35-55) 
2mg HEL + 0.25mg MOG(35-55) 
2mg HEL + 0.125mg MOG(35-55) 
1 -Ethyl-3 -(3 -Dimetyhlaminopropyl)carboiimide Hydrochloride (EDC) was prepared 
at 10mg/mi in ddH20, and 100tl added to each reaction immediately (EDC is labile 
once solubilised). Samples were mixed gently and incubated for two hours at room 
temperature in the dark. 
For purification of conjugate, lOmi Dextran de-salting columns (provided in kit) 
were first prepared by washing with 50m1 purification buffer (50mM sodium 
phosphate, 150mM sodium chloride, pH7.2). The conjugate sample was then added, 
allowed to run through, and 0.5m1 purification buffer at a time added and run through 
while collecting 0.5m1 fractions. The absorbance (A280) of the collected fractions 
was measured by spectrophotometry. Positive fractions were checked for presence of 
protein bands of the correct size (using HEL as positive control) on protein gels, then 
pooled and final conjugate concentrations calculated using the BCA protein 
estimation kit (Pierce). Concentrations: A: 1.28mg/mi; B: 0.66mg/mi; C: 0.7mg/mi; 
D: 0.42mg/mi; E: 0.7mg/mi. 
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2.3.4. Testing HEL-MOG(35-55) conjugate 
B cells were prepared from MD4 mice, which bear transgenic BCR specific for HEL 
(281) (provided by Dr Andy Knight) or B6 mice by CD43-based negative selection 
(section 2.5.2). Purity of B cells used in this assay was greater than 97%. MOG(35-
55)-reactive cell lines were provided by Claire Sweenie and used to detect 
presentation of MOG(35-55) by B cells in these assays. 3x10 4 T cells were cultured 
in triplicate with 2x10 5 B cells and a dose range of conjugate, or uncoupled HEL and 
MOG(35-55) in RPMI-5 tissue culture medium for three days. 0.5p.Ci tritiated 
thymidine was added for the last 18 hours of culture and assays were harvested using 
a liquid scintillation 13-counter (Wallac). 
2.4. In vivo manipulations 
2.4.1. EAE induction 
B6 mice were immunised in both hind legs with a total of lOOjg MOG(35-55) per 
mouse in complete Freund's adjuvant (CFA) containing 500gIml of heat-killed 
Mycobacterium tuberculosis H37Ra (Sigma). 200ng of pertussis toxin (ECACC, 
Dorset, UK) in 0.5m1 PBS was given intraperitoneally on the same day and two days 
later. Mice were monitored daily for clinical signs of EAE and scored as follows, 0: 
no signs; 1: flaccid tail, 2: imbalance and impaired righting reflex, 3: partial hind 
limb paralysis, 4: complete hindlimb paralysis, 5: partial forelimb paralysis, 6: 
moribund or dead. Mice scored as grade 5 for two consecutive days were culled. 
Hydrated food was provided to cages containing mice at grade 3 or above to afford 
easier access to food and water. 
2.4.2. Reinduction of EAE 
For reinduction experiments in chapter 3, mice were immunised as above with 1 00tg 
MOG(35-55) in CFA over two sites in the flank, and 200ngIml Pertussis toxin given 
on days 0 and 2. In chapter 5, mice were immunised with 100tg MOG(35-55) in 
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incomplete Freund's adjuvant (IFA) rather than CFA, as above. Mice were 
monitored and scored as above. 
2.4.3. Statistics 
Statistical analysis of EAE disease scores was performed using the Mann Whitney 
test (when the experiment contained two test groups) or the Kruskall Wallis test 
(when more than two experimental groups were compared). The non-parametric rank 
sum test was used because the measurements of EAE scores are discrete. 
One flaw in the method used to compare groups in this project was that individual 
disease scores throughout the experiment timecourse were compared rather than 
cumulative disease scores (area under the curve of individual mice), and these are 
clearly not independent measurements. However, due to the small n number in 
individual experiments (4-7 mice/group), and the relatively weak statistical power of 
rank sum tests, when several experiments shown in this thesis were analysed by 
comparing cumulative scores in a rank sum test they were apparently not significant. 
For example, figures 34A and 3-4, which show a clear difference in mean disease 
severity between groups, did not reach statistical significance when comparing area 
under the curve of individual mice. Increasing the size of groups would have 
overcome the weak statistical power of this method, but this was not economically or 
ethically feasible. Therefore, comparing individual disease scores by a rank sum test, 
while keeping greater emphasis on the biological significance rather than statistical 
sigfnificance of any result, was the best compromise for analysing results of 
experiments using EAE. 
In published reports of EAE data from this lab the Mann Whitney test has been 
standardly used and accepted (20, 59). Analysis of results in the EAE field is 
generally problematic, and some labs use parametric tests for analysis of EAE (142, 
191, 231), which are inappropriate since the data are discrete, or choose not to 
analyse their data statistically (183). 
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For statistical analysis of percentage of CD4CD25 cells or percentage of IL-10 +  
cells at different time points in chapter 4 and percentage suppression by CD4CD25 
cells in chapter 5, an unpaired student's t test (a parametric test) was used since these 
are indiscrete variables. 
2.4.4. Cell transfers 
For all experiments in which cells were transferred into mice, the prepared cells were 
resuspended in Dulbecco's PBS (Gibco) and filtered to remove any clumps. Cells 
were injected in a final volume of 200p.l intravenously into the tail vein of pre-heated 
mice. 
2.4.5. In vivo depletion of CD25 cells 
ling per mouse of anti-CD25 (PC61) or rat IgGi (MAC49) was given 
intraperitoneally in PBS (average volume 500p.l per mouse). Depletion of peripheral 
CD25 cells was confirmed by taking a small (< 50.xl) sample of blood from the tail 
and staining for FACS with anti-CD4-APC and anti-CD25-FITC. Importantly, the 
mAb clone used for anti-CD25 FACS staining was 7D4 not PC61. 
2.4.6. Production of Ab for in vivo depletion experiments 
The PC61 hybridoma that produces anti-CD25 mAb (rat IgGi) was a kind gift from 
Dr. Fiona Powne, University of Oxford. The MAC49 hybridoma (that produces anti-
phytochrome mAb, rat IgG 1) was obtained from the European Collection of Cell 
Culture, Wiltshire, UK and used as an isotype control Ab. Both hybridomas were 
grown initially in RPMI-5 medium in 1 Oml culture flasks (Costar) until sufficient 
cell density was achieved. 2.5x10 7 hybridoma cells in 15ml cultivation medium were 
inoculated into the cultivation chamber of an Integra CL 1000 (Integra Biosciences), 
and 1000ml nutrient medium was added to the nutrient chamber, as per instructions. 
On day 7, and every 3 days thereafter, 7.5m1 of the cultivation medium was removed 
and replaced with fresh medium, and the entire nutrient medium was exchanged. The 
removed medium was centrifuged at 2000rpm for 5 minutes to remove hybridoma 
cells and the supernatant stored at —20 0C until Ab purification. 
Antibodies were purified using an Aktaprime automated chromatography system 
(Amersham Biosciences) with a 5m1 High Trap protein G column (Amersham 
Biosciences). Antibody supernatant to be purified was passed through a 4micron 
filter. All buffers and wash solutions were passed through a 2micron filter before use 
in the Aktaprime. The affinity step gradient programme was used, a summary of the 
process is as follows: both the Aktaprime machine and column were first washed 
with water then PBS ("System Wash" programme). The Ab suspension was loaded 
onto the column (the flowthrough was collected at this stage in order to save any Ab 
not loaded onto the column), the column was then washed with 5x column volume 
PBS. Ab was then eluted with 20m1 0.lM Glycine pH5, and 3m1 fractions were 
collected into tubes containing imi 9M Tris to neutralise the pH. The column and 
machine were then washed with water followed by 70% Ethanol for storage. Eluted 
Ab was dialysed into PBS and concentration calculated using the BCA Protein Assay 
kit (Pierce) as per manufacturer's instructions. 
2.5. Preparation and Purification of Cell Populations 
2.5.1. Preparation of mononuclear cell populations from CNS 
Mice were sacrificed by CO2 asphyxiation. Immediately after death mice were 
perfused with lOml PBS through the left ventricle of the heart. Spinal cords were 
removed by intrathecal hydrostatic pressure using cold PBS. Brains (when used) 
were removed by dissection. Cords and brains were cut into small pieces and 
digested at 37 0C for 30 minutes in Wash Buffer containing 2.5mg/ml collagenase 
(Worthington Biochemicals, NJ) and lmgIml deoxyribonuclease (Sigma), followed 
by mechanical disaggregation to obtain a single cell suspension. Cells were washed 
once in 30% Percoll(Gibco) (made up with Wash Buffer), then resuspended in 30% 
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Percoll and underlaid with 70% Percoll. These discontinuous gradients were spun at 
2000g for 20 minutes without brake (16, 176). The gradient interface was removed 
and cells washed thoroughly in wash buffer before sorting or stimulation. 
2.5.2. B Cell Purification (MACS selection) 
Single cell suspensions were obtained from LN and/or spleen by mashing. Red blood 
cells were lysed by incubating cells in Red Blood Cell Lysis Buffer (Sigma) for two 
minutes at room temperature, followed by washing in MACS Buffer three times. 
Cells were resuspended in MACS buffer and counted. 45tl MACS buffer and 5p,l 
anti-CD43 microbeads (Miltenyi Biotec) were added per 108  cells, and incubated for 
15 minutes at 4 0C, followed by washing in MACS buffer. Cells were resuspended at 
10 8  cells/ml in MACS buffer. The cell suspension was then run through a pre-
prepared MACS CS depletion column, (Miltenyi Biotec) on a VarioMACS magnet 
(Miltenyi Biotec), and the flow-through (CD43-negative fraction containing B cells) 
was collected. A sample of the cells was stained with anti-B220-PcP and the purity 
was analysed by FACS. Purity of B cells was consistently above 80% and usually 
above 90%. 
2.5.3. CD4 Cell Purification (MACS positive selection) 
Single cell suspensions were obtained from LN and/ or spleen by mechanical 
disaggregation. Red blood cells were lysed as above followed by washing. Cells 
were resuspended in MACS buffer and counted. 90p.l MACS buffer and 10.il anti-
CD4 microbeads (Miltenyi Biotec) were added per 108  cells, and incubated for 15 
minutes at 4 0C, followed by washing in MACS buffer. Cells were resuspended at 10 8 
cells/ml in MACS buffer. The cell suspension was then run through a pre-prepared 
MACS LS positive selection column (Miltenyi Biotec), and the cells retained in the 
column (positive fraction - CD4 cells) were collected. A sample of the cells was 
stained with anti-CD4-FITC and the purity of the preparation analysed by FACS. 
Purity was consistently above 90% and usually above 95% CD4 cells. 
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2.5.4. CD4 Cell Purification (Dynal negative selection) 
Single cell suspensions (as above) were resuspended at 2x10 8 cells/ml in a cocktail of 
the following antibodies, produced in-house, all rat IgG: anti-CD8 (clone 53.6.72), 
anti-B220 (clone RAB832), anti-Maci (M1/70), and anti-class II (M5/1 14.15.2) each 
at lop.gIml in MACS buffer. After incubating for 20-30 minutes on ice, cells were 
washed and resuspended at 108  cells/mi. An equivalent volume of washed sheep anti-
rat IgG M450 Dynabeads (Dynal Biotech Ltd, Wirral, UK) (concentration 10 8 
beads/ml) was added and the mixture incubated with rotation at 4 0C for 20-30 
minutes. The tube was then placed in a magnetic field and the supernatant (enriched 
for CD4 cells) collected. This step was repeated once more to remove all 
contaminating beads. A sample of cells was stained with anti-CD4-FITC and the 
purity of CD4+ cells analysed by FACS. Purity was consistently above 70%. 
2.5.5. CD4CD25 purification 
2.5.5.1. MACS sorting 
CD4 cells were enriched by Dynal bead negative selection (section 2.5.4). Cells 
were resuspended at 108  cells/mi, with 40j.il/ml anti-CD25PE (Miltenyi Biotec), and 
incubated for 15 minutes at 4 0C. After washing, 90.tl MACS buffer and 1 Ojtl anti-PE 
microbeads (Miltenyi Biotec) per 108  cells were added and the cells were incubated 
for a further 15 minutes at 4 0C. Cells were washed and resuspended at 2x10 8/ml and 
run over a MACS LS positive selection column (Miltenyi Biotec) as per 
manufacturer's instructions, collecting the cells retained in the column. Purity was 
checked by FACS and was consistently above 75-80% 
2.5.5.1. FA CS sorting 
Cells were enriched for CD4 cells by Dynal selection (section 2.5.4). Cells were 
then stained with anti-CD4-FITC (Pharmingen) and anti-CD25PE (clone 7D4, 
Miltenyi Biotec) in MACS buffer. Cells were then washed and sorted on a Becton 
Dickinson FACSTAR machine by Andrew Sanderson. Purity of CD4CD25 cells 
was consistently above 95%, and of CD4CD25 cells above 97%. 
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2.6. Ex vivo/ in vitro readouts 
2.6.1. Ex.vivo stimulation of cells to test for cytokine production 
Single cell suspensions were prepared by disaggregating LNs and spleens through 
gauze, and CNS cells were prepared as described above. Cells were incubated in 24 
well plates at 2-5x10 6 cells/well with RPMI-5 containing 50ngIml PMA (Sigma), 
1 tg!ml lonomycin (Sigma) and 1 j.xl golgistop (BD Pharmingen, La Jolla, USA). 
After 4 hours cells were washed and stained for FAGS analysis. For analysis of Ag-
specific cytokine production, cells were stimulated with 30tM MOG(35-55) in the 
presence of lj.illml Golgistop, or medium alone with Golgistop for 5 hours as 
indicated. 
2.6.2. FACS analysis 
Single cell suspensions were obtained as above. For staining of cell surface 
molecules, cells were stained with the indicated antibody (Ab) (see Table 2.1 for Ab 
clones and concentrations used) in FAGS buffer, usually with the addition of anti-Fe 
receptor Ab (20igIml) to block non-specific uptake of Ab. For intracellular staining 
of cytokines and GTLA-4, cells were first stained for expression of cell surface 
molecules, then fixed and permeabilised using the cytofix/cytoperm kit (BD 
Pharmingen) according to manufacturer's instructions. All staining was performed at 
40C for 15-40 minutes (intracellular cytokine staining was always > 30 minutes). 
Cells were then washed and analysed using a Becton Dickinson FAGScan flow 
cytometer with GeliQuest (Becton Dickinson, UK) software for collection of data, 
and FlowJo (Treestar, USA) software for analysis of data. Unless otherwise 
indicated, all antibodies were obtained from BD Pharmingen. 
Table 2.1: Antibodies used for FACS analysis 




CD4* GK1.5 FITC/APC 1/100 
CD8 53-6.7 PE 1/100 
CD1Ic HL3 FITC 1/100 
B220 RA3-6132 PcP 1/100 
CDI9* 1D3 FITC 1/200 
CD25 7D4 PE**/bi otin 1/100 
CD25 PC6I PE 1/100 
CD44 1M7 PE 1/100 
CD69 H1.2173 Biotin 1/100 
0X40 OX-86 Biotin 1/100 
IL-10 JES5-16E3 PE 1/100 
IL-2 JES6-5H4 PE 1/100 
IL-4 BVD4-24G2 PE 1/100 
IFNy XMGI.2 FITC 1/100 
CTLA4 UCIO-417 10- 
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PE 1/50-1/100 
GITR* DTA-1 FITC 1/100 
Ly5.1 A20 FITC 1/100 
Fc receptors 2.4.G2 Unconjugated 1150 
*purifi ed and conjugated in-house **from  Miltenyi biotec 
2.6.3. Cell-based ELISAs for quantification of antigen-specific 
cytokine production 
Single-cell suspensions of cells (number and source indicated in figure legend) were 
cultured in flat-bottomed 96-well microtiter plates (Becton Dickinson, Mountain 
View, CA), with the indicated antigen dose(s). X-Vivo 15 serum-free medium 
(BioWhittaker, Maidenhead, UK) supplemented with 5x 10-5  M 13-mercaptoethanol 
and 2 mM L-glutamine (Gibco, Life Technologies, Paisley, UK) was used as culture 
medium. After 48 h of culture, 100tl of cells were resuspended and cytokines 
measured as described below, using the protocol of Beech et (282). 
Under sterile conditions, 96-well MaxiSorb microtiter plates (Nalge Nunc 
International, Roskilde, Denmark) were coated overnight at 4°C with SOp.l per well 
of capture antibody (anti-IL-2, (clone JES-1Al2), anti-IL-4 (1 1B1 1), anti-IL-10 
(JES5-2A5) or anti-IFNy (R4-6A2), all from BD Pharmingen) diluted to 2jig/ml in 
carbonate/bicarbonate buffer (0.05 M, pH 9.6). After washing twice in PBS/Tween 
(0.1%), plates were blocked at 37°C for 1 h with 200tl per well of a sterile PBS/BSA 
(1%) solution. After two washes in PBS/Tween followed by two further washes in 
PBS, cytokine standards diluted in PBS/BSA were added at lOOi.tl per well in 
duplicate (IL-2 and IL-4 top concentration: 1000pg/ml, IL-10 and IFN7 top 
concentration: lOOngIml) and two-fold dilutions performed to give a standard curve 
for each plate. Samples of each culture were resuspended and added at lOOj.xl per 
well in duplicate. Samples and standards were then incubated at 37°C in a humidified 
atmosphere of 5% CO2 for 20-24 h. After this period, plates were washed four times 
in PBS/Tween and incubated with lOOp.l per well biotinylated anti-cytokine detecting 
antibody (anti-IL-2 (clone E56-5H4), anti-IL-4 (BVD6-24G2), anti-IL-10 (SXC-l) 
or anti-IFNy (XMG 1.2), all BD Pharmingen) diluted to SngIml for IL-2 and IL-4 and 
bOng/mi for IL-10 and IFNy, in PBS/BSA for one hour at room temperature. Plates 
were washed a further six times before incubation with a 1/1000 dilution (final 
concentration >2p.g/ml) of ExtrAvidin peroxidase (Sigma) in PBS/BSA at lOOpi per 
well for 30 mm. Plates were washed six times before addition of 100l per well of 
Tetramethylbenzidine (TMB; Sigma) substrate (prepared by adding 100tl of 10 
mg/ml TMB in DMSO to 9.9m1 of phosphate citrate buffer pH5 and 3p.l of hydrogen 
peroxide) followed by 100.il of 2M sulphuric acid to stop the reaction. At this point, 
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absorbance values were read at 450 nm using a Multiskan plate reader (Labsystems, 
Basingstoke, UK). 
2.6.4. ELISAs to measure MOG-specific Ab in serum 
Using a protocol optimised by the Gray lab, flat-bottomed 96-well MaxiSorb 
microtiter plates (Nalge Nunc International, Roskilde, Denmark) were incubated with 
50tl/well of MOG(35-55) or rMOG (50igIml diluted in 0. 1M bicarbonate buffer 
pH9.6) overnight at 4 0C (plates were wrapped in clingfilm to prevent evaporation). 
Plates were washed three times in PBS. Non-specific antibody binding was blocked 
by adding 200m1/well of l%BSA in PBS for one hour at 37 0C. After a further three 
washes in PBS, serum samples (50j.tl) were added in duplicate. Plates were incubated 
for one-two hours at 37 0C then washed three times with PBS. 50j.il  alkaline 
phosphatase (AP) -conjugated anti-Ig secondary antibody (diluted 11500) was added 
to each well and plates were incubated for two hours at room temperature. Plates 
were washed four times in PBS and developed by adding PNPP (one tablet dissolved 
in 5m1 ELISA buffer: 400ml ddH 20, 24.5mg MgC12 .6H20 and 48ml diethanolamine, 
stored wrapped in foil to prevent degradation by light). 
Plates were read at 450nm using the Multiskan ELISA plate reader (Labsystems) 
once wells had turned yellow. 
When peptide was added in for experiments to measure blocking of antibody binding 
to rMOG (Figure 3-7), the indicated concentrations of peptide or PBS were mixed 
with the serum at the time it was added to the ELISA plate. 
2.6.5. Suppression assays 
For assays to test suppression by CD4CD25 cells from jMT versus B6 mice 
(Figure 5-4), assays were set up similarly to those described in the literature (96). 
2x104 CD4CD25 responder cells were cultured with 10 5 irradiated B6 splenocytes 
as APC in flat-bottomed 96-well plates (See Appendix Figure A-2) for test of 
optimal APC numbers, jMT splenocytes proved inefficient APC in one experiment 
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so were not used). MACS-sorted CD4CD25 cells were titrated in at numbers 
indicated on graph axes. The purity of MACS-sorted cells was between 70-85%, but 
always comparable within each experiment. Cultures were stimulated with 0.5tgIml 
anti-CD3, clone 145.2C11 (this concentration was chosen as the optimal 
concentration for stimulation of CD4CD25 cells without preventing suppression by 
CD4CD25 cells, see Appendix figure A-i for dose response). Cells were cultured 
at 370C for 72 hours, with tritiated thymidine added for the last 18 hours of culture 
before assays were harvested. 
For the suppression assays comparing CD4CD25 cells from the LN of mice with 
EAE and naïve mice (Figure 5-2), conditions were further optimised in separate 
experiments using TCR transgenic cells by Dr Leigh Stephens. The main changes 
were to culture the cells in round-bottomed 96 well plates to optimise cell contacts, 
and to extend the culture time to 96 hours, which proved to be helpful when 
investigating antigen-specific responses of small numbers of cells. CD4CD25 cells 
were selected by MACS-sorting from mice 16 days after immunisation with MOG in 
CFA with or without the addition of pertussis toxin (the results of assays using cells 
from these two conditions were similar). In all assays, 1.6xlO 5 1.6x10  irradiated splenocytes 
from naïve mice were added as APC. Between 10 and 4xiO 4 CD4CD25 responder 
cells were added and CD4CD25 cells were titrated in. The source and number of 
responder cells and CD4CD25 cells used for each assay are indicated in the figure 
legends. 
To test suppression by CNS CD4CD25 cells (Figure 5-1), mononuclear cells were 
prepared and CD4CD25 cells purified by FACS sorting (see section 2.5.5) and 
titrated into assays containing 10 4 CD4CD25 cells purified from LN of naïve mice 
were used as responder cells. 1 .5x10 5 irradiated splenocytes from naïve mice were 
used as APC. Cells were stimulated in round-bottomed 96 well plates with 2.5j.tg/ml  
anti-CD3 (clone 145.2C11) in RPMI-5 tissue culture medium for 96 hours. 0.5p.Ci 
tritiated thymidine (Amersham Intl) was added for the final 18 hours of culture 
before assays were harvested. 
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2.6.6. Proliferation responses of CD4CD25 cells (Figure 4-10) 
CD4CD25 cells were purified by MACS sorting from LN or CNS of mice with 
EA-E. In conditions similar to the above suppression assays, 2x10 4 cells were 
cultured with 1.6x10 5 APC, and the antigen and IL-2 concentrations indicated in 
figure legend, in round-bottomed wells for 96 hours. 
2.6.7. Foxp3 rtPCRs 
CD4 cells were enriched from spinal cords and inguinal LN of mice 20 days after 
induction of EAE and mRNA extracted using the Micro-FastTrack 2.0 Kit 
(Invitrogen Life Technologies, UK). cDNA was made using the Stratascript First-
Strand Synthesis System (Stratagene, UK) Foxp3 PCR was performed using the 
following primers (MWG Biotech, Milton Keynes, UK), designed by Angie Harris: 
5' -CCTGGCCCACCTGGGATCAA-3' (spanning exons 3 and 4 to avoid genomic 
DNA amplification); 5 '-TTCTCACAACCAGGCCACTTG-3'. 
As a control 13-actin PCR was also performed 




A method adapted by Dr Steve Anderton from the protocol described by Taylor, 
Thomas and Mills (283) was used. B6 congenic Ly5.1 mice were used to allow 
eventual tracking of the cells in vivo. On day 18 after EAE induction, CD4CD25 
cells from LN and CD4 cells from CNS were purified and plated out at limiting 
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dilutions ranging from 30 to 600 cells/well/plate, with 3.5x10 5 irradiated splenocytes 
as APC, 10.xM MOG(35-55) and 100u/ml IL-2. After 1 week wells were checked for 
the presence of growing T cells by microscopy, and positive wells were restimulated 
weekly with APC, 4tMMOG(35-55) and 100u/ml IL-2 until cells had expanded 
sufficiently to be tested for reactivity to MOG(35-55). Wells, from plates in which 
less than 20% of wells scored positive for growing cells were considered clonal. All 
these wells were restimulated weekly in 24 well plates with 3x10 6 APC, 2j.xM 
MOG(35-55) and 100u/ml IL-2. 
Attempt 2: 
Cells were prepared and plated out as described above, except that 200pg/ml IL-10  
(R&D Systems, Abingdon, UK) (88) was added for the first two rounds of 
stimulation, and 1 OOng/ml IL-1 5 (R&D Systems) was added for every restimulation 
(as well as for the initial stimulation). After 9 weeks, the concentration of IL-2 added 
for restimulation was increased to 1000u/ml. 
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3. B cells as Regulatory Cells Mediating Recovery from EAE 
3.1. INTRODUCTION 
B cell deficient mice and chimeric mice in which B cells are unable to produce IL- 10  
fail to recover from EAE (59, 273). It has also been reported that rats in remission 
from EAE are resistant to further induction of EAE, and that this may be mediated by 
a combination of T cells and B cells (257). In this chapter, the susceptibility of 
recovered B6 mice to the reinduction of EAE is examined. Possible mechanisms 
behind both recovery and resistance are investigated, focussing on the role of B cells. 
3.2. RESULTS 
3.2.1. Mice that have recently recovered from EAE are resistant to 
reinduction of disease 
Induction of EAE in B6 mice using the MOG(35-55) peptide in this lab results in a 
monophasic course of disease, and relapses are very seldom observed after 
remission. It has been known for some time that Lewis rats that have recovered from 
EAE induced with MBP are resistant to rechallenge with MBP(284). To test this in 
our model, B6 mice that had recovered from EAE were rechallenged with a second 
immunisation with MOG(35-55). Most of the mice developed EAE with an earlier 
onset after reinduction, indicating a memory response. However, the disease severity 
in most of these mice was mild and the duration of disease shortened when compared 
to mice immunised for the first time (Figure 3-1a). This resistance to reinduction was 
only effective when mice were rechallenged at early points after recovery (1-3 
weeks). When mice were were rechallenged 6 to 8 weeks after recovery from 
primary disease, they were found to be fully susceptible, and developed EAE of 
similar severity and duration to the primary disease. (Fig 3-1b). 
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Resistance to reinduction of disease after recovery from EAE suggests two possible 
scenarios. First, during recovery pathogenic T cells may be deleted or made anergic 
and therefore unable to respond to a second challenge. Although in vitro LN and 
spleen recall responses are depressed after recovery compared to early points in the 
disease, they are not completely abolished(59), suggesting that MOG(35-5 5)-reactive 
Thl effectors are still present. Also, mice that did develop EAE after rechallenge had 
an earlier onset of disease (1 to 2 days before controls, Figure 3-1) consistent with a 
memory response that was then rapidly regulated. Therefore, an active mechanism of 
controlling pathogenic cell re-activation and/or priming of fresh CD4 cells after 
rechallenge can be proposed. Since this is likely to be the same mechanism employed 
to control autoaggressive T cells and mediate recovery, resistance to reinduction 
provided a useful starting point for investigating the recovery process. 
3.2.2. MOG(35-55)-reactive CD4 T cells with pathogenic potential 
are still present in mice after recovery from EAE 
To determine whether the CD4 T cell compartment in EAE-recovered mice 
contained cells with either pathogenic or regulatory potential, CD4 cells from the 
pooled spleen and inguinal LN of mice 30 days after EAE induction were transferred 
into naïve recipients. One day later, EAE was induced in recipients, as well as 
control mice that had not received cells, and disease course monitored. The disease 
incidence and severity was consistently slightly higher in mice receiving CD4 cells 
compared to controls (Fig 2). Also, disease onset was slightly accelerated in 
recipients of post-EAE CD4 cells (1 to 2 days earlier than controls). However, in 2 
out of 3 experiments the differences between CD4 recipients and controls did not 
reach statistical significance. Although this difference was admittedly not marked, 
earlier onset and increased disease in recipients suggested the presence of pathogenic 
memory cells in the CD4 compartment of recently recovered mice, and that the 
effects of these cells was dominant over any regulatory cells that may have been 
present in the spleen/LN populations that were used. 
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To further examine the contribution of transferred post-recovery CD4 cells to 
disease in recipients, cells were tracked in vivo after transfer. For this purpose, EAE 
was induced in B6 congenic mice bearing the Ly5. 1 allele of CD45 (present on all 
leukocytes). On day 30 after immunisation (when all mice had recovered), Ly5.1 
CD4 cells were transferred into wildtype B6 mice (which have only the Ly5.2 
allele) and EAE was induced 1 day later. Inguinal LN, spleen and spinal cord were 
harvested at the peak of disease (days 13-15 after induction), and pooled cells from 
each organ analysed by FACS for surface expression of Ly5.1 and CD4, and 
intracellular cytokine levels after stimulation with PMA and ionomycin. 
Thirteen to fifteen days after induction of EAE, Ly5. I + CD4 cells could be detected 
by FACS in the inguinal LN, spleens and spinal cords of recipient mice (Figure 3-
3a). Compared to LN and spleen, Ly5.1 cells were greatly enriched in the CNS, 
constituting 27.93% ± 4.47 % (mean ± std deviation) of total CD4 cells in 3 separate 
experiments, while only reaching 2.03% ± 1.04% in inguinal LN and 3.5% ± 1.32% 
in spleens of the same animals (Table 3-1a). A proportion of these Ly5.1 cells 
produced IFNy after ex vivo restimulation with PMA and ionomycin, consistent with 
expansion of Thi effectors (Figure 3-3b). The proportion of Ly5.1 cells producing 
IFNy in 2 experiments was greater in the CNS (mean ± SD: 28.5% ± 14.9%) than in 
inguinal LN (8.25% ± 4.6%) (Table 3-1b), consistent with enrichment of effector 
cells in CNS rather than LN, on day 15. However, although the percentage of CD4 
cells that were Ly5.1 was around 8-fold lower in spleen, the proportion of Ly5.1 
cells producing IFNy was similar in CNS and spleen (38% ± 5.66%) (Table 3-1b). 
Although for this set of experiments transfer of naIve. CD4 Ly5. 1 cells was not 
done, in later experiments (where CD4CD25 cells were transferred), naïve Ly5.1 
CD4 cells were not found to accumulate in the CNS of recipients after EAE 
induction (Fig 3c). The percentage of Ly5.1 cells in the CNS is lower in this 
experiment, but this can be explained by a lower number of cells transferred - only 
2x105 compared to 3xl0 6 for whole CD4 cell transfers. 
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Without a full time course it is difficult to draw conclusions regarding numbers of 
cells in lymphoid sites after transfer. In other transfer systems, using transgenic T 
cells, the peak of expansion of memory cells occurs around day 5, followed by a 
contraction phase (285). In a recent study the proportion of PLP( 139-151)-specific 
CD4 cells in the LN of SJL mice after EAE induction with PLP(139-151) was 
analysed by tetramer staining (286). Tetramers are multimeric complexes of MHC 
and peptide incorporating fluorescent dye (287). This allows direct identification by 
flow cytometry of T cells bearing TCRs that specifically bind those MHC peptide 
complexes, i.e. Ag-specific T cells, within a lymphoid population without the 
requirement for transfer of transgenic TCR cells. Consistent with other studies 
examining in vivo responses to various Ag using tetramers, the peak of expansion of 
PLP(1 3 9-15 1) -specific CD4
+  cells in the LN occurred between days 6 and 8 
(PLP(139-15 1)-specific cells represented 0.9-1.5% of total CD4 cells), followed.by  
a rapid decline to background levels between days 16 and 20 (0.5% of total CD4 
cells) (286). So, by day 14 after EAE induction the proportion of MOG(35-55)-
specific cells would be expected to have returned to low levels in the LN and spleen. 
In one experiment in which Ly5.1 + cells were analysed on days 8 and 15 after 
immunisation with MOG(35-55), the proportion of cells on day 8 was higher than 
day 15 (percentage of CD4 cells that were Ly5.l in inguinal LN on day 8 was 9.4% 
compared to 3.1% on day 15; and in spleen Ly5.l cells made up 6.9% of total CD4 
cells compared to 5% on day 15), suggesting expansion of MOG(35-55)-specific 
cells. Given that the transferred cells were from a non-transgenic mouse and taken at 
a late timepoint in the disease course, the frequency of any expanded MOG-reactive 
cells would only be a small proportion of Ly5. 1 cells labelled. A method for 
staining MOG(35-55)-specific cells, such as tetramer staining for FACS, would be 
highly useful for singling out this small population, particularly in LN and spleen. A 
further control group of non-immunised post-recovery transfer recipients would have 
been useful for determining the starting proportion of Ly5.1 cells, but due to 
restraints in mouse numbers this was not done. 
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These results confirm that potentially pathogenic cells remain in the spleenlLN of 
mice recently recovered from EAE, arguing against deletion of autoreactive cells as 
the mechanism behind recovery. After transfer into naïve recipients at least a 
proportion of these cells can be expanded by antigen challenge and contribute to 
CNS inflammation, further suggesting that resistance to reinduction of EAE is not 
due to deletion or anergy of pathogenic MOG(35-55)-reactive cells, but rather 
involves active regulation of these pathogenic cells in recovered mice. 
3.2.3. Post-recovery B cells are able to transfer resistance to 
induction of EAE 
Given that B cells are required for recovery from EAE(59, 273), B cells present in 
recovered mice were tested for their ability to regulate activation of MOG(35-55)-
reactive T cells in vivo. B cells were purified from pooled spleens and inguinal LN 
of mice on day 30 post-immunisation and transferred into naïve recipients one day 
before EAE induction. 
In contrast to CD4 cells, post-recovery B cells were able to transfer some resistance 
to induction of EAE (Figure 3-4). The level of protection achieved varied between 
experiments, but disease severity of recipients of B cells was consistently lower than 
untransferred controls in four separate experiments. An important control of naïve B 
cell transfer was only done in one experiment (see Figure 4-2), and in this 
experiment was not protective compared to post-EAE B cells. Transfer of whole 
splenocytes from naïve mice also gave no protection (data not shown). 
One might expect that the efficacy of post-EAE B cells in reducing disease may be 
enhanced by co-transfer of post-EAE CD4 T cells which would more efficiently 
provide early "help" to activate these B cells. Indeed, it has been reported that a 
combination of B cells and T cells from rats that have recovered from EAE can 
protect recipients from induction of EAE, but neither cell population was effective in 
isolation (257). However, in 4 separate experiments in which whole post-recovery 
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splenocytes were transferred, disease was enhanced in 2 experiments and decreased 
in 2 experiments (Fig 3-5), therefore co-transfer of CD4 cells does not seem to be 
required for B cell transfer of resistance to induction of EAE. 
3.2.4. Antigen specificity of B cells during recovery? 
The above data as well as published data (59) suggests that post-recovery B cells, but 
not B cells from mice at the peak of disease or from naïve mice, are able to transfer 
resistance to induction of EAE. This suggests expansion of protective antigen-
specific B cells during the course of EAE, and particularly the recovery phase. In 
order to be able to further phenotype these cells, attempts were made to enumerate 
numbers of MOG-reactive B cells and determine their fine specificity. 
i) Detection of MOG-specific B cells by FAGS 
In order to detect antigen-specific B cells by FACS it is necessary to label the BCR 
in a specific manner. One way of doing this is to fluorescently label the antigen 
recognised by the BCR, allow antigen binding by B cells, then look for labelled cells 
by FACS. For this purpose, recombinant MOG protein (rMOG) was biotinylated. LN 
cells from mice on day 28 as well as LN cells from naïve mice were stained using 
MOG-biotin followed by streptavidin-APC. Cells were also labelled with antibody 
against the B cell marker B220. The background staining of MOG-biotin positive 
cells in naïve cell preparations was unacceptably high, and there were no differences 
discernable between cells from naïve and MOG(35-55)-immunised mice (Figure 3-
6a). To minimise high background due to non-specific staining, several approaches 
were taken: a dose range of rMOG-biotin was tested; dead cells and macrophages 
were excluded from FACS analysis by staining with propidium iodide and F480-PcP 
and excluding positive cells; all staining and blocking was done using FACS buffer 
containing 10% FCS to reduce non-specific "stickiness" of cells for protein. 
However these approaches did not improve the background staining and it remained 
impossible to distinguish MOG-specific B cells (Figure 3-6c). 
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ii) Detection of MOG-specflc antibody in serum of mice with EAE by EL ISA 
Since it was not possible to detect MOG-specific B cells directly, the presence of 
MOG-specific Ab in serum was used as a measure of whether MOG-specific B cells 
were being activated during EAE. Serum was collected at time of sacrifice on days 
14 and 30 post-EAE induction. Serum IgGi, IgG2a and total IgG binding to 
recombinant MOG protein (rMOG) were tested. In six separate experiments, around 
half the mice were found to have detectable serum antibodies against rMOG on day 
30, while in one experiment only 2 out of 10 mice had weak anti-rMOG responses on 
day 14 (Table 3-2/fig 3-7a). As negative controls sera from naïve mice were used and 
showed no reactivity to rMOG (Figure 3-7a). 28 of 49 mouse sera tested had anti-
rMOG responses of the IgGl isotype, while only 12 of 44 mice had IgG2a responses 
(Table 3-2), surprisingly suggesting a Th2-dominated response. However, in the 
absence of MOG-specific antibody standards it was not possible to quantify antibody 
concentrations, and comparing relative isotype responses was not possible since there 
may have been differences in sensitivity between the ELISAs. ' 
By conventional ELISA, anti-MOG(35-55) responses appeared to be very low. This 
could be due to poor binding of MOG(35-55) to ELISA plates, or changes in 
structure when bound to the plate causing decreased antibody binding efficiency. 
Therefore, an indirect blocking study was undertaken: ELISA plates were coated 
with rMOG as before, then different concentrations of MOG(35-55) were added in 
with the serum during incubation on the plate. As can be seen in Figure 3-7b, 
addition of MOG(35-55) blocked binding of serum antibodies to rMOG in a dose-
dependent manner. This blocking was observed in 8 individual positive mouse sera 
(Figure 3-7c), as well as pooled positive sera from 10 different mice (data not 
shown), strongly suggesting the presence of B cells specific for an epitope(s) within 
MOG(35-55). 
To further define specificity of antibody, a truncated peptide, MOG(35-50), was 
tested in the blocking assay. Interestingly, removal of the amino acids at position 51- 
55 almost completely abrogated blocking, with only slight effects at high peptide 
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concentrations compared to MOG(35-55) (Figure 3-7b), showing that the p50-55 
portion is required for BCR binding. 
3.2.5. Resistance to induction of EAE transferred by post-recovery 
serum - is B cell protection mediated by antibody? 
Given that anti-MOG(35-55) antibody was detectable in around half of the mice 
tested on day 30 of EAE, the question arose could B cell protection in fact be 
mediated by antibody? It has been reported in a rat model of EAE that serum from 
rats in remission from MBP-induced EAE can protect recipients (288, 289). To test 
whether serum could protect in our B6 mouse model, two experiments were 
performed. First, 1 50.xl of pooled sera from mice at day 30 or day 14 of EAE (made 
up to 200tl with PBS), or PBS alone, were transferred on days —1, +1, 4 and 6, and 
EAE induced on day 0. In this experiment, a significant reduction of disease severity 
was observed in mice receiving day 30 serum but not day 14 serum (Figure 3-8a). 
Since day 14 sera were found to be almost completely lacking in anti-rMOG 
responses compared to day 30 (Table 3-2), the experiment was further refined to 
transfer pooled day 30 sera which had tested either positive or negative by ELISA for 
anti-rMOG antibodies. 150 j.il sera were transferred on days —1, +1 and 3. In this 
experiment, a small reduction in maximum disease scores was observed in both 
groups that received serum compared to controls, but there was no difference in the 
protection afforded by anti-rMOG positive versus negative sera (fig 3-8b). Collection 
of sufficient sera to perform these experiments was very restrictive in determining 
how many repeats and variations could be done, Interpretation of the results is also 
complicated - see discussion (section 3.3). Therefore, while it appears that serum 
transfer is able to confer some protection on recipients, this line of investigation was 
not continued further. 
3.2.6. Do post-recovery B cells inhibit in vitro T cell responses? 
As reported(59), anti-MOG(35-55) T cell responses in vitro are consistently lower on 
day 30 (recovery phase) than on day 10 (effector phase) in wildtype B6 mice. 
However in 1.xMT mice, these responses are not depressed, correlating with impaired 
recovery. Given the observations that transferred post-recovery CD4 cells could be 
activated after immunisation and that transferred post-recovery B cells inhibit EAE 
induction, it was possible that B cells present in the in vitro cultures could be 
regulating proliferation and cytokine production of MOG(35-55) reactive cells. This 
could be mediated by IL- 10 production by antigen-presenting B cells, or inhibition of 
antigen presentation due to BCR binding of peptide. To test this, MOG(35-55)-
specific cytokine production by CD4 cells from mice 30 days after EAE induction 
(d30 EAE) was tested in the presence of different APC: purified B cells or CD4-
depleted splenocytes from the same (00 EAE) mice, or from naïve mice. 
In an initial experiment, stimulating the CD4 T cells in the presence of naïve APC 
or naïve B cells did appear to enhance IL-2 and IFNy production in comparison to 
cells stimulated in the presence of d30 EAE APC (Figure 3-9a). In contrast, IL-10  
and IL-4 were marginally decreased in the presence of naïve APC or naïve B cells, 
although the overall levels of production of these cytokines, particularly IL-10, was 
low. This experiment was repeated twice using B cells from naïve mice or d30 EAE 
mice, but the results were not consistent with the first experiment (not shown). The 
experiment was further refined by culturing d30 EAE CD4 cells with MOG(35-55) 
in the presence of splenic CD1 1c DCs (from naïve mice) and titrating in d30 EAE B 
cells. However, while a small decrease in IL-2 was observed with increasing 
numbers of B cells, IFNy was increased under the same conditions (Figure 3-9b). 
Therefore, it does not appear that B cells significantly inhibit cytokine responses in 
these in vitro assays. 
3.2.7. Requirements for B cell antigen presentation during recovery 
from EAE - making an antigen to specifically target B cells in vivo 
IL-10 production by B cells has been shown to be important for EAE remission in 
the B6 model (59). In the same paper it was shown that the presence of IL-10  
sufficient B cells with restricted specificity for hen egg lysozyme (HEL), and 
therefore unable to take up and present CNS antigens via their BCR, were unable to 
promote recovery. This was the case even when mice were additionally immunised 
with HEL at the time of EAE induction (SMA - personal communication). This 
result suggests that mere activation of B cells is insufficient for mediating recovery. 
Rather, direct B cell interactions with pathogenic T cells via presentation of MHC-
peptide complexes may be required. 
To further refine this model, it is desirable to be able to activate B cells in vivo while 
concurrently immunising with CNS antigen either separately or targeted to these B 
cells via BCR. Production of a conjugate of HEL and MOG(35-55) was therefore 
attempted. Chemical coupling of the HEL protein and MOG(35-55) protein was 
chosen because this is a far quicker process than designing and producing a genetic 
construct of the conjugate. Coupling of the MOG(35-55) peptide rather than MOG 
protein avoided the difficulties associated with the poor solubility of MUG protein, 
particularly at the pH required for optimal chemical coupling. The EDC coupling kit 
from Pierce was chosen because it is particularly recommended for coupling haptens 
or peptides to carrier proteins by the manufacturers. When added to a mixture of 
peptide and protein, EDC initially reacts with carboxyl groups to form amine-
reactive intermediates, which then react with amine groups to form a link between 
the two compounds. 
It was a concern that using too high a concentration of MOG(35-55) peptide during 
the coupling procedure would lead to blocking of HEL uptake by B cells, and 
conversely that too low a peptide concentration would lead to insufficient peptide 
presentation to activate T cells. Therefore, a range of 5 peptide concentrations was 
used, with a fixed concentration of HEL. The conjugates were then tested in vitro. It 
is known that B cell presentation of antigens taken up via BCR-binding is accelerated 
and more efficient compared to non-specific uptake by fluid phase pinocytosis, so 
that much lower concentrations of antigen are required to activate T cells (67). All B 
cells from MD4 mice bear a transgenic receptor specific for HEL (281). Therefore, 
presentation of MOG(35-55) after HEL-MOG(35-55) conjugate uptake by MD4 B 
cells, was compared to presentation by wildtype B6 B cells. Antigen presentation 
was measured by proliferation of MOG(35-55)-reactive CD4 cell lines in 3 day 
cultures. 
The expected result was observed in a preliminary experiment: T cell stimulation by 
MD4 B cells occurred at much lower concentrations of conjugate, with 100 to 10000 
fold increases in concentration required for equal stimulation by B6 B cells (fig 3-
10). The minimum concentration of conjugate required for antigen presentation was 
lowest for the conjugate made with the highest peptide concentration, and the 
concentrations required increased stepwise correlating with decreasing peptide 
concentrations. 
These results would appear to confirm that the conjugate is able to target presentation 
of MOG(35-55) to HEL-specific B cells in vitro, and that presence of a HEL-specific 
BCR is required for presentation of lower concentrations of conjugate, as would be 
expected to occur in vivo. However, when the control resultswere analysed serious 
doubt was cast on this conclusion. For controls, free MOG(35-55) peptide was added 
in conjunction with, but separately to, HEL. This should have excluded any 
advantage gained by antigen-specific BCR-mediated uptake and presentation, 
resulting in equal stimulation of T cells in those cultures. This was not the case: the 
MD4 cells again induced greater proliferation at lower peptide concentrations than 
B6 B cells, and the levels of stimulation observed closely correlated with conjugate-
driven stimulation by the respective B cell populations (Figure 3-10). This could be 
explained by an up-regulation of class II molecules on the surface of MD4 B cells 
being activated via BCR (67). However, similar results were observed when peptide 
alone was added - MD4 B cells stimulated T cells better than B6 B cells. It has also 
been reported that naïve MD4 mice have a high background level of serum HEL-
specific antibody (281), suggesting that their B cells may have a higher activation 
status than wildtype B6 B cells, although this was not investigated. 
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While further validation is required, this approach is potentially useful for setting up 
a system for targeting antigen to specific B cells in vivo to separate requirements for 
B cell activation and antigen presentation from B cell activation alone. One major 
drawback with the protocol used in this project was the amount of conjugate 
generated per reaction, this would have to be scaled up for use in vivo. Also, the 
conjugate would have to be tested in vivo for ability to induce EAE at different 
concentrations in the presence or absence of HEL-specific B cells, since it is only 
possible to estimate the amount of peptide present. 
3.3. DISCUSSION 
It has been known for some time now that after recovery from EAE induced by 
immunisation with MBP, Lewis rats are resistant to further induction of disease(284). 
This resistance only occurs after active induction of disease by immunisation with 
encephalitogenic peptide - EAE induced passively by transfer of in vitro-activated 
encephalitogenic T cells does not result in resistance to further disease after 
recovery(290). The resistance or susceptibility of other strains of rats or mice has not 
been extensively characterised, although it is known that SJL mice are not resistant 
to rechallenge after recovery(29 1), and interestingly this strain has a relapsing-
remitting disease course(178). 
B6 mice were resistant to reinduction after primary active immunisation with 
MOG(35-55) (Figure 3-1). Interestingly, this resistance was not very long-lived, and 
by 7 weeks after recovery (11 weeks after primary immunisation), mice were once 
again fully susceptible to induction of EAE. This is in contrast to findings in the 
Lewis rat model, where lifelong resistance develops(284). Whether mice were 
reinduced 2 weeks or 7 weeks post-recovery the average day of onset of clinical 
signs was 1 to 2 days earlier than control mice immunised for the first time, 
consistent with a memory response. In addition, transfer of CD4 cells from post-
recovery mice into naïve mice followed by immunisation with MOG(35-55) resulted 
in activation of these cells and accumulation of Ly5. 1 Thi effectors in the CNS of 
recipients, contributing to a slightly enhanced severity of disease. These results 
suggest an active mechanism(s) of regulation that comes into force during recovery 
and continues to protect for several weeks. 
The role of B cells in EAE pathogenesis and recovery is controversial. B cell 
deficient mice on the B10.PL background fail to recover from EAE induced by the 
MBP peptide Ac(1-11) (273). We have corroborated this result in the B6 model of 
ENE (59, 292). Our results in B cell IL-10 chimaeras additionally showed B cell 
IL-10-production to be very important for recovery from EAE (59). In contrast, 
Cross et al have described a role for B cells in the pathogenesis of EAE in B6 mice 
(189, 292). They found that .tMT mice on the B6 background were resistant to EAE 
induction by immunisation with whole MOG protein, but not MOG(35-55), despite 
apparent activation of MOG-reactive Thi cells (292). The resistance to MOG-
induced EAE could be overcome by transfer of B cells from MOG-immunised mice 
or serum from MOG-immunised but not MOG(35-55)-immunised wildtype mice 
(189), and this was attributed to pathogenic effects of CNS-specific antibody in the 
CNS. However, these studies used recombinant human MOG protein for EAE 
induction, and when we immunised with recombinant mouse MOG full EAE could 
be induced in either B cell sufficient or deficient mice (59). Oliver et al have 
described similar discrepancies in a study directly comparing the ability of human 
and rodent MOG to induce EAE (293). 
In this chapter, the presence of MOG-specific serum antibody as well as the ability of 
transfers of day 30 EAE B cells or serum from recovered mice to protect in the B6 
MOG(35-55)-induced EAE model have been investigated. B cells from recovered 
mice were protective when transferred 1 day prior to immunisation, suggesting a role 
for B cells in resistance to reinduction. In the published study from our lab it was 
found that transfer of B cells from wildtype mice on day 14 of EAE into B cell IL-10 
' chimaeras was not protective (but did allow the mice to recover) (59), suggesting 
preferential expansion of "regulatory" B cells during the recovery phase. The only 
caveat to this finding is the fact that the method used for B cell purification was the 
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commonly-used negative selection based on lack of expression of CD43 on B cells. 
However, CD43 is upregulated on activation of B cells (294), and it could be 
proposed that selecting B cells in this way at the peak of disease may have in fact 
removed the very cells which would have given protection - activated MOG-reactive 
B cells - while by day 30 these cells are once again in a resting state and have 
downregulated CD43. 
Transfers of whole splenocytes from recovered mice were also done, but these gave 
very variable results, with a decrease in disease severity observed in half the 
experiments but an increase in disease severity observed in the other half. Therefore, 
unlike reported results in rats (that used a mixture of purified CD4 and B cells) 
(257), in B6 mice B cells were most consistently able to protect when transferred 
without T cells. This is most likely due to the transfer of pathogenic T cells 
concomitant with T cells "helpful" to B cells (these may in fact be the same cells) 
when transferring whole cell populations. It seems unlikely that naïve B cells would 
offer any protection from EAE upon transfer, given that transferred cells only make 
up around 1% of total B cells in recipients (see Figure 4-2). However, without having 
done this control it cannot be ruled out. Transfer of CD4CD25 cells from naïve 
mice has been shown to give some protection from EAE induction (49), but there are 
important differences: the frequency of endogenous CD4CO25 cells present in 
naïve recipients is only 5-15% of total CD4 cells, and the numbers required to give 
protection (2x 106  cells) would lead to an approximate doubling of the total number 
+ 	± 	
i 	
± of CD4 CD25 cells n the recipient. Also, CD4 CD25 ±  cells are thought to be 
positively selected on high affinity for self-antigen (9), while B cells would be 
deleted under these conditions (21), therefore the proportion of self-Ag reactive cells 
would be expected to be far lower in the transferred cohort of naïve B cells than 
CD4CD25 cells. 
The mechanism of B cell-mediated resistance to induction of EAE is unclear. This 
lab has shown B cell IL- 10 to be important for recovery from EAE, and that B cells 
can be induced to produce IL-10 in vitro by stimulation with MOG(35-55) in the 
presence of anti-CD40 (59). Suppression of T cell and APC activation by IL-10 is a 
well characterised function of certain types of regulatory T cell (55). Since memory 
CD4 cells with pathogenic potential appear to be present in the spleens of recovered 
mice (Figures 3-2 and 3-3), it was intriguing to speculate that B cells may be 
producing IL-10 to suppress T cell cytokine production and proliferation in the in 
vitro assays performed on day 30 of EAE. However, while an increase in Thi 
cytokines was initially observed when day 30 EAE B cells were replaced with naïve 
B cells (Figure 3-9), the effect was small and inconsistent. This may not be a 
sensitive enough method for measuring effects of IL-10 production by B cells on T 
cells, since in an in vitro assay most B cells are likely to present peptide, while only a 
relatively small proportion of those B cells may be producing IL-b. In vivo, this 
small-scale production would be locally targeted to T cells recognising peptide:MHC 
on MOG-specific B cells, so the effects would be greater. MOG(35-55)-specific Ab 
in sera of recovered mice suggests that a proportion of post-recovery B cells that 
were transferred into naïve recipients before EAE induction would have BCRs 
specific for MOG(35-55), and may therefore present this peptide early after 
immunisation, without the requirement for release of MOG from the CNS during 
inflammation. 
An alternative role for IL-10 is on the B cells themselves: while IL-10 has mostly 
downregulatory effects on immune cells, it is in fact an important growth factor for B 
cells, with particular functions in promoting Ab production (233). A protective role 
for serum antibody has been described in the Lewis rat model of EAE induced by 
MBP (289). In this model, serum from recovered rats suppressed disease in 
recipients when transferred either before or early after immunisation with MBP. 
Also, the severity of disease in non-transferred rats after immunisation with MBP 
was found to inversely correlate with levels of serum MBP-specific antibody. In a 
further study, a panel of antibodies with specificities for different MBP epitopes was 
found to have effects varying from highly pathogenic, to no effect, to protective, 
after transfer (188). Very early studies in this rat model also suggested that transfer 
of B cells from recovered rats could protect recipients - at the time limited sorting 
techniques were available, so the protective fraction of cells was shown to be nylon 
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wool adherent cells, of which 80% were Ig - and later it was found that co-transfer 
of both MBP-specific B cells and T cells from recovered rats was necessary for 
protection (257, 288). However it must be said that this group mainly favours 
expansion of a TGFI3-producing suppressor T cell as the mechanism of resistance to 
reinduction (254). 
The role of MUG-specific antibodies in EAE and MS is still unclear. It has been 
reported that many MS patients have MUG-specific antibody in their serum (162), 
and plasma exchange can have a beneficial effect on disease in some patients (286). 
Anti-MUG Ab has also been found in the lesions of active MS (186). 
Anti-MUG Ab are likely to contribute to pathology by opsonisation of myelin, 
leading to complement deposition and accelerated clearance of myelin debris by 
macrophages (187). A study in marmosets showed that antibodies recognising linear 
epitopes from MUG were essentially non-pathogenic, presumably due to inability to 
effectively bind native protein in the CNS, while antibodies recognising 
conformational (discontinuous) epitopes were able to initiate demyelination in the 
CNS (295). Interestingly, mice on the H-2b background appear unable to generate 
antibodies against discontinuous epitopes of MUG, only producing antibodies 
against linear epitopes (296). This finding could explain the differences in 
requirements for B cells for induction of EAE observed when B6 mice are 
immunised with MOG.from humans or rodents (hMOG or rMOG) (293). After 
immunisation with rMUG, pathogenic antibodies cannot be produced, so disease is 
mainly T cell-dependent and induction of EAE is not affected by the absence of B 
cells (59). However, immunisation with hMOG stimulates production of cross-
reactive antibodies specific for discontinuous epitopes of MUG (i.e.pathogenic), 
while the T cell response is reduced due to a single amino acid difference in the T 
cell epitope between mMUG and hMUG (187, 293, 297). Therefore, when 
immunising with hMUG, disease is highly B cell dependent, and can only be induced 
in B cell deficient mice by co-transfer of serum containing antibodies generated by 
immunisation with 1iMOG (187). 
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In the experiments described in this chapter, serum from recovered mice was able to 
transfer some resistance to EAE induction, although these studies were not extensive. 
It was interesting that specificity of MOG-binding antibody in recovered mice 
appeared to be completely directed against the MOG(35-55) epitope. Due to 
differences in the way BCRs and TCRs recognise antigen - BCRs tend to recognise 
epitopes formed by tertiary folding of the protein, while TCRs bind small peptides 
(primary structure) - generated by processing of protein and presented on MHC 
molecules by APC, it is generally thought that for most proteins the dominant BCR 
and TCR epitopes will be different, and that BCR will not recognise peptide 
epitopes. However, as has already been discussed, antibodies with specificity for 
linear peptide epitopes from CNS antigens are commonly observed in both EAE and 
MS (162, 187), and it has been reported that the dominant B cell epitope within 
MOG does in fact span MOG(35-55) (298). 
The location of Ab epitopes in relation to TCR epitopes within a protein can have 
important consequences for subsequent antigen presentation whether by B cells after 
BCR-mediated uptake or APC taking up opsonised Ag. Both enhancement and 
inhibition of presentation of epitopes close to or within the BCR binding domain has 
been observed, and this appears to be highly dependant on the individual epitope 
(299). Therefore, it could be that transfer of serum containing MOG(35-5 5)-specific 
antibodies prevents activation of T cells after immunisation with MOG(35-55) by 
binding to the peptide and blocking its presentation. It may also be possible that 
MOG(35-55)-specific B cells contribute to reduced activation of pathogenic T cells 
by binding and internalising MOG(35-55) without subsequent presentation on 
MHCII. 
Around half the mice tested had MOG-specific Ab in their sera on day 30 after 
immunisation, and very few had MOG-specific Ab at the peak of disease (Table 3-2). 
It cannot therefore be said that serum antibody as detected by ELISA correlated with 
recovery, since there were no observable differences in disease severity or remission 
rates in mice with detectable antibody compared to those without serum antibody 
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(data not shown). However, the most conclusive way to rule out any role for 
antibody would be to use mice in which B cells are unable to secrete antibody but do 
have membrane immunoglobulin (BCR), so can internalise and present antigen 
specifically. The effects on disease course of transfer of post-recovery serum into 
.iMT mice with EAE would also be informative. However, additional effects of 
serum cytokines or other factors when transferring serum from recovered mice 
cannot be ruled out. 
In conclusion, this chapter has shown that B6 mice are resistant to rechallenge with 
MOG(35-55) shortly after recovery from a primary bout of EAE induced by 
immunisation with MOG(35-55). This resistance to rechallenge can be mimicked in 
naïve mice by transfer of B cells from mice that have recently recovered from EAE, 
but not total CD4 cells from these recovered mice. Approximately half of recovered 
mice had detectable levels of anti-MOG antibody in their serum, and serum from 
recovered mice also had some protective effect when given around the time of EAE 
induction. However, these studies are inconclusive in terms of defining whether B 
cells regulate EAE through production of IL-10 during B:T cell interactions, or 
through effects of antibody binding to MOG(35-55). More refined methods are 
necessary for elucidating the requirements for B cell antigen presentation and direct 
interactions with MOG-reactive T cells during recovery from/resistance to EAE, 
such as use of MOG-specific BCR transgenic mice in conjunction with MOG-
reactive TCR transgenics, or use of antigen targeted to B cells in vivo. 
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Figure 3-1: Mice are resistant to reinduction of EAE early after recovery. 
Closed symbols: EAE was induced by immunisation with MOG(35-55) in CFA 
and PTx on day 0. Mice were rechallenged with MOG(35-55) on day 43 (A - 10 
mice) or 74 (B - 4 mice) after first immunisation. Open symbols: As controls, 5 
mice were immunised for the first time with MOG(35-55) and Ptx on the same 
day as the reinductions. Disease burden in mice reinduced on day 43 (A) was 
significantly lower than controls (p<0.05), while disease burden in mice 
reinduced on day 74 (B) was not statistically different from controls. A is 
representative of 3 separate experiments in which mice were reinduced within 2 
weeks post-recovery; B is representative of 2 separate experiments in which 
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Fig 3-2: Transfer of post-recovery CD4 cells exacerbates disease CD4 
cells were purified from pooled spleens and inguinal LN of mice recovered 
from EAE (day 30 after immunisation). 3x10 6 CD4 cells were transferred and 
EAE was induced in recipients (5 mice) one day later. 5 mice which did not 
receive a transfer were also immunised as controls. In this experiment 
(representative of 3 similar experiments), disease severity was not 
significantly greater than controls (P<0.0594). 
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Figure 3-3: Tracking transferred CD4+ cells at the peak of disease. A/B: 
CD4 cells were purified from spleens of Ly5.1' B6 congenic mice on day 30 
post-EAE induction. Cells were transferred into wt B6 mice (Ly5.2) and EAE 
was induced 1 day later. At the peak of disease (day 15), inguinal LN, spleens 
and spinal cords harvested after perfusion with PBS, single-cell suspensions 
were stimulated with PMA/ionomycin, and stained for FACS(ICCS). FACS plots 
show percentage of CD4 cells which were Ly5.1 and lFNy, gated on CD4 
cells, and represent 2-3 mice/plot. C: 2x10 5 CD4CD25 Ly5.1 post-EAE or 
naïve cells were transferred one day prior to EAE induction. The percentage of 
CD4 cells which are Ly5.1 in CNS on day 14 is shown for one mouse/FACS 
plot, representative of 2 mice/group. 
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Table 3-1a Ly5.1' cells as % of total CD4 cells 
Day post- 
immunisation 
LN spleen CNS 
13 1.2 2.5 30 
14 1.7 3 22.8 
15 3.2 5 31 
Mean ± SD 2.03 ± 1.04 3.5 ± 1.32 27.9 ± 447 
Table 3-Ib: IFN'y cells as % of total Ly5.1'CD4 4 cells 
Day post- 
immunisation 
LN spleen CNS 
13 11.5 42 18 
14 ND ND ND 
15 5 34 39 
Mean ± SD 8.25 t.  4.6 38 ± 5.66 28.5 ± 14.85 
Table 3-1: CD4 cells were purified from Ly5.1 mice 30 days after EAE induction 
and transferred into naïve Ly5.2 recipients. One day later, EAE was induced and 
at the peak of disease (days 13-15), inguinal LN, spleen, and CNS were 
harvested, cells were stimulated with PMAlionomycin, and the total percentage of 
Ly5.1 cells (la) and proportion of Ly5.1 cells producing IFN7 (1 b) analysed by 
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Figure 3-4: Post-recovery EAE B cells can transfer resistance to 
induction of EAE, more consistently than whole splenocytes B cells were 
purified by removal of CD43 cells from spleens of day 30 recovered EAE 
mice and transferred (3x106 cells/mouse) one day prior to induction of EAE. 
Control mice did not receive any cells prior to EAE induction. The data shown 
are for 5 mice/group and representative of 4 similar experiments. In this 
experiment, B cells gave significant protection to recipients (p<0.041) 
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Figure 3-5: Transfer of post-recovery splenocytes gives inconsistent 
effects on EAE induction. Single cell suspensions were obtained from 
spleens of mice on day 30 post-EAE induction, 3-5x10 6 cells transferred, and 
EAE induced I day later. These results are representative of a total of 4 
experiments. The difference between group scores in A was not significant 
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Figure 3-6: Attempts to identify MOG-specific B cells ex-vivo by FACS 
Spleens and inguinal LN were harvested from naïve mice or mice on day 28 
post-EAE induction. Single cell suspensions were made and cells stained with 
anti-13220PE, and rMOG-biotin at the dilution shown followed by streptavidin-
APC. A shows two separate experiments testing different concentrations of 
rMOG-biotin In B cells were stained with B220PE and rMOG-biotin followed by 
streptavidin-APC, and additionally stained with F4-80-PcP and propidium 
iodide: all FL3 cells (macrophages and dead cells) were excluded from the 
analysis. 
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Figure 3-7: Serum antibody responses and specificity to rMOG and MOG(35-
55) A: Pooled serum from mice on day 30 of EAE (10 mice) or naive mice (2 mice) 
was incubated on ELISA plates coated with rMOG with the indicated concentration 
of soluble MOG(35-55) peptide, or OVA(323-339) as control. Binding of MOG-
specific Ab was then detected in the usual way. B: As for A, except only sera from 
EAE mice was used, and an additional test group was added, in which MOG(35-
50) was added at the time of serum incubation. C: Individual mouse sera from day 
30 of one EAE experiment, showing effects on binding to MOG of adding PBS or 
MOG(35-55) to serum during incubation on the plate. 
100 
IgGi 	IgG2a 
Day 30 EAE sera 	28/49 	12/44 
Day 14 EAE sera 	2/10 	0/10 
Table 3-2: numbers of mice with MOG-specific lgGl and lgG2a on day 30 
and day 14 post-EAE induction Serum was harvested from mice on days 14 
or 30 after induction of EAE and tested for presence of rMOG-specific antibody 
by ELISA. Shown is the number of individual mice testing positive for Ab out of 
total mice tested. Not shown: Sera from all naïve mice tested was negative for 
MOG-specific Ab. 
101 
—0— PBS control 
114 EAE serum 
130 EAE serum 
-ci- PBS control 
iti-MOG +ve serum 



















Figure 3-8: Effects of serum transfer on recipient EAE disease course A: 
Sera were pooled from mice at day 30 (recovered) or day 14 (peak disease) of 
EAE. 150iil of sera were injected iv into mice on days —1, +1,4 and 6, with EAE 
induced on day 0. Significant difference between control and recipients of day 
30 sera (P<0.0135). No significant difference between controls and recipients of 
day 14 sera. B: Day 30 sera which had tested positive for antibodies against 
rMOG were pooled, as were negative sera. 150j.tl sera was injected iv on days 
—1, +1 and 3, with EAE induced on day 0. There was a significant difference 
between controls and recipients of negative sera (P<0.0391), but no significant 
differences between controls and positive sera recipients, or recipients of 
positive versus negative sera. 
10 	20 	30 




0 	- - -- 
qj CO  









0 105 3x10 
3000 
2000 ::IJi 
0  o 10 3x105 
IL-2 (pg/mi) 
100 0.7 
50 11 	0.00 0.501 	i 0.2 140 o 10 3x105 	0 10 3x105 




Figure 3-9: Do post-recovery EAE B cells inhibit MOG(35-55) CD4+ cell 
responses in vitro? A: 105  day post-EAE (day 30) CD4 cells were incubated 
with 4x105 irradiated CD4-depleted splenocytes (APC) or B cells, both from the 
same day 30 mice ("EAE") or from naive mice in the presence of 101.tM MOG(35-
55) (filled bars), or medium only (open bars). Cytokines were measured in 
duplicate by ELISA. B: 105 post-EAE CD4+ T cells were cultured with 5x10 3 
CD1Ic+ splenic DCs from naïve mice and the indicated number of post-EAE B 
cells (not irradiated) per well in the presence of lOp.M MOG(35-55) (filled bars), 
or medium only (open bars). Cytokines were measured by ELISA from duplicate 
wells. 
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Figure 3-10: Testing of HEL-MOG(35-55) conjugates MD4 (closed symbols) 
and B6 (open symbols) B cells were purified by MACS negative selection using 
anti—CD43 beads (>97% purity) and 2x105 B cells cultured with 3x104 
MOG(35-55)-reactive I cells in 96 well plates for 72 hours with the indicated 
concentration of conjugate. Tritiated thymidine was added for the last 18 hours 
of culture. Conjugates A-E were made with decreasing concentrations of 
MOG(35-55), starting with the highest in A down to the lowest in E (see 
materials and methods). As controls for non-specific presentation of peptide, 
cells were incubated with a fixed concentration of HEL (1 MM) and a dose range 
of MOG(35-55). Controls not shown: B cells alone with conjugate, no antigen 
controls - in each case proliferation was not above background. 
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4. Phenotyping of IL-10 producing cells in the CNS during 
Recovery Reveals Regulatory T cells, not B cells 
4.1. Introduction 
As described in chapter 3, B cells appear to be playing a role in the active resistance 
to reinduction of EAE after recovery, and it is already known that B cells are 
normally required for recovery from EAE (273). IL-10 is vital for recovery from 
EAE, since mice which are unable to produce IL-10 fail to control disease (231). 
Also, levels of IL-10 mRNA increase in the CNS during recovery from EAE in rats 
(236). In vivo expression of IL-10 by transfected replication-deficient adenovirus 
prevents EAE induction in naïve mice, accelerated remission in mice with EAE and 
prevents relapses when given in a relapsing-remitting model of EAE (241). However, 
this exogenous production of IL-10 was only effective when targeted directly to the 
CNS and had no effect when the engineered virus was given systemically (241). 
Similarly, OVA-reactive transgenic cells stimulated in vitro to become IL-10- 
producing regulatory T cells could prevent induction of EAE, but only when 
ovalbumin was injected into the brain, presumably to localise Tregs (and therefore 
IL-10 production) to the CNS (62). Given these reports, and the finding that B cell 
IL-10 is important for recovery from EAE (59), the obvious next step was to 
investigate the location of B cells after transfer, and analyse which cell populations 
produce IL-10 in the CNS during the normal recovery from EAE. 
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4.2. RESULTS 
4.2.1. Few B cells are present in CNS at any point during normal 
recovery from EAE 
In order for B cells to directly downregulate CNS inflammation via IL- 10 they would 
have to migrate to the CNS. Therefore, at different time points during EAE lymphoid 
cells in the CNS were stained for the presence of B cells, using Ab against two 
separate cell-surface markers: B220 and CD19. Very few B cells were observed in 
the CNS at any time point (Figure 4-1), with the proportion of total CNS 
mononuclear cells staining positive for CD19 or B220 never rising above 10%, and 
frequently falling below 1% (Figure 4-1b). The proportion of B cells observed in the 
CNS varied in a non-time dependent manner, i.e. there was no apparent increase in B 
cell frequency as mice recovered (Figure 4-1b). For B220 cells, many of the cells 
appeared to express this marker at low levels compared to B220 cells in the spleen 
or LN (Figure 4-1a). This was suggestive of the recently described plasmacytoid DC 
(300), and in support of this hypothesis, a high proportion of these B22010 cells were 
found to co-express CD11 c  and CD8 (Figure 4-1 c). Thus, very few B cells were 
present in the CNS. 
4.2.2. Post-recovery B cells do not accumulate in the CNS of transfer 
recipients after EAE induction 
As described in chapter 3, transfer of post-recovery B cells results in some resistance 
to induction of EAE in recipients. To determine whether post-recovery B cells 
mediate these effects in the LN/spleen or in the CNS, Ly5.1 B6 congenic B cells 
from recovered mice were transferred into B6 recipients (Ly5.2) and EAE was 
induced. 14 days after immunisation the inguinal LN, spleen and CNS of these mice 
were examined by FACS for the presence of Ly5.1 B cells. In contrast to transfer of 
post-recovery CD4 cells, transferred post-recovery B cells were mainly found in 
lymphoid sites, and were not present above background levels in the CNS (Figure 4-
2). There were no obvious increases in the proportion of Ly5.1 B cells in LN or 
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CNS of mice receiving post-recovery compared to naïve B cells (Figure 4-2). 
However, as discussed in chapter 3, the lack of markers for MOG-specific B cells 
within the polyclonal Ly5. 1 population makes measurement of in vivo expansion in 
LN difficult. 
4.2.3. IL-10 production can be detected in cells from the CNS of 
recovering mice 
Since IL-10 mRNA is known to increase in the CNS during recovery (236), the 
production of IL-10 protein by mononuclear cells in the CNS was investigated by 
FAGS (Figure 4-3). IL-10-producing cells were detected in the CNS, constituting up 
to 5% of total mononuclear cells in different experiments. The few B cells present in 
the CNS did not produce significant levels of IL-b. Likewise, GD11 c dendritic 
L 	 . 
cells did not appear to major contributors to IL-10 production in this assay 
Interestingly, over half of the IL-10-producing cells were CD4, and this was 
confirmed in further experiments. Some of the IL-10 produced appeared to be from 
CD8 cells, although this has not been confirmed. 
The CNS was greatly enriched for cytokine-producing CD4 cells compared to LN - 
25-50% of CD4 cells produced IFN'y in the CNS in comparison to less than 5% of 
CD4 cells in LN, and negligible IL-10 was detected in LN at any time (see Figure 4-
7c) - fitting with accumulation of effector cells in the CNS. Although the proportion 
of CD4+  i cells n the CNS producing IL- 10 ex vivo was small in comparison to those 
producing JFNy (25-50% IFNy compared to 2-13% I1-1), when comparing 
several experiments in which IL-10 production was measured, there was an overall 
increase in proportion of IL-10 CD4 cells over time, correlating with recovery 
(Figure 4-4a/b). It was interesting to note that the proportion of CD4 cells producing 
IFNy did not appear to decrease as mice recovered (Figure 4-4c), although 
stimulation with PMA and ionomycin only indicates cytokine-producing potential, 
not whether the cytokines detected were actually being produced in vivo. 
107 
4.2.4. Analysis of production of IFNy and IL-4 by IL-10 producing 
CD4 cells in CNS of mice with EAE. 
Production of IL-10 is characteristic of some Treg cells. However, both Thi and Th2 
cells can also produce IL-10 in conjunction with IFNy or IL-4, respectively (233). 
Ex-vivo production of IL-10 by CD4 cells from the CNS of mice with EAE was 
therefore analysed in conjunction with IFN7 and IL-4. A large proportion of CD4 
cells produced IFNy (this typically ranged from 25 to 50% in different experiments), 
and some of these cells were double-positive for IL-10 (Fig 4-5a). The proportion of 
IFNy cells also staining positive for IL-10 production varied between experiments. 
However, there was always a population of CD4 cells that exclusively produced IL-
10. IL-4 production was detected at low levels in a small proportion of CNS CD4 
cells (Fig4-5b). Double staining for IL-10 and IL-4 production in the same cell was 
not possible at the time due to the antibodies having the same fluorescent dyes, but 
the percentage of IL-4 cells was lower than the percentage of IL-10 cells, 
suggesting that at least half, if not all, of the IL- 10 producers did not produce IL-4. 
4.2.5. Expression of CD25 by IL-10- and IFNy-producing cells in the 
CNS suggests two distinct populations 
Production of IL- 10 and IFNy by separate cell populations suggested the presence of 
both Tregs and pathogenic T cells. CD25 is constitutively expressed by some Treg 
populations (45), therefore expression of CD25 by cytokine-producing CD4 cells in 
the CNS was examined. There was a clear contrast: IL-10 1 cells were CD25, while 
IFNy cells were CD25 (Figure 4-6a). Cells positive for both IL- b 0 and IFNy tended 
to show a mixed phenotype, with at least half being CD25- while some expressed 
CD25 at intermediate or high levels (Figure 4-6b). IL-2-producing cells were also 
negative for expression of CD25 (Figure 4-6c). This result supports the hypothesis 
that IFN-y-producing cells are pathogenic Thi effectors, while IL-10-producing cells 
may have a regulatory function. 
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4.2.6. The number of CD4CD25 cells in the CNS increases during 
EAE, correlating with recovery 
Tregs have been shown to expand/accumulate in draining lymph nodes after 
immunisation or in response to tissue inflammation (145), as well as at the site of 
inflammation (123). Since the proportion of CD4iL-10 cells was observed to 
increase in the CNS during recovery, and these cells expressed CD25, the proportion 
and number of total CD4CD25 cells in the inguinal LN, spleen and CNS at 
different time points during EAE were analysed. In the LN and spleen, the 
percentage of CD4 cells that expressed CD25 remained fairly constant throughout 
the disease course, with no marked increases in numbers of CD25 cells (Figure 4-
7a). However, there was a marked increase in the percentage of CD4 cells 
expressing CD25 in the CNS as EAE progressed from days 13 through to day 20 
(Figure 4-7a). The total number of CD4CD25 cells also increased over time 
(Figure 4-7b), although the cell counts from the CNS are variable between 
preparations and therefore cell numbers are really estimates. This increase in 
CD4CD25 cells correlated with progression of the recovery phase of disease (the 
peak of disease is usually reached around day 14). Approximately one third of CNS 
CD4CD25 cells consistently produced IL-10 after ex vivo stimulation, while the 
proportion of LN CD4CD25 cells that produced IL-10 after ex vivo stimulation 
was low (Figure 4-7c). 
4.2.7. CD4CD25 cells in the CNS phenotypically resemble naturally-
occurring CD4CD25 cells 
Although no unique cell surface marker has yet been described for Tregs, the so-
called naturally-occurring CD4CD25 cells are known to constitutively express 
several T cell activation markers in addition to CD25 (94). The CD4CD25 and 
CD4CD25 populations in LN and CNS were compared for their expression of 
GITR, CTLA-4, CD44, CD69 and aE7 (Figure 4-8). CD4CD25 cells in the CNS 
displayed a similar phenotypic profile to CD4CD25 cells in the LN of both naïve 
hi mice and those with EAE: they were GITR, CTLA-4 and CD44. In contrast, 
CD4CD25 CNS cells expressed GITR and CTLA-4 at low levels, albeit slightly 
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higher than LN CD4CD25 cells. The majority of CD4 cells in the CNS were 
CD44'', confirming the presence of mainly antigen-experienced/activated cells at the 
site of inflammation. The proportion of both CD25 and CD25 cells expressing 
CD69 was also greater in the CNS than LN, suggesting recent activation within the 
CNS, and indeed CD69 cells appeared to be the major cytokine producers ex-vivo 
(data not shown). Expression of the integrin ctEI37 has recently been found to 
correlate with a more potently suppressive subpopulation of CD4CD25 cells(30 1, 
302) that preferentially migrates to sites of inflammation(30 1). It was therefore 
interesting to note that CD4CD25 cells in the CNS of mice with EAE were 
enriched for aEI37-expression. 
The levels of expression of CTLA-4 and GITR were higher on CD4 cells (both 
CD25 and CD25) from the CNS compared to LN of naïve mice or those with EAE 
(Figure 4-8), and this was particularly evident on CD25 cells, again suggesting a 
high activation status of cells in the CNS. It is interesting to note that naïve and EAE 
LN were phenotypically similar apart from a slight increase in the proportion of 
CD25- hi cells which were CD44 and CD69 hi  , and an increased proportion of CD25 + 
cells which were CD69hi,  correlating with activation of only a proportion of cells in 
the draining LN of immunised mice, while CNS cells appear highly enriched for 
activated cells. In summary, CNS CD4CD25 cells bear the phenotype described for 
CD4CD25 Tregs, and appear to be highly activated compared to LN cells. 
4.2.8. FoxP3 expression 
CD4CD25 cells express the transcription factor FoxP3, and this appears to be 
important for their function (99, 100). In mice this expression appears to be limited 
to regulatory cells (although not exclusively to CD25 regulatory cells) and has not 
so far been found to be upregulated significantly during activation of naïve T cells. It 
was not possible to obtain mRNA in sufficient quantities from the small numbers of 
CD4CD25 cells purified from the CNS in these studies, so rtPCR was performed 
using whole CD4tenriched cells. CD4 cells from both inguinal LN and CNS were 
positive for FoxP3 expression (Figure 4-9), indicating that at least some of the cells 
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in the CNS are likely to be FoxP3-expressing regulatory T cells. One of the major 
limitations of the rtPCR approach is the failure to identify what proportion of a cell 
population express the gene in question, and the production of mAb to identify 
FoxP3 by FACS, and also mice that have GFP expression linked to FoxP3 
expression, should be major steps forward in analysing the homogeneity of CD25 
Treg populations. 
4.2.9. Ag-specificity of CD25 cells: in vitro proliferative responses 
and ex vivo analysis of cytokine production in response to 
MOG(35-55) 
The specificity of CD4CD25 regulatory T cells involved in preventing 
autoimmunity is a subject of great debate, and in most cases has not yet been defined 
unless TCR transgenic systems are used. The best approach to identify MOG(35-55)-
specific CD4 cells would be to use class II AbMOG(3555)  tetramers or liposomes 
to label individual cells for FACS, but these tools were not yet available for use in 
this system. Therefore, two alternative approaches were attempted: measurement of 
proliferation and cytokine production by CD4CD25 cells in response to MOG(35-
55). 
i) proliferation assays 
It is now well established that CD4CD25 Tregs are anergic in vitro, in that they fail 
to proliferate to antigenic stimulus in the absence of exogenous IL-2. CD4CD25 
cells purified from the LN and CNS of mice with EAE were therefore cultured with 
APC and MOG(35-55) in the presence or absence of exogenous IL-2, or with IL-2 
alone. As a further control, cells were cultured with anti-CD3 with or without IL-2. 
The results in the presence of anti-CD3 confirmed that CD4CD25 cells in the CNS 
were anergic - they only responded when exogenous IL-2 was added (Fig4-lOa). 
The results of LN cells in the presence of MOG(35-55) were less clear-cut. 
+ 	+ CD4 CD25 cells failed to proliferate when peptide alone was added, but did 
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proliferate when exogenous IL-2 was present (fig 4-10b/c). However, the 
proliferation of CD4CD25 cells in response to MOG(35-55) in the presence of IL-2 
was similar to responses to IL-2 alone in some of the assays performed. This high 
background of proliferation in the presence of IL-2 without antigen may make any 
additional responses to MOG(35-55) insignificant. Due to the small numbers of cells 
obtained from the CNS, these assays also suffered from low proliferation counts. 
Therefore it was not possible to conclusively determine the level of antigen-specific 
responses by this method, although the presence of MOG(35-55)-reactive 
CD4CD25 T cells in the LN is suggested. 
ii) cytokine production ex vivo 
As described, ex vivo stimulation with the non-specific stimulants PMA and 
ionomycin was used to determine cytokine-producing potential of CD4 cells in the 
CNS. This method was refined to determine the proportion of cells which produce 
cytokine in response to MOG(35-55) ex vivo. Since IL-10 production by Tregs has 
not been described to require addition of IL-2, these assays were performed by 
culturing whole CNS or LN cells with or without MOG(35-55). The addition of 
splenocytes as APCs was found to have no affect on CNS cell cytokine production so 
was not included. 
IFNy production in response to MOG(35-55) was readily detectable by FAGS and 
significantly higher than controls cultured for the same length of time without 
antigen. (Figure 4-11 a). The proportion of cells producing IFNy was 3-fold lower 
after stimulation with MOG(35-55) than with PMA and ionomycin. It is difficult to 
compare these stimuli directly, but it does appear that MOG(35-55)-reactive cells 
may only make up a proportion of the Thl cells in the CNS. 
IL-10 production by CD4 +  CNS cells was not above background in response to 
MOG(35-55), although there was a suggestion of increased IL-10 in some mice (Fig 
4-11 b). In the experiments in which this assay was tested the IL- 10 response to PMA 
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and ionomycin was quite low, and it may have been more fruitful to test IL-10 in 
response to MOG(35-55) at later time points when IL-10 production increases (i.e. 
day 20 rather than day 16). 
4.3. DISCUSSION 
Investigating the location of B cells during normal recovery from EAE and after 
transfer of post-recovery B cells was the first step to identify the location of action of 
B cells. It was apparent that B cells are not major contributors to the cellular infiltrate 
into the CNS at any point during EAE in B6 mice (Figure 4-1), never being observed 
at greater than 10% of total mononuclear cells (and as already described, many of the 
B220 cells observed are likely to be DCs not B cells). Downregulation of B cell 
surface markers by B cells in the CNS is unlikely to explain the lack of B cells, since 
two separate surface markers were used to identify them (CD 19 and B220). After 
transfer, post-EAE Ly5.1 B cells localised to the LN and spleen, but did not 
accumulate in the CNS at either the peak of disease or during recovery (Figure 4-2), 
further confirming that B cell entry into the CNS does not occur to a great extent in 
this model. IL-10 production was not observed from the few B cells that were present 
in the CNS. However, lack of IL-10 production by transferred post-recovery B cells 
under the same stimulation conditions (data not shown) raises the possibility that the 
conditions used were not sensitive enough for detecting IL- 10 production by B cells. 
Taken together, these results suggest that B cells principally act in the draining LN 
and/or spleen, but not CNS, to contribute to recovery from EAE induced with 
MOG(35-55) in B6 mice. During T cell activation, a proportion of T cells enter B 
cell follicles where they may engage with B cells expressing their cognate Ag. These 
interactions promote the maturation of the B cell response through formation of 
germinal centres and class switching in response to cytokines(69). At this stage, B 
cells may also influence the interacting T cells through expression of costimulatory 
molecules and production of cytokines. It is likely therefore that B cell IL- 10 may act 
in a highly localised manner to downregulate specific T cells. It is also possible that 
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B cell IL- 10 has a more indirect effect through non-specific down-regulation of APC 
within the lymphoid organ. As discussed already, IL- 10 is an important growth factor 
for B cells(233), therefore effects of IL-10 on B cells themselves to promote some 
other activity of B cells (such as Ab production or expression of costimulatory 
molecules) cannot be ruled out as yet. 
As an aside, it was interesting to note the presence of cells with the phenotype of 
plasmacytoid dendritic cells (pDCs), i.e. cells expressing low levels of B220, CD8 
and CD1 ic. This subpopulation of DCs has recently been under intense 
investigation, and similar to other DC subsets may have roles in Th1/Th2 
polarisation, in type-1 IFN related inflammatory diseases in humans, and in 
regulatory T cell induction(303-306). 
IL-10 mRNA transcripts increase in the CNS during recovery(23 6), and targeting 
exogenous production of IL-10 to the CNS can prevent or ameliorate EAE(241). The 
lack of B cells in the CNS therefore suggested that another cell population(s) may 
promote recovery via IL-10 production in the CNS. Further investigation revealed 
CD4 cells to be a major IL-10-producing population, and the proportion of IL-10  
producing cells appeared to be generally higher during the later recovery phase (day 
19 on) than at the peak of disease, fitting with the reported increase in total IL-10 
mRNA during recovery. These IL-10-producing CD4 cells expressed CD25, and 
other activation markers, and appeared to be a phenotypically distinct population 
from [FNy-producing CD4 cells in the CNS (Figures 4-3 to 4-8). 
It could be argued that the CD4CD25 cells in the CNS were simply the most 
recently activated effector cells, particularly since they also exhibited high 
expression of other activation markers including GITR and CTLA-4, in contrast to 
CD4CD25 cells which were low for these markers (Figure 4-8). However, the 
CD4CD25 cells were also CD44hi  and a proportion were CD69hi,  indicating that 
CD4CD25 cells in the CNS are indeed antigen-experienced cells, and some have 
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recently seen antigen - probably in the CNS. A high proportion of CD4CD25 cells 
also produced IFN'y ex vivo, suggestive of Thi effectors, while CD4CD25 cells 
were only observed to produce IL-10 (Figure 4-6). Therefore, the hypothesis that IL-
10-producing CD4 cells were regulatory T cells was supported by their phenotype. 
While it is surprising that the IFNy-producing cells are negative for expression of 
activation markers such as CD25, a similar dichotomy of expression of cell surface 
markers on effector and regulatory T cells has been reported in the synovial fluid 
from the joints of patients with JIA (214), and in the subcutaneous lesion site during 
Leishmania infection (52), both situations in which the initiating Ag are also still 
abundant. CD25 upregulation by effector cells in the CNS has been reported by 
Flugel et al, using GFP-transfected MBP-specific cell lines in rats (307) and also by 
Bischoff et al, using tetramers to stain PLP(139-151)-specific T cells in SJL mice 
with EAE (286). However, in the cell line transfer studies, CD25 upregulation by 
MBP-specific cells was an early event after entry into the CNS, while in this project, 
CD25 expression in relation to cytokines was only investigated from day 13 on, 
while disease onset begins around day 8. Also, in the Bischoff study (286) no 
increase in the percentage of CD25 PLP-specific cells in the CNS over the course of 
disease was observed, and cytokine production by CD25' or CD25 cells was not 
investigated. SJL mice develop a relapsing-remitting course of EAE, and do not 
become resistant to rechallenge after recovery (291). It has recently been reported 
that SJL mice may have an relative defect in the generation ofPLP(l39-151)-specific 
CD4CD25 cells(191). Therefore it appears that the mechanisms of recovery from 
EAE, in terms of regulation by CD4' 1'CD25 cells, may be different between SJL and 
B6 mice. 
It was interesting to note that a proportion of CD8 cells from the CNS also produced 
IL- 10 ex vivo (Figure 4-3). IL- 10 production is not thought to be a major mechanism 
of regulation by CD8 cells. While CD8 cells with a regulatory phenotype have 
been reported to protect from EAE (57), these cells were induced in vitro by 
stimulation in the presence of TGFI3. CD8 cells that produce TGF3 and prevent 
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EAE have also been induced in rats during induction of oral tolerance (308). A recent 
report using B6 mice found that mice depleted of CD8 cells prior to induction of 
EAE developed disease of increased severity, suggesting some form of regulation by 
CD8 cells (265), although the mechanism was not investigated. 
As described in Chapter 1, regulatory T cells can be broadly categorised into 
"naturally-occurring" CD4CD25 cells which are generated in the thymus, and 
peripherally-induced regulatory cells. The phenotype of the CD4CD25 cells in the 
CNS was most consistent with the thymically-generated CD4CD25 Tregs (94). 
This implies that pre-existing CD4CD25 Tregs were expanded by Ag presented 
either as a result of the initial immunisation or after damage to the CNS by DC 
migrating from the inflamed brain and spinal cord. Proliferation of CD4CD25 cells 
in the inflamed gut has been reported in a model of colitis (105), so expansion of 
Tregs in the CNS itself cannot be ruled out. The increase in the proportion of CD4 
cells expressing CD25 during recovery could either be due to continued/preferential 
recruitment of Tregs over Teffectors to the CNS, or due to enhanced survival of 
Tregs compared to Teffectors. The increase in numbers of CD4CD25 cells in the 
CNS, although not a reliable measure, suggests the former, but rates of recruitment 
or death in the CNS have not been investigated. 
Initial reports of CD4CD25 cells described them as classically anergic, i.e. failure 
to proliferate to antigenic stimulus in vitro in the absence of exogenous IL-2 (106, 
112), and it was assumed that CD4CD25 cells would similarly fail to expand to 
immunisation in vivo, as has been observed for tolerant T cells (285). However, 
several studies have now shown that CD4CD25 cells do proliferate in response to 
immunisation with antigen in adjuvant or antigen-pulsed mature DCs, and also that 
antigen-specific Tregs accumulate in vivo in sites draining that antigen (145). 
Therefore, it is feasible, if not likely, that CD4CD25 cells are expanded after the 
immunisation with self-Ag used to induce EAE, and/or in response to self-Ag 
presented on DC activated by CNS inflammation. 
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In a mouse model of diabetes induced by expression of inflammatory molecules on 
pancreatic 13  cells, a localised accumulation of CD4CD25 cells was found to occur 
in the pancreatic LN (122). Likewise, in a mouse model of IBD (in which colitis is 
induced by transfer of CD4CD25- cells and can be prevented by co-transfer of 
+ 	+ 	
i 	
+ 	+ CD4 CD25 cells) there s a localised accumulation of CD4 CD25 cells in the MLN 
compared to other LN, as well as entry into the intestine itself (105). In this project, 
an accumulation of CD4CD25 cells was not observed in the inguinal LN or spleen 
as mice recovered from EA-E. 
The specificity of CD4CD25 cells in the CNS is an intriguing question. It is known 
that the major encephalitogenic epitope in MOG is MOG(35-55) (168), and since this 
is the peptide used for induction of EAE one might predict that most of the CD4 
cells would be specific for this epitope. However, it is known that during 
inflammation, "bystander" effector cells that are not specific for the tissue, can be 
recruited by the local inflammatory environment, although it is generally thought that 
Ag recognition is required in order for cells to remain and perform effector functions 
in the site (175, 309). Focussing on CD4CD25 cells, in several models expansion 
has been found to be localised to the LN draining the target organ or site of 
immunisation, i.e. CD4CD25 expansion appears to be Ag-specific, or at least 
driven by localised inflammation (77, 145, 148). Prevention of diabetes in NOD mice 
by transfer of CD4CD25 cells also appears to require a relatively high frequency of 
+ 	+ CD4 CD25 cells with specificity for pancreatic islet Ag, since protection was 
provided by CD4CD25 cells with transgenic TCRs specific for pancreatic antigens, 
but not by cells with polyclonal TCRs (153, 154). 
The attempts to determine Ag-specificity of CD4CD25 cells in this project were 
hampered by high background proliferation of cells in the presence of IL-2 alone 
(figure 4-10), and low frequencies of IL- b -producing cells (Figure 4-11) after ex 
vivo stimulation. Without more refined tools such as MOG(35-55)-A" tetramers, it 
has so far been impossible to conclusively determine the proportion of CD4
+  CD25 +  
cells with specificity for MOG(35-55). 
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Taken together, the results of this chapter indicate that CD4cells but not B cells are 
able to produce IL-10 in the CNS during recovery from EAE. These CD4iL-10 
cells express CD25, in contrast to IFNy cells, and further analysis of CD4CD25 
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Figure 4-1: Few B cells are present in the CNS of B6 mice with EAE. Spinal 
cords and inguinal LN were removed from mice and cells stained for FACS 
analysis of expression of either B220 or CDI9 as indicated. Fig A shows typical 
FACS staining of cells from mice on day 14 post-EAE induction (4 mice/plot). B: 
Combined results from several experiments in which the percentage of B cells in 
the CNS (4-6 mice pooled for each point) was measured on the day indicated 
after EAE induction. Mean % B cells on days13/14 = 4.44% 0.64% (n12) and 
on days 19-21 = 4.46% ± 1.04% (n=7), there waon tatistical difference in % B N & 
cells between these time points. C: CD1 1 c and C 	xpression by B220 cells in 




























Figure 4-2: Transferred post-recovery B cells do not accumulate in the 
CNS after EAE induction. B cells were purified by depletion of CD43 cells 
from pooled spleen and inguinal LN of Ly5.1 mice on day 30 post-EAE 
induction, and from spleens of naïve mice. 3x10 6 B cells were transferred into 
B6 recipients and EAE was induced the following day. 14 days later inguinal LN 
and CNS were harvested and cells stained for FACS. For LN, each plot 
represents a single mouse and the mean percentage of Ly5.1 + B cells (. SD) for 
three mice is shown above each plot. For CNS, each plot represents 3 mice and 
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Figure 4-3: IL-10-producing cells can be detected in the CNS, and CD4 
cells appear to be major producers of IL-10. Spinal cords were removed 
from 4 mice 28 days after EAE induction and mononuclear cells were 
stimulated with PMA and ionomycin. Cells were stained for surface markers 
B220, CD1 ic, CD8 or CD4 followed by intracellular staining of IL-b. 
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Figure 4-4: The proportion of IL-10-producing, but not IFNy-producing, 
CD4 cells increases over the course of EAE. A: percentage of CD4 
cells positive for IL-10 after 4 hours ex vivo stimulation with PMNionomycin 
at peak (days 13-16) or recovery phase (19-28 days after EAE induction), 
from several experiments. B shows the same data (solid lines) overlaid with 
a representative EAE plot (dotted line). C: percentage of CD4 cells positive 
for IFNy in the same experiments. 
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Fig 4-5: Comparison of IL-b, IFNy and IL-4 production by CD4 cells in 
CNS mononuclear cells were isolated from 4 mice 28 days after EAE 
induction and stimulated with PMNionomycin. Cells were then stained for 
surface expression of CD4 and intrascellular IL-b, IL-4 or IFNy as indicated. 
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Figure 4-6: CD25 expression by cytokine-producing cells in the CNS Spinal 
cords were harvested from 4 mice 20 days after EAE induction and 
mononuclear cells were stimulated for 4 hours with PMA/ionomycin then stained 
for surface expression of CD25 and CD4, and intracellular IL-b, IFNy and IL-2 
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Fig 4-7: The proportion of CD25 cells in the CNS, but not LN or spleen, 
increases during recovery A/B: On days 12, 16 and 20 post-EAE induction, 
inguinal LN, spleen and CNS were harvested, cells stimulated with 
pma/ionomycin and stained for FACS (ICCS). A: The percentage of CD4 cells 
expressing CD25 in these sites is overlaid with the mean EAE scores of the 
same mice. Results shown are pooled data from 2 representative experiments in 
which 4-5 mice/group were analysed at each timepoint. The percentage of 
CD25 cells in CNS is significantly higher on day 20 than on day 13 (p<0.0096). 
B shows mean number of cells obtained from pooled spinal cords from 4 
mice/day in the same 2 experiments. C shows typical IL-10 production profile by 
CD4 cells in inguinal LN and CNS on day 20 post-immunisation. 
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Figure 4-8: CD4CD25 cells in CNS phenotypically resemble naturally-occurring 
Tregs CNS and inguinal LN cells from 4 mice on day 20 post-EAE induction as well as 
LN from 3 naïve mice were stained for FAGS. Plots shown are gating on CD4 cells and 
thin line shows isotype control stain. MFI for GITR and GTLA-4 staining and percentage 
hi for GD44, GD69 and aE37 staining are shown in top right corner of histogram plots. 
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Figure 4-9: FoxP3 expression can be detected in CD4 cells from CNS and 
LN of mice with EAE 20 days after EAE induction CD4 cells were enriched 
from CNS and LN of 5 mice. rtPCR was performed to detect FoxP3 and Pactin. 































Figure 4-10: Proliferative responses of CD4+CD25+ cells to MOG(35-55) 
and/or IL-2. A: 2x104 purified CNS cells from mice on day 16 after EAE 
induction were stimulated with 1 .tg/ml anti-CD3 with/without 100u/ml IL-2. 
B/C:2x10 4 CD4CD25 cells were purified from the inguinal LN of mice 16 (B) 
or 18 (C) days after EAE induction, and stimulated with 301.tM (A) or 201iM (B) 
MOG(35-55) and IL-2 as indicated in graph legend. In A and B cells were 
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Figure 4-11: Ex vivo cytokine production by CNS CD4 cells in response to 
MOG(35-55) or PMA and ionomycin. 16 days after EAE induction, spinal cords 
were harvested from 4 mice and mononuclear cells from single mice stimulated 
with 10pM MOG(35-55), PMNionomycin, or medium alone before ICCS. The 
PMA (isotype control) group shows the background staining with cytokine isotype 
control Ab of cells stimulated with PMA and ionomycin. These results are 
representative of two separate experiments. 
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5. Functional. Characteristics and in vivo Importance of 
CD4+CD25+ cells During Recovery from EAE 
5.1. 	Introduction 
Concentration of IL-10 production within the CD4CD25 T cell compartment in the 
CNS suggested that a regulatory CD4 T cell population may be recruited to the CNS 
during recovery. CD4CD25 cells have been shown to downregulate the activation 
of CD4+  and CD8
±  T cells (94, 104) as well as B cells (71, 72) and cells of the innate 
immune system (105). Most studies have looked at their roles in preventing these 
responses rather than controlling active disease. However, cure of colitis (121, 123) 
and early-onset diabetes (153, 154) by transfer of CD4CD25 cells has been 
demonstrated. CD4CD25 cells with protective function have been found to 
accumulate in the pancreatic LN in a murine model of diabetes (122), although these 
cells ultimately did not prevent diabetes. Also, human studies in rheumatoid arthritis 
have shown the accumulation of regulatory T cells at the site of inflammation (the 
joint), and these cells do not appear to mediate resolution of disease (214, 215), 
although in one study there was a correlation between Tregs and disease 
progression(2 14). Therefore, the demonstration of regulatory T cells playing a role in 
controlling an ongoing autoreactive response, without the use of transgenic cells or 
artificial manipulation, was a very exciting prospect, but the functional importance of 
CD4CD25 cells in the CNS remained to be demonstrated. 
5.2. RESULTS 
5.2.1. Attempts to clone MOG(35-55)-specific CD4CD25 cells from 
the CNS 
Obtaining sufficient cells from the CNS to perform functional experiments is 
difficult without using high numbers of donor mice. For human therapeutic 
applications, Tregs would ideally be purified from peripheral blood of the patient, 
manipulated in vitro and then returned. Cloning of these cells would allow the 
selection of cells with known Ag-specificity and function, reducing the risk of 
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expanding and returning pathogenic cells to exacerbate disease. For this project, 
cloning of cells from the CNS would allow more concise identification and 
functional characterisation of regulatory cells in terms of cell surface markers and 
requirements for IL- 10 production for regulation in EAE. 
For cloning, B6 congenic Ly5.1 mice were used to allow eventual tracking of the 
cells in vivo. CD4CD25 cells from LN and CD4 cells from CNS were purified 
from mice 18 days after EAE induction and cloned by limiting dilution in the 
presence of IL-2 (see section 2.7 for details). 32 LN CD4CD25 clones and 75 CNS 
CD4 clones were initially restimulated. By 4 weeks this had decreased to only 6 LN 
clones and 33 CNS clones still growing. By 2 months all of the LN clones had died, 
but 12 CNS clones were still growing. These continued to grow in culture and 11 
eventually reached sufficient numbers to be tested between 2 and 4 months after 
initial cloning. Appendix Table A-i summarises the results of this cloning attempt. 
Clones were tested for responsiveness to MOG(35-55) in the presence or absence of 
IL-2, and for MOG(35-55)-specific IL-10 and IFNy production (summarised in Table 
A-2, Appendix). 8 of the ii clones tested proliferated in a dose-dependent manner to 
MOG(35-55), but none were anergic. All clones that proliferated to MOG(35-55) 
also produced IFNy in a MOG(35-55)-specific manner. 5 of the 8 clones also 
produced IL-b, in varying amounts. Since these clones from the CNS have a Thi 
phenotype, they would be predicted to be pathogenic, although this has not yet been 
tested in vivo. 
It was apparent from this initial cloning attempt that the CD4CD25 cells died more 
quickly in vitro than the whole CD4+  cells, and given the phenotype of surviving 
clones they were most likely generated from CD25 cells. There are very few 
published reports on cloning of Tregs ex vivo. In one report, IL-10 was added to the 
initial rounds of stimulation (88). IL-15 is also known to be a survival factor for 
some memory T cells (310), and can augment human Trl expansion in vitro (311). 
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CD4CD25 cells were purified from the LN of mice early in the recovery phase of 
EAE and plated out for cloning as before, except IL-10 was added for the first two 
rounds of stimulation, and IL-15 was included in each restimulation. This approach 
did appear to enhance the survival of clonal cells, and by nine weeks 13 out of 46 
wells initially scored as positive still contained living lymphocytes (see Table A-3 
for summary). However, despite apparently enhanced survival, the cells failed to 
expand significantly upon restimulation. 
In vitro expansion of CD4CD25 cells has recently been reported (153), with up to 
200 fold expansion in two weeks achieved by stimulating purified CD4CD25 cells 
with anti-CD3 and anti-CD28 bound to beads, with the addition of 2000U/ml 
recombinant human IL-2. This type of approach, to either initially expand cells 
before cloning or directly clone CD4CD25 cells from the CNS, followed by testing 
for MOG(35-55)-reactivity, although more laborious may ultimately prove more 
successful than the attempts described here. This may also have the advantage of 
cloning out regulatory cells that may have specificity for other CNS Ag, since cells 
would initially be expanded polyclonally. 
5.2.2. In vitro assays to measure suppressive properties of LN and 
CNS cells from EAE mice 
One of the commonly used functional assays to test for regulatory cells is the in vitro 
suppression assay. This involves culturing responder cells - in these experiments 
CD4CD25 cells were used - with APC and either Ag or anti-CD3, in the presence 
or absence of CD4CD25 cells. Responder cell proliferation should be suppressed in 
the presence of regulatory T cells. 
The suppression assay conditions were first optimised for conditions such as 
concentration of anti-CD3 used and number of APC per responder cells (see 
Appendix Figure A-i and A-2). Further optimisation was done by Dr Leigh Stephens 
using TCR transgenic cells (see section 2.5.5). For assays using cells from all 
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peripheral LN and spleen of naïve mice, the number of CD4CD25 cells obtainable 
was reasonably high (around one million/mouse). However, when using cells from 
draining inguinal LN or CNS of immunised mice it was necessary to use as few cells 
as possible per well. The number of APC proved to be particularly important for 
facilitating suppression - a T cell:APC ratio of approximately 1:1 gave best results, 
and raising APC numbers eventually abrogated suppression, presumably due to 
spatial separation of responder and CD4CD25 cells in the well (cell contact appears 
to be important for in vitro suppression by CD4CD25 cells). Different methods of 
purifying cells were also attempted, as described in section 2.5.5. A combination of 
CD4 magnetic enrichment followed by FACS sorting gave consistently higher 
purities and reasonable yields. 
5.2.3. CNS CD4CD25 T cells suppress in vitro proliferation 
In two separate experiments, CD4CD25 cells obtained from the CNS of mice in the 
recovery phase of EAE (day 20 after EAE induction) were able to suppress the 
proliferation of naïve CD4CD25 cells in response to anti-CD3 (Fig 5-1). 
Importantly, this confirms that these are indeed functional regulatory cells. It was 
also interesting to note that CNS CD4CD25 cells appeared to be more potent than 
naïve CD4CD25 cells, giving greater inhibition of CD25 cells and suppressing at a 
lower number of CD25 cells. Likewise, the suppression by EAE LN CD4CD25 
cells appeared more potent than naive CD4 +  CD2S +  cells, as has been observed in 
other experiments - see below. EAE LN CD25 cells also appeared more potent thari 
EAE CNS CD25 cells, but this may reflect differences in the purity of the cells used 
in the experiment: the CNS cells were only 85% CD4CD25, while the EAE LN 
± 	+ cells were 98% CD4 CD25 
5.2.4. Testing In vitro Suppression by LN CD4CD25 cells 
Tregs are thought to suppress in a non-Ag-restricted but specific manner, in that the 
responder TCR and Treg TCR may recognise different Ag (106), however, the Tregs 
must first themselves be activated by cognate peptide:MHC (106). If MOG(35-55)-
reactive CD4CD25 cells are expanded during EAE, one would predict that 
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CD4CD25 cells from the draining LN of mice in the early recovery phase would 
therefore be able to suppress responder T cells in a MOG(35-55)-specific manner. 
CD4CD25 cells were purified from the inguinal LN of mice 16 days after EAE 
induction, the time point when CD25 cells are beginning to accumulate in the CNS 
(Figure 4-7). These LN CD4CD25 cells were tested for their ability to suppress the 
proliferative response of CD4CD25 cells from the same LN in the presence of 
MOG(35-55). To address their specificity, their ability to suppress OT-11 CD4 cells 
(which are specific for an unrelated Ag pOVA) was tested in the presence of either 
pOVA alone or pOVA in conjunction with MOG(35-55). 
5.2.5. CD4CD25 cells from inguinal LN of mice with EAE suppress 
in vitro, but do not appear to require restimulation with Ag 
In three separate experiments CD4CD25 cells, but not CD4CD25 cells, from day 
16 EAE mice were able to suppress the proliferative response of CD4CD25 cells 
(from the same mice) to MOG(35-55) (Figure 5-2a). The counts per minute (cpm) 
were low for these assays, probably due to the low cell numbers used and the 
relatively long time after immunisation, but background proliferation was also 
correspondingly low. The same CD4CD25 cells also suppressed responses of OT-
T! CD4 cells to pOVA in the presence of MOG(35-55) (Fig 5-2b). Surprisingly 
though, in these assays OT-11 CD4 cell responses were also suppressed when pOVA 
alone was added (Fig 5-2b). This suggests that CD4CD25 cells mediating 
suppression did not need to be activated by Ag in vitro. 
5.2.6. Suppression of Ag-specific Responses by Naïve CD4CD25 
cells 
It has been shown that Tregs that have been recently activated are able to suppress in 
vitro without further TCR ligation (106). Thus, it was possible that the EAE LN cells 
were already in a sufficiently activated state ex vivo to mediate suppression without 
further activation. Therefore, CD4CD25 cells from non-immunised mice were 
included as a negative control. Perhaps even more surprisingly, naïve CD4CD25 
cells were also able to suppress both MOG-specific and OVA-specific responses in 
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an apparently completely Ag non-specific manner (Figure 5-2c,d). It could be argued 
that suppression of OT-11 cells was somehow an effect due to using transgenic cells, 
for example the OT-11 mice may not have been fully backcrossed onto the B6 
background allowing presentation of minor histocompatibility Ag to the Tregs. 
However, the suppression of MOG-specific CD4CD25 cell proliferation by naïve 
CD4CD25 T cells from completely syngeneic mice ruled this possibility out. 
5.2.7. Draining LN CD4CD25 T cells may have enhanced 
suppressive capability 
It was noticeable that in all conditions where both EAE and naïve CD4CD25 cells 
suppressed responder cells (responses to MOG(35-55), pOVA or anti-CD3 Figure 5-
2), the cells from mice with EAE gave consistently better suppression than naïve 
cells, and this was particularly evident at lower Treg:responder ratios. Also, 
suppression of OT-11 CD4 cells by EAE-derived CD4CD25 cells appeared to be 
enhanced when MOG(35-55) was present in addition to pOVA (Figure 5-2b). Within 
each experiment, the purity of CD4CD25 cells from the different sources was 
similar (90-98%). 
In summary, results of suppression assays using LN cells suggest that CD4CD25 
cells from mice in the early recovery phase of EAE may have enhanced suppressive 
capability compared to CD4CD25 cells from naïve mice. However, suppression of 
OVA-specific responses in the absence of MOG(35-55) suggests this suppression 
may not require specific activation of these Tregs in vitro. Suppression of peptide-
specific responses by CD4CD25 cells from naïve mice in the same assays confuses 
interpretation of any of the results, so no real conclusions can be drawn regarding 
expansion of MOG(35-55)-reactive CD4 +  CD25
+  cells during EAE. 
5.2.8. Are CD4CD25 defective in B cell-deficient mice? 
It has been reported that jtMT mice have a reduced frequency of CD4CD25 cells in 
the periphery (312). This was confirmed in the mice in our animal house (data not 
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shown), including those with EAE (Fig 5-3). However, although tMTs had a 
consistently lower frequency of peripheral CD4CD25 cells, this was still within the 
levels generally considered to be normal (5-15% of total CD4 cells (94)). It was 
interesting to note that although the frequency of CD4CD25 cells was reduced in 
peripheral lymphoid organs of p.MT mice, the frequency in the CNS was similar to 
that in B6 mice and likewise increased during recovery (Fig 5-3). Hence the failure 
of .LMT mice to recover cannot be attributed entirely to a failure to expand or recruit 
sufficient numbers of CD4CD25 cells into the CNS. 
Suppressive capacities of CD4CD25 cells from j.iMT versus B6 mice were 
compared in vitro. CD4 +  CD25 +  cells from p.MT mice were consistently less 
suppressive than those from wildtype B6 mice, whether responder cells were from 
B6 or MT mice in these assays (Figure 5-4). When comparing results from three 
separate experiments, the 1.iMT CD25 cells gave significantly less inhibition of 
responder cell populations at ratios of 0.5:1 or 0.25:1 of CD25:CD25. It was 
interesting that at the lowest ratio of Treg to responder (0.25:1), the B6 CD4CD25 
cells were also significantly less able to suppress iMT Cb4CD25 cells than 
CD4CD25 cells from wildtype mice (Figure 5S'c). Hence, it does appear that 
CD4CD25 cells from MT mice are inherently less potent than CD4CD25 cells 
from wildtype mice. 
NOD mice have a lower frequency of peripheral CD4CD25 cells (around 5% of 
total CD4 cells (48)), which may contribute to their enhanced susceptibility to 
autoimmune disease although this is controversial (313). An increased incidence of 
autoimmunity has not been reported in B cell deficient mice, and in fact development 
of diabetes in NOD mice is B cell dependent (314). Also, in the B cell IL-10- 
deficient chimaera model, recovery from EAE is restored in chimaeric mice that 
receive B cells from IL-10 sufficient mice (59). This suggests that B cell IL-10 is not 
required for peripheral CD4CD25 maintenance in this model, since transfer of IL-
10 sufficient B cells immediately prior to EAE induction is unlikely to allow enough 
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time for restoration of a major defect in levels of peripheral CD4CD25 cells. This 
does not rule out a role for B cell IL-10 in somehow expanding CD4CD25 cells 
after EAE induction. While the proportion of peripheral CD4CD25 cells has not 
been assessed in naïve IL-10-deficient B cell chimaeras, during EAE the proportion 
of CD4CD25 cells in LN and CNS appeared similar to wt-B cell chimaeras (data 
not shown). 
5.2.9. Depletion of CD25 cells prior to induction of EAE exacerbates 
disease and delays recovery 
The data presented so far suggest that regulatory T cells accumulate in the CNS 
during recovery, but their importance in vivo had yet to be established. Therefore, in 
vivo depletion of CD25 cells was performed to determine whether CD4CD25 
cells are actually required for recovery. Use of the anti-CD25 monoclonal antibody 
PC61 for the depletion of CD25 cells in vivo has now been widely reported. 
Administration of 1mg PC6 1 intraperitoneally three days before induction of EAE 
allowed enough time for over 90% CD25 cell depletion (Figure 5-5). Depletion of 
CD25 cells was found to persist for at least two weeks before a gradual increase in 
the percentage of peripheral CD25 cells was seen, presumably due to thymic 
generation of CD4CD25 cells, and levels returned to normal by four weeks after 
administration of PC61 (Figure 5-5). 
Mice treated with PC61 three days prior to EAE induction were found to develop 
disease of increased severity compared to isotype-treated controls (Fig 5-6). 
Importantly, the recovery of PC6 1-treated mice was consistently impaired in several 
experiments (Fig 5-6). It was notable that towards the end of several experiments 
(day 25-35), some mice were showing signs of recovery, i.e. a decrease in clinical 
score by at least one grade. The length of experiment has not been extended beyond 
35 days, but it would be predicted that eventually some, if not all, mice would make 
a full recovery. 
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5.2.10. 	The proportion of CD4CD25 cells gradually increases 
after depletion, and this may be accelerated in mice with EAE 
As shown in Fig 5-5, administration of PC61 in vivo does not lead to permanent 
depletion of CD25 +  cells. Therefore, the delay in recovery could be explained by the 
time taken for the gradual repopulation of peripheral CD4CD25 cells from the 
thymus, so that recruitment of Tregs to the CNS is delayed but not abolished by 
PC61 treatment. The proportion of CD4CD25 cells in the LN, spleen and CNS of 
mice either given PC61 or isotype-control Ab was measured over the time-course of 
EAE. 
When comparing PC6 1-treated or untreated mice with EAE, in three experiments the 
proportion of CD4CD25 cells in the CNS at the peak of disease (dayl4/15) was 
found to be 2 to 3 fold lower in PC61-treated mice than controls (Figure 5-7). 
However, on days 21 and 28, the CD4 +  CD25 +  cells in the CNS of PC6 1-treated mice 
had reached similar levels to controls (Fig 5-7). Results in the LN and spleen were 
not as clear - in two experiments the proportions of CD4CD25 cells in the LN of 
PC61-treated mice with EAE were similar to controls on day 15 (Fig 5-7b), while in 
a third experiment the PC6 1-treated mice had markedly lower frequencies of CD25 
cells (not shown). By day 28, the CD4CD25 levels were the same in all 
experiments (not shown), as expected since levels of CD25 cells had returned to 
normal in non-immunised mice by this time point (Figure 5-5). 
There was some evidence that CD4CD25 cells may be recruited/expanded more 
quickly in mice treated with PC6 1 then immunised, compared to mice given PC6 1 
but not immunised. In two experiments, the mean proportion of CD4CD25 cells in 
the (draining) inguinal LN on day 15 was 2 to 4 fold higher in PC61-treated mice 
with EAE compared to PC6 1-treated alone (Figure 5-7b). However, the groups were 
too small (2-3 mice/group) to achieve statistical significance. In the spleens of these 
mice, there was a similar increase in CD4CD25 cells of PC61-treated and 
immunised mice in one experiment, but no increase in the other, consistent with a 
localised rather than systemic effect (not shown). 
138 
Depletion of CD25 cells in vivo prior to immunisation has been shown to enhance 
the level of T cell activation (particularly numbers of cytokine-producing effector 
cells) (155), and it could be argued that the increase in frequency of LN CD4CD25 
cells could be due to an increased frequency of activated T cells rather than Tregs. 
This would be conclusively answered by performing in vitro suppression assays 
using CD4CD25 cells from these mice, although this has not yet been done. Levels 
of IL-10 production were low in all sites in these experiments (data not shown). 
However, cytokine production profiles of CD4 cells argue against the CD25 cells 
being activated/effector cells: IL-2 production after ex vivo stimulation of cells from 
PC6 1-treated mice with EAE was mainly from CD4CD25 cells (Figure 5-8a), and 
this was also the case for IL-2 and IFNy production by CD4 cells from the CNS 
(Figure 5-8b). 
Taken together, these results suggest a delayed, but not abolished, accumulation of 
CD4CD25 cells in the CNS of PC61-treated mice with EAE may contribute to 
delayed recovery. Also, the eventual accumulation of CD4CD25 cells in the CNS 
of PC6 1-treated mice appears to be preceded by an accelerated recruitment or 
expansion of fresh CD4CD25 thymic emigrants in the draining LN of some mice. 
5.2.11. 	Administration of PC6I during EAE has variable effects 
on disease outcome 
As stated already, depletion of CD4CD25 cells has effects on activation of naïve T 
cells that are difficult to distinguish from the effects of reduced availability of Tregs 
for expansion and recruitment to the CNS. Also, as discussed above, repopulation by 
CD4CD25 cells does gradually occur in PC6 1-treated mice and appears to correlate 
with a gradual recovery in some of these mice. PC61 was therefore given on different 
days after the induction of EAE in an attempt to target the recovery phase after the 
activation of effector cells has taken place. 
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1mg PC61 was given intrapentoneally on days 8, 15 or 20 after induction of EAE. In 
two out of three experiments, depletion of CD25 cells on day 8 after immunisation 
resulted in significantly milder disease compared to untreated controls (Figure 5-9a), 
although in a third experiment disease was significantly enhanced (not shown). In 
one experiment disease was more severe in PC6 1-treated mice. Likewise, CD25 cell 
depletion at the peak of disease (days 14-16) significantly accelerated recovery in two 
out of three experiments, and had no effect in one (Figure 5-9b). Treatment on day 
20 had little effect (Figure 5-9c), although most mice are already recovering by this 
stage so the effect of treatment on day 20 after EAE induction is more difficult to 
judge. Overall then, depletion of CD4CD25 cells had the surprising effect of 
reducing disease severity in most experiments. 
5.2.12. 	Transfer of low numbers of CD4CD25 cells from 
recovering mice protects naïve recipients against EAE induction 
Transfer of high numbers of CD4CD25 cells purified from the peripheral LN of 
naïve mice reduces the severity of EAE in recipients ((49, 50) and Figure 5-10a). 
Activation of Tregs in vitro is thought to increase their potency (106, 153, 154). 
Therefore, one would predict that CD4CD25 cells that have accumulated in the 
CNS during inflammation should be highly potent, may have increased frequencies 
of MOG(3 5-55)-reactive cells, and should be able to reduce or prevent EAE severity 
in recipients at low cell numbers. 
CD4CD25 cells from the CNS of recovering mice were FACS sorted and 
transferred into naïve recipients either on the same day as, or one day after, 
immunisation to induce EAE. In each case, 1-3x10 4 CNS CD4CD25 cells/mouse 
significantly reduced disease severity in recipients, while the same number of naïve 
LN CD4+  CD25+  cells had no effect (Figure 5-10b). Although the protection achieved 
was not complete, the number of cells transferred was very low, and it may be that 
transferring slightly higher numbers would give greater protection. Overall, CNS 
CD4CD25 cells were able to transfer equivalent protection at 100-fold lower 
numbers than naive CD4 +  CD25
+  cells. Therefore, CD4 +  CD25+  cells in the CNS of 
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recovering mice do indeed appear to be highly potent. It also seems likely that this 
CD25 cell population is enriched for CNS-specific cells. 
CNS-specific Tregs are likely to be activated and expanded in lymph nodes prior to 
migration to the CNS (where they may undergo further expansion). Without using 
transgenic cells it is difficult to determine where CD4CD25 cells are expanded. 
There are two likely options: first, CD4CD25 cells may be activated and expanded 
in the inguinal LN, that drain the subcutaneous immunisation site, in response to 
MOG(35-55) and other (non-CNS related) Ag. Alternatively, or additionally, 
CD4CD25 cells may be expanded by CNS Ag presented on activated DC migrating 
fro duringthe inflamed CNS dung EAE. CD4
+  CD25 +  cells sorted from the inguinal LN 
of recovering mice were also able to protect at low frequencies (l-4x10 4 CD4CD25 
cells) (Figure 5-11) However, the effect was less consistent than with CNS cells, 
with a reduction in disease severity achieved in only 3 out of 6 experiments. This 
may reflect differences in the proportion or activation state of the relevant 
"protective" cells in the CNS compared to LN, since the CNS is enriched for IL-10- 
secreting cells compared to LN, and CD4CD25 cells in the CNS phenotypically 
appear more activated (Chapter 4). CD4CD25 cells from the cervical LN were not 
tested for protective ability. 
5.2.13. 	Depletion of CD25 cells after recovery restores 
susceptibility to reinduction of EAE 
As shown in Fig3 -1, for a time after recovery from EAE mice are relatively resistant 
to induction of a second bout of disease, suggesting that the mechanisms involved in 
recovery are still dominant immediately afterwards. Post-recovery splenic B cells 
appear able to transfer resistance to induction of EAE, suggesting they may 
contribute to active resistance to reinduction. Likewise, transfer of CD4CD25 cells 
from recovering mice conferred protection on recipients. To investigate whether 
CD4CD25 cells are required for post-recovery resistance to EAE induction, CD25 
cells were depleted in vivo 30 days after primary EAE induction (after most mice 
had recovered). Mice were then rechallenged 3 days later with MOG(35-55) in IFA 
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and pertussis toxin. As expected, isotype-treated mice remained resistant to 
reinduction (Figure 5-12). However, mice depleted of CD25 cells developed EAE of 
similar severity to their primary EAE (Figure 5-12), although unlike naïve mice 
treated with PC6 1, rechallenged mice did not show a markedly impaired recovery. 
Hence, CD4CD25 cells play a role in the active resistance to reinduction of 
disease. 
5.3. DISCUSSION: 
The presence of a large proportion of CD4 cells having phenotypic characteristics of 
regulatory T cells and IL-10-producing capacities strongly suggested a role for 
regulatory T cells acting in the CNS to control inflammation. The results presented in 
this chapter show that these CD4CD25 cells from the CNS possess the functional 
characteristics of regulatory T cells, in that they are able to suppress naive T cell 
proliferation in vitro and transfer protection against induction of EAE to recipients. 
Also, the requirements for CD4CD25 cells in recovery and resistance to 
reinduction of EAE were demonstrated by the effect of depletion of CD25 cells in 
VIVO. 
Demonstration of suppressive capability of CNS CD4CD25 cells in vitro (Figure 5-
1) was important in establishing that these cells did not merely represent a stage in 
effector cell differentiation (although cytokine production profiles suggested this was 
unlikely). Due to the constraints in cell numbers obtainable, this was only done with 
anti-CD3 as stimulus, but the ability of CD4CD25 cells obtained from the CNS to 
inhibit the proliferation of naïve CD4CD25 cells showed that these were indeed 
regulatory cells. It also appeared that they were more potent than naïve CD4CD25 
cells, since they gave stronger inhibition of responder cells, particularly at lower 
Treg:responder ratios. 
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The results of the suppression assays using CD4CD25 cells purified from the LN 
of either mice with EAE or naïve mice (Figure 5-2) were intriguing and confusing. 
Suppression of peptide-specific responses by polyclonal CD4CD25 cells from mice 
that have not been exposed to that Ag was a surprising result. Several studies have 
reported the requirement for interaction with cognate Ag by CD4CD25 cells for 
suppression to occur, including in assays very similar to those described in this 
project: polyclonal CD4CD25 cells from syngeneic Balb/c mice are unable to 
suppress the proliferation of D01 1.10 CD4 cells in response to pOVA alone, but do 
suppress a response to anti-CD3 (106, 153). This requirement for Ag-specific 
activation can be met if the CD4CD25 cells are pre-activated with Ag immediately 
before addition to the cultures, and pre-activation also increases the potency of 
CD4CD25 cells (106). This could offer an explanation for the non-specific 
suppression by CD4CD25 cells from mice with EAE, since it could be argued they 
have been activated in vivo. There were indications that CD4CD25 cells from the 
LN of EAE mice were indeed more potent than those from naïve mice, giving 
consistently greater suppression at lower Treg:Tresponder ratios. However, extensive 
pre-activation of regulatory cells is unlikely to explain the suppression observed by 
CD4CD25 cells from naïve mice housed in a specific pathogen free facility. 
The reduced severity of EAE in vivo after transfer of low numbers of CD4CD25 
cells from the CNS (Figure 5-10), and to a variable extent inguinal LN (figure 5-11), 
suggests two possibilities. Since recent activation of Tregs increases their potency 
(153, 154), it could be that CD4CD25 cells from mice with active disease are 
enriched for activated cells, and therefore have an equivalent efficacy to high number 
of CD4CD25 cells from naïve mice. The expression profiles of CD4CD25 cells 
from CNS compared to naïve LN certainly support this hypothesis, since CNS cells 
had higher expression levels of most of the markers analysed. CD4CD25 cells in 
the LN of EAE mice were more similar to naïve mice, with only slight increases in 
the proportion of cells expressing markers such as CD69. Also, the CNS was highly 
enriched for cytokine-producing cells compared to LN. This difference in the 
activation status of CD4CD25 cells in the LN and CNS of mice with EAE may also 
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go some way to explaining the disparity in the levels of protection afforded by 
CD4CD25 transfers: CNS CD4CD25 cells gave consistent protection, while LN 
CD4CD25 cells protected in only half the experiments. 
The mechanism of action of CD4CD25 regulatory T cells in this model remains 
unclear. However, IL-10 seems a likely candidate based on the proportion of 
CD4CD25 cells in the CNS observed to produce IL-10 ex vivo, and the known 
importance of IL- 10 for recovery in this model (231). One way to determine whether 
IL-10 production plays an important role in protection mediated by CNS 
CD4CD25 cells would be to transfer these cells from IL-10 knockout mice. This 
was attempted, but unfortunately disease incidence in this experiment was extremely 
poor so no conclusions could be drawn. However, it was observed that the 
proportions and phenotype of CD4 +  CD25 +  i cells n the CNS of IL-10 -I- mice did not 
differ greatly from those in B6 mice on day 16 after EAE induction (data not shown). 
In vivo depletion studies further confirmed the importance of CD4CD25 cells 
during recovery from EAE. Administration of PC61 three days prior to induction of 
EAE gave sufficient time for depletion of CD25 cells (Figure 5-5), and also for 
removal of much of the Ab from the system (315) so that effector T cells should be 
unaffected. Depletion of CD25 cells prior to induction of ENE is likely to result in 
an increased number of effector pathogenic T cells, and indeed the severity of 
disease was increased in CD25-depleted mice. In addition to this effect, the rate of 
recovery was markedly slower than would normally be expected even for untreated 
mice with a high maximum disease score, suggesting that removal of Tregs had 
impaired the recovery process as well. The effects of CD25 cell depletion in vivo 
prior to induction of EAE have been reported by three groups so far, with conflicting 
results. Montero et al (265) and Zhang et al (50) reported enhanced severity of 
disease in B6 mice and SJL mice, respectively, and in SJL mice a significant increase 
in mortality was observed (265). Both these groups used PC61 for CD25 depletion, 
In contrast, Kohm et al reported no effect of CD25 cell depletion, using 7D4 Ab in 
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SJL mice (142). Importantly, none of these studies looked at the effect of CD25 
depletion on the recovery phase of EAE. 
The accelerated recovery of mice treated with PC6 1 after the induction of EAE was 
perhaps surprising (Figure 5-9). While the peak of disease occurs around 14 days 
after immunisation, the peak of effector T cell expansion is more likely to occur 
around 7 to 10 days after immunisation (286), so treatment with PC61 8 days after 
immunisation could deplete or prevent further expansion of pathogenic T cells as 
well as Tregs, resulting in reduced severity of disease. In EAE provoked by 
immunnisation of SJL with PLP(139-151), specific CD4 cells were tracked in vivo 
using AsPLP(  139-151) tetramers (286). In this model, the peak of expansion of 
PLP(139-15 1)-specific cells in the draining LN occurred on day 8 after 
immunisation, at which point 80% of these cells expressed CD25. The proportion of 
PLP( 139-151)-specific CD4 cells expressing CD25 then gradually declined, to 
reach normal levels between day 16 and 20. Likewise, on days 16 and 20 the data 
from this report suggest that the majority of effector Thi cells do not express CD25. 
However, since MOG(35-55)-specific CD4 cells cannot yet be tracked in B6 mice, 
the expression of CD25 by pathogenic cells in the LN cannot be excluded. If newly-
generated effector T cells are depleted in addition to regulatory T cells, the overall 
effect may be a reduction in pathology, since the source of continued inflammation is 
cut off. Indeed, a humanised anti-CD25 mAb has been licensed for use in the 
prevention of renal transplant rejection (in combination with other 
immunosuppressive agents) (316), and in a small clinical trial had a beneficial effect 
in ten patients with multiple sclerosis (317). 
CD25 cells depletion by PC61 treatment is transient, and by 4 weeks the numbers of 
peripheral CD4CD25 cells have returned to near normal, probably mainly due to 
thymic generation of new Tregs. It was interesting to observe that in some mice, 
immunisation with MOG(35-55) to induce EAE appeared to drive a more rapid 
increase in the proportion of CD4CD25 cells, particularly in the draining LN 
(Figure 5-7). Cytokine production profiles of these cells suggested that they were not 
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effectors (Figure 5-8), and the initial increase in LN CD4CD25 cells was followed 
by an increase in CD4CD25 cells in the CNS so that these reached similar levels to 
untreated controls more quickly than expected. Given the data showing expansion of 
Tregs in response to activated DC and immunisation, this is the most likely 
explanation for this observed increase in CD4 +  CD25 +  cells after immunisation, and 
the effect may be heightened by a reduction in homeostatic pressure by PC61 
treatment. This result indirectly supports the hypothesis that CD4CD25 cells are 
initially expanded in LN then migrate into the CNS. 
It is surprising that the proportions of CD4CD25 cells in the CNS appeared to 
reach similar levels between PC61-treated and control mice. However, in these 
experiments the number of inflammatory cells, such as macrophages, was not 
enumerated. In experiments where a four hour ex vivo stimulation was performed, a 
film of cells, presumably macrophages, were observed to adhere to the culture plates 
after removal of cells for FACS analysis. Therefore, although the proportion of total 
CD4 cells is directly comparable between groups, the proportion of total cells that 
were CD4CD25 cells may not be comparable. It has been shown that disease 
severity correlates more closely with levels of macrophage recruitment than T cells 
in rats (173), and it could therefore be argued that although similar levels of Tregs 
were obtained by 20 days post EAE induction, the levels of inflammation that have 
to be controlled may be higher in PC61-treated mice, which do develop increased 
severity of disease. 
In vivo depletion of CD25 cells after recovery was in some ways more informative 
than depletion prior to induction of EAE, since any other (non-CD4CD25) 
regulatory mechanisms contributing to recovery and the active resistance to 
reinduction should remain unaffected by this treatment ; Indeed, while CD25 cell 
depletion resulted in increased susceptibility to reinduction, confirming the role of 
Tregs in recovery, the rate of recovery in those mice was consistently more rapid 
than in mice treated with PC61 and immunised for the first time (Figure 5-11). Thus, 
it appears that there may be additional mechanisms in force to reduce the severity of 
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a second bout of EAE - such as B cells. The reason for the gradual loss of this 
protection remains unclear. It may be that the relevant CD4
+  CD25+  cells lose their 
potency and/or undergo attrition, as CNS Ag is no longer presented after resolution 
of CNS inflammation, and the balance shifts back to the susceptible state found in 
naïve mice. 
Taken together, these results further confirm that CD4CD25 cells with regulatory 
function accumulate in the CNS and play an active and central role in mediating 
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Figure 5-1: CD4CD25 cells isolated from the CNS of mice recovering 
from EAE are suppressive in vitro. CNS and inguinal LN were harvested and 
pooled from 12 mice 20 days after induction of EAE, and all peripheral LN from 
one naïve mouse. For LN samples CD4 cells were first enriched by Dynal bead 
negative selection. CD4CD25 cells were purified by FAGS sorting to purity 
greater than 95% for LN and 85% for CNS. Naïve GD4GD25 cells were used 
as responder cells at 104  cells/well, with 105  irradiated splenocytes as ARC and 
the indicated number of CD4CD25 cells. Cells were stimulated with 2.5ig/ml 
anti-CD3 for 96 hours. One result of two similar experiments is shown. 
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Figure 5-2A-B: Testing in vitro suppression by CD4CD25 cells from LN of 
mice with EAE and naive controls. Inguinal and para-aortic LN were pooled 
from mice on day 16 after EAE induction, or all peripheral LN from naïve OT-11 
mice were pooled. CD4CD25 cells were purified by Dynal bead and MACS 
sorting. Source of suppressor and responder cells is indicated in schematic next 
to each graph. In A, 4x10 4 CD4CD25 cells were used. In B, 104  CD4CD25 
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Figure 5-2(C-E): Testing in vitro suppression by CD4+CD25+ cells from LN of 
mice with EAE and naïve controls. Inguinal and para-aortic LN were pooled from 
mice on day 16 after EAE induction, and all peripheral LN were pooled from naïve 
naïve B6 or OTII mice. CD4CD25 cells were purified using using Dynal beads 
and MACS sorting. Cell source and Ag used are indicated in schematic next to 
each graph. In C, 4x10 4 EAE d16 CD4CD25 cells were used. In D, 10 
CD4CD25 OTII cells were used. In E, 4x10 4 CD4CD25- cells were used. 1.6x105 
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Figure 5-3: Proportion of CD4CD25 cells is reduced in peripheral 
LN/spleen of tMT mice EAE was induced in ltMT and B6 mice, and on days 
12 and 16 post-induction inguinal LN, spleen and CNS were removed, pooled, 
and the proportion of CD4CD25 cells analysed by FACS (4 mice/group). 
151 
A 	 B 
1:1 0.5:1  
044 
100 .. 
o - a 
. 	75 	• V 
U) 
a) 




Cn 25 	 ' 
0 
CD25': B6 B6 .tMT jMT 











B6 B6 pMT p.MT 
B6 .tMT B6 jMT 
C 
0.25:1 	p<O 004 
**p.(Q 011 	
-- 136 CD4CD25 



















CD25: B6 B6 p.MT .MT 
° 	0.25 0.50 0.75 1.00 
CD25: B6 1tMT B6 p.MT 	 No. CD4CD25 cells 
per B6 responder cell 
Figure5-4: CD4"CD25 1 cells from j.tMT appear to be defective in vitro. 
CD4CD25 cells were purified from peripheral LN of naïve B6 and ltMT mice by 
MACS selection. 2x104 CD4CD25 responder cells/ well from either B6 or PMT, 
7.5x105 irradiated B6 APC/well and the indicated numbers and of 136-derived or 
p.MT-derived CD4CD25 cells/well added. Cells were stimulated with 0.5mg/mI 
for 72 hours. Results shown are pooled from three separate experiments, in 
which similar purities of B6 and tMT CD4 4CD25 cells were obtained. A-C show 
percentage inhibition of CD4CD25 cells from 86 or MT mice at different 
Treg:effector ratios. D shows combined data on the percentage inhibition of B6 
cells at different Treg ratios. 
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Figure 5-5: Administration of PC6I effectively depletes CD25' cells in 
vivo. 1mg PC61 or isotype control Ab (MAC49, rat lgGl) was given 
intraperitoneally on day 0. Mice were bled on days indicated and percentage 
CD4CD25 cells analysed by FACS (using anti-CD25 clone 7D4). Results 
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Figure 5-6: Depletion of CD25 cells 3 days prior to EAE induction results 
in exacerbated disease severity and delayed recovery. 1mg PC61 or 
isotype control Ab was given ip on day —3. Depletion of peripheral blood CD25 
was checked by FACS on day of immunisation and was greater than 85% in all 
mice. EAE was induced on day 0 and mice scored daily for clinical EAE signs. 
The disease burden in PC61-treated mice was significantly greater than 
controls (p<0.001). This result is representative of 5 experiments in which 
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Figure 5-7: The percentage of CD4CD25 cells rises in CNS and LN after 
PC6I administration and EAE induction. 1 m PC6I was given 3 days before 
EAE induction ("PC61 +EAE"), "EAE" groups received isotype control Ab before 
EAE induction, "PC61" received PC61 but EAE was not induced. On the days 
indicated, inguinal LN and CNS were harvested and cells stained for FACS 
analysis of CD4CD25 cells. Results in A show mean percentage 
CD4CD25 cells in CNS from 2-3 mice, and in B, percentage CD4CD25 
cells in LN from individual mice are shown, and are representative of three 
separate experiments using 2-3 mice/group. 
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Figure 5-8: CD4CD25 - cells not CD4+CD25+ from LN and CNS are the 
producers of IL-2 and IFNy ex vivo. PC61 was given 3 days prior to EAE 
induction. 14 days later, inguinal LN and CNS were harvested and cells 
stimulated with PMA and ionomycin in the presence of golgistop for 4 hours, 
followed by FACS staining of cell-surface CD4 and CD25 and intracellular 
staining of IL-2 and IFNy. Results shown are mean of 2-3 mice/group (stained 
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Figure 5-9: Treatment with PC6I after EAE induction ameliorates disease. 
EAE was induced on day 0 and mice scored daily for clinical signs of EAE. 1 m 
PC6I was given intraperitoneally on the day indicated (A:day 8, B: day 16, C: 
day 20), controls remained untreated. Each result is representative of 2-3 
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Figure 5-10: CD4CD25 cells from the CNS decrease EAE at low numbers 
compared to CD4CD25 cells from naïve mice CD4CD25 cells were sorted 
from the peripheral LN of naïve mice, or from the CNS of mice on day 20 post 
EAE induction. In A 2x10 6 or 104  naïve CD4CD25 cells were transferred and 
EAE induced 1 day later. In the only experiment in which this was done (5 
mice/group), 2x106 cells gave significant reduction in EAE severity (p<0.00I). In 
B, 1 -3x1 0 CD4CD25 cells from CNS or naïve LN were transferred and EAE 
induced. The plot shows combined results from 2 experiments (total 10-11 
mice/group) in which cells were transferred on the day of immunisation or on day 
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Figure 5-11: Transfer of CD4CD25 cells from LN of mice with EAE 
gives variable protection 1-4x104 CD4CD25 cells from the inguinal LN of 
mice on days 16 or 20 post EAE induction were purified and transferred into 
naïve recipients on days —1, 0 or 1 of EAE induction. The results shown are 2 
experiments representative of 6 separate experiments in which 4-7 
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Figure 5-12: Depletion of CD25' cells after recovery restores 
susceptibility to reinduction of EAE EAE was induced in 11 mice on day 0 
by immunisation with MOG(35-55) in CFA and pertussis toxin given on days 0 
and 2. On day 30, mice were split into two groups according to EAE scores so 
that each group had comparable mean EAE scores in the first 30 days after 
induction. 6 mice received 1 m PC61 and 5 mice received 1 m isotype control 
Ab ip on day 30. Depletion of CD25 cells from peripheral blood was checked 
and mice were immunised with MOG(35-55) in IFA on day 33, pertussis toxin 
was given on days 33 and 35. PC61-treated mice had significantly higher 




6.1. Regulation of T cell mediated CNS-targeted autoimmune 
disease by IL-10 
Regulation of immune responses is vital for maintaining health. This regulation may 
take the form of reducing collateral damage by turning off responses after an 
invading pathogen has been removed, or preventing the activation of harmful 
responses against self or innocuous foreign antigens. This project addressed the 
mechanisms of regulation of an induced autoimmune response against the auto-
antigen MOG after inflammation had been established in the CNS. Previous studies 
have reported a requirement for IL-10 in recovery from EAE (231, 235), and an 
increase in IL-10 and Th2 cytokines in the CNS is associated with recovery (229, 
237). B cells have been identified as an important source of IL-10 in EAE (59). This 
project has further shown that B cells do not appear to migrate to the CNS in 
significant numbers, suggesting that their main site of action is the LN. Rather, CD4 
T cells were identified as the major lymphoid source of IL-10 in the CNS. These 
cells possessed phenotypic and functional characteristics of the well-described 
+ 	+ 	 + CD4 CD25 regulatory T cells. In vivo CD25 cell depletion studies further 
confirmed the importance of these cells in the regulation of the MOG-directed 
inflammatory response in EAE. 
IL-10 could potentially be involved in downregulating all of the steps in the 
inflammatory feedback loop induced during EAE (See schematic page 166 for 
overview). Thi cells entering the CNS produce cytokines such as IFNy and 
TNFa that activate macrophages. These cytokines may also be involved in breaking 
down the blood-brain barrier (13). Activated migratory macrophages and DC, as well 
as resident microglia in turn produce chemokines to recruit further effector cells 
(198), and express • MHC and costimulatory molecules to activate effector T cell 
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function within the CNS (176, 177). Activated DC may also migrate to the LN, to 
present CNS antigens and activate a fresh wave of Thi cells. 
IL-10 decreases expression of costimulatory molecules and peptide-MHC complexes 
on APC, and decreases IL-12 production (233, 318, 319). This may serve two 
functions during EAE: first, to reduce effector T cell functions in the CNS; second, 
to decrease the recruitment of fresh waves of T cells from the LN (by preventing 
activation of Thi -stimulating DC in the CNS and by downregulating effector T cell 
differentiation in the LN). IL-10 produced in the CNS may also act directly on the 
activated macrophages and T cells to turn off production of cytokines such as TNFa, 
IFNy and IL-23. In this way, the inflammation will be quelled, and the stimuli 
involved in breaking the blood-brain barrier and recruiting new effector cells 
removed. 
The results from this project suggest that a large proportion of the IL-10 found in the 
CNS is provided by CD4CD25 regulatory T cells. These cells accumulate in the 
CNS during recovery from EAE, so are in the prime location for downregulating 
inflammation. What is the source of these regulatory T cells? Their phenotype and 
the expression of FoxP3 within the CD4 compartment in the CNS suggest that at 
least some of these cells are derived from the "naturally-occurring" population of 
CD4CD25 cells constitutively present in normal mice (94). The impaired recovery 
observed when CD25 cells are depleted prior to EAE induction adds further weight 
to this proposal. If this were the case, the likely scenario is that CNS-specific 
CD4CD25 cells are expanded in draining LN in response to presentation of these 
antigens by DC migrating from the immunisation site or the inflamed CNS. Although 
proliferation of CD4CD25 cells has been observed in the inflamed gut epithelium 
(123), this was in a lymphopaenic model of colitis, and other non-lymphopaenic 
autoimmune models have found expansion to occur mainly in the draining LN (77, 
122). After expansion in the LN (where they may also have some effects through 
interactions with DC and/or Thi pathogenic cells), the regulatory cells will migrate 
to the CNS to downregulate inflammation there. 
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An alternative hypothesis for the source of IL-10-producing T cells in the CNS is 
that they are generated de novo from naïve T cells during the course of EAE, i.e. they 
are Trl cells. Since this process is likely to occur in the LN, where differentiating T 
cells are located, B cell production of IL-10 could feasibly be involved in this 
generation in two ways. First, B cell IL-10 may maintain local DC in an immature 
state (234), which in turn may induce the differentiation of IL-10 producing T cells 
(320, 321) specific for CNS antigens. The problem with this hypothesis is that the 
dendritic cells carrying antigen from the CNS are likely to already be in a mature 
state. Second, B cells presenting antigen and producing IL-10 could influence T cell 
differentiation directly. 
Whether B cell IL-10 acts directly on T cells in EAE is at present unknown. B:T 
interactions form part of the normal course of an immune response (69). Indeed, 
these interactions are required for induction of the "regulatory" function of B cells, 
since chimaeras in which B cells alone are deficient in CD40 (and therefore unable to 
receive signals through CD40 ligation by CD40L on T cells) also fail to recover from 
EAE (59). As Ag-specific B cells expand and mature during an immune response, 
they become prime contenders to interact with and influence the developing T cell 
response. Thus, IL- 10 may act directly on T cells later in the response. While B cells 
have been shown to be capable of activating naïve T cells in vitro (322), it is thought 
that in vivo B cells are more likely to interact with T cells that have first been 
activated through interactions with dendritic cells (69, 323). This is largely due to the 
separate locations of these cells in the LN or spleen: naïve T cells move into the T 
cell zone after arriving in the LN, while B cells (mostly) move towards follicles. 
Only after activation by antigenic stimuli will these cells move towards each other to 
interact (323). Nevertheless, T cell differentiation takes several rounds of stimulation 
and division before a polarised phenotype emerges (324), and T cells have been 
observed to interact with B cells at early stages after activation (323), so direct 
induction of Tr Is by B cells remains a possibility. 
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Another, perhaps more likely, hypothesis is that IL-10 from B cells will act to turn 
off the effector functions of previously activated T cells. It was thought for some 
time that only Th2 cells could enter B cell follicles, however Thi cells have been 
shown to interact with B cells in follicles to aid the production of Thl-type antibody 
isotypes (325, 326). It is therefore likely that a proportion of T cells interact with B 
cells in the LN during their differentiation in the EAE model, before migrating to the 
CNS. However, since interaction with a B cell is not mandatory for an effector T cell 
before it leaves the LN, this mechanism of B cell regulation would be incomplete. 
Therefore, additional mechanisms of regulating effector cells in the CNS are likely to 
be required: since B cells do not enter the CNS in great numbers, IL- 10 producing T 
cells could perform this role. 
It was interesting to note that while depletion of CD25 cells restored susceptibility 
to reinduction of EAE after recovery, these mice did not experience the impaired 
recovery observed in mice depleted of CD25 cells prior to primary induction of 
ENE (Figures 5-1 1 and 5-6). This suggested that CD4CD25 cells are involved in 
recovery but are not acting alone, fitting with the observed requirement for B cells in 
recovery from EAE. 
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Schematic of regulatory circuits operating during recovery from EAE, 
showing the possible cellular targets of IL-10 produced by B cells and 
CD4CD25 (Tr) cells 
165 
6.2. Questions remaining 
This project has shed some light on the cellular sources of IL-10 during recovery 
from EAE, as well as defining a role for CD4CD25 cells in control of established 
disease in this model. From these results, some obvious new questions arise. 
6.2.1. What is the mechanism of suppression by CD4CD25 cells in 
this model? 
Although not yet proven, the mechanism of regulation by CD4CD25 cells in this 
model is suggested to be IL-b, since these cells were initially identified through 
their production of IL-10 in the CNS. IL-10 has been shown to be an effector 
mechanism for CD4CD25 cells in other models in which IL-10 deficiency also 
leads to more severe disease, such as colitis (105, 114, 115). Transfer of large 
numbers of naïve CD4CD25 cells was able to reduce EAE severity only if the 
transferred cells were able to produce IL-10 (50), suggesting that IL-10 plays a role 
at least in resistance to EAE. Transfer of CD4CD25 cells from the CNS of IL-10 
mice would be one way of determining whether IL-10 is indeed required for the 
function of CNS regulatory T cells. 
Another immunoregulatory candidate for CD4CD25 function is TGFI3. An increase 
in TGFI3 within the CNS during the recovery phase of EAE has been reported in two 
mouse models (229, 327), in one of these IL-10 was also investigated and found to 
increase along with TGFI3 (229). Until recently, TGFI3 was not considered to be a 
major effector mechanism for CD4CD25 cells, but it has now been shown to be 
important for regulation in mouse models of both diabetes and colitis. A cursory 
examination of surface-bound TGFI3 (data not shown) found both CD4CD25 and 
CD4CD25 cells in the CNS to be TGF3-negative, but production of soluble TGFI3 
was not investigated as IL-10 was the focus of this study. 
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6.2.2. What is the Ag-reactivity of the IL-10 producing B cells and 
CD4CD25 cells, and how are they expanded in vivo? 
The antigen-reactivity of both B cells and CD4CD25 cells involved in the recovery 
from EAE remain unidentified. As discussed in the relevant chapters, the 
investigation of receptor specificity requires the production of tools to specifically 
label the BCR or TCR, such as fluorescently conjugated antigen, in the case of B 
cells, and tetramers or liposomes for T cells. 
Knowing the target Ag(s) of regulatory cells may give some clues as to their origins 
and how they are expanded during EAE, an important question in terms of 
therapeutic applications. For example, if the CD4CD25 cells found in the CNS are 
expanded as a result of the immunisation with MOG(35-55), they will be reactive for 
this Ag, and it may also be possible to track the timing of their appearance and/or 
expansion in the LN. One complicating factor may be expansion of regulatory cell 
reactive against components of CFA. On the other hand, if CD4CD25 cells are 
expanded as a result of presentation of antigen by CNS-derived DC, the population 
may have reactivity for more than one CNS Ag. Expansion or induction of Tregs by 
DC migrating from the CNS versus the immunisation site may affect the timing and 
location of their appearance and/or expansion. Understanding the signals that lead to 
the accumulation of CD4CD25 cells in the CNS may point to methods for 
expanding these cells in the clinical setting of MS. 
6.2.3. Is there a relationship between regulatory T cells and B cells 
It has been shown that CD4+CD25± cells may regulate B cells to prevent autôAb 
production (71, 72). There is little evidence available as to the effects of interactions 
with B cells on Tregs themselves. It has been observed that MT mice have a 
decreased frequency of CD4CD25 T cells (312), and experiments in this project 
suggested that the CD4CD25 cells present in p.MT mice may be defective 
compared to CD4CD25 cells from B cell-sufficient mice (Figure 5-4). It remains to 
be established whether B cells interact with CD4+CD25+ cells during recovery from 
EAE. This could be approached by investigating whether normal recovery is restored 
167 
in p.MT mice by transfer of CD4CD25 cells from wildtype mice, and conversely 
whether B cells from recovered mice are able to protect recipients that have been 
depleted of CD25 cells prior to EAE induction. 
6.3. Therapeutic potential of regulatory T cells. 
The ultimate goal in autoimmunity is to restore a state of tolerance to self without 
affecting immune responses to foreign antigens. In healthy individuals, Tregs appear 
to play a major role in maintaining this desired balance, and disruption of their 
function may be involved in the development of autoimmunity. Therefore, regulatory 
T cells may be ideal candidates as tools for restoring the tolerant state. The results of 
this project suggest that Tregs are activated and expanded under inflammatory 
conditions as well as pathogenic cells. Other reports have shown directly that 
CD4CD25 cells may be expanded by immunisation with Ag in CFA or Ag-pulsed 
DC that have been activated by treatment with LPS. It is promising that Tregs can be 
expanded under these conditions, since patients with established disease present an 
inflammatory environment in which to attempt to restore regulation. However, 
approaches that are likely to lead to the activation of pathogenic cells along with 
Tregs are clearly not desirable. Several investigators have developed methods for 
inducing or expanding Tregs that (hopefully) circumvent this problem, and some of 
these will be discussed. 
6.3.1. Ex vivo expansion of Tregs 
The Bluestone and Steinman labs have recently described the in vitro expansion of 
regulatory T cells capable of both preventing and curing diabetes in mice (153, 154). 
In both studies, protection relied on the use of transgenic CD4CD25 cells with 
reactivity for islet antigens, while polyclonal NOD CD4CD25 cells were 
ineffective. This may reflect an inherent defect in regulatory T cells from NOD mice, 
or more likely a requirement for antigen-specificity in regulation. Thus, selective 
expansion of antigen-specific cells from the polyclonal population in humans is 
likely to be required if this is to become a useful therapy. 
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Hafler's group have reported a reduced cloning efficiency (using a non-antigen-
specific stimulus) of CD4CD25 cells from the peripheral blood of patients with MS 
(211). These cells also displayed reduced suppressive capacity compared to cells 
isolated from healthy controls. A similar reduction in numbers of peripheral 
CD4CD25 cells has been reported in patients with type-I diabetes (212). Expansion 
of a patient's own regulatory cells may therefore turn out riot to be an effective 
therapeutic tool. 
In studies of human arthritis, CD4CD25 cells have been observed to accumulate in 
the inflamed joints (214, 215), and in this project CD4CD25 cells accumulated in 
the inflamed CNS. Therefore, the relevant antigen-reactive cells may be in sites not 
readily accessible for purification from humans, particularly those with MS. 
The ex vivo expansion and reinfusion of patients' own regulatory cells, while 
promising in concept, may ultimately prove too impractical (and expensive) for 
clinical applications. A more feasible approach may be to develop a regime capable 
of expanding pre-existing regulatory cells, or inducing them de novo, in multiple 
patients. Several potential methods for doing this have been developed in mice, and 
some have been attempted in clinical trials in humans. 
6.3.2. Non-antigen-specific expansion of Tregs in vivo 
Administration of agonistic anti-CD3 mAb has been shown to be an effective method 
for inducing tolerance in NOD mice with overt type I diabetes (328, 329). Anti-CD3 
appears to have different effects on subpopulations of T cells in vivo: deleting Thl 
cells but promoting Th2 cells (330). Chatenoud et al have recently demonstrated that 
remission from type I diabetes in NOD mice given anti-CD3 treatment corresponds 
with an enhanced frequency of CD4CD25 cells in vivo, particularly in the LN 
draining the pancreas (331, 332). In vivo neutralisation of TGFI3 abrogates this 
169 
protective effect, and also prevents the increase in CD4CD25 cells (331), 
suggesting de novo generation of FoxP3 regulatory cells by TG93. 
Humanised anti—CD3 mAb has been tested in small clinical trials involving patients 
with recently-diagnosed type-I diabetes (333) or allotransplantation of pancreatic 
islets (to treat type I diabetes) (334), with fairly impressive results. In the 
allotransplantation study, an increase in CD4CD25 cells was observed in patients 
with graft acceptance, and these cells were able to at least partially suppress 
responses to donor antigens in vitro (334). 
Using a similar approach, Wood et al have induced tolerance to alloantigens by 
giving non-depleting anti-CD4 at the time of donor cell infusion in mouse models of 
allotransplantation (53, 335). Administration of anti-CD4 at the time of grafting 
appears to induce CD4 +  CD25 +  regulatory T cells that are able to adoptively transfer 
specific tolerance to naïve recipients (53, 336). 
The advantage of this type of approach is that the specific Ag involved in the 
autoimmune or rejection process do not have to be identified. These treatments do 
appear to target cells that are responding to Ag within a relatively short window of 
time, thereby conferring a degree of specificity and reducing the risks associated with 
the long-term general immunosuppressive therapies currently used. 
6.3.3. Ag-specific Induction/Expansion of Tregs in vivo 
Administration of antigen by the oral route has proved to be an effective mechanism 
for inducing tolerance against Ag encountered through systemic routes (56, 337). 
One of the mechanisms through which oral tolerance may act is via regulatory T 
cells. Indeed, two groups have demonstrated the induction (81) or expansion (82) of 
CD4CD25 regulatory cells by feeding Ag. In the EAE model, Weiner et al 
described that feeding mice with MBP induced CD4 regulatory T cells that could 
prevent EAE induction through secretion of TGF3, so-called Th3 cells (248, 338). In 
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rats a similar phenomenon was observed, except the protective cells were CD8 
(339). 
These promising results led to a clinical trial in which patients with MS were fed 
bovine myelin (340). While an increase in TGFI3 production in response to MBP was 
observed in some of these patients, the therapy was not found to be beneficial 
clinically. It may be that regulatory cells activated via the oral route are able to act in 
lymph nodes to prevent activation of pathogenic cells, but are unable to home to the 
CNS to quell inflammation there. Therefore the ability of orally-induced Th3 cells to 
mediate remission in MS remains debatable. 
It has recently been demonstrated that injection of MBP-coated DC that have been 
pre-treated with TGFI3 can protect against EAE through the generation of CD8 
regulatory T cells in mice (57). Indeed, therapeutic administration of DC is attractive 
in many fields of immunology due to the ability to target T cells in an antigen-
specific manner, and also the potential to manipulate the type of response those DC 
will induce. Immature DC have been shown to induce tolerance (320), and while this 
has largely been attributed to the lack of costimulatory molecules on these cells, 
induction or expansion of regulatory T cells may also play a part (341). 
DC manipulation requires purification and culture of indidual patients' DC. A more 
simple approach is to give peptide directly. Wraith and colleagues have shown that 
intranasal administration of peptide may induce Ag-specific TrI cells. Unlike Weiner 
et al, who found TGFI3 produced in response to orally administered antigen (56), 
intranasal peptide administration resulted in IL-10 producing TrI cells able to 
transfer tolerance (63). Administration of low doses of peptide via the intravenous 
route (81), or continuous infusion of low doses of peptide by a subcutaneously-
placed osmotic pump (83), have also been shown to induce Ag-specific CD4CD25 
cells in vivo. 
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Administration of Ag can therefore induce regulatory T cells in vivo, in a route- and 
dose-dependent manner. However, one drawback of these approaches is that the 
relevant Ag are to some extent still unclear in many autoimmune diseases, and may 
differ between patients. The ability of regulatory T cells to mediate bystander 
suppression may compensate if at least one antigen is known. These studies have 
been performed in laboratory mice that, unlike humans, are not subject to 
concomitant challenge by infectious agents, which may provide "danger" signals to 
the immune system, leading to active immunity rather than tolerance. Also, it must 
be considered that pathogenic effector or memory T cells, which require less 
costimulation than naïve cells, may be reactivated by this protocol. However, 
currently used general immunosuppressive treatments also carry risks, and 
specifically stimulating the body's own regulatory mechanisms still seems a 
desirable alternative for therapy of autoimmunity and allergy. 
6.4. Conclusions 
Diverse mechanisms exist to prevent or control immune responses against self 
tissues. When these break down autoimmune disease results. Therapy of autoimmune 
disease, as well as allergy and transplantation, aims to restore or establish tolerance 
under conditions of inflammation. While tolerance protocols that are effective in 
mouse studies may turn out to be beneficial in humans, many offer an approach akin 
to shutting the stable door after the horse has bolted, in that they are effective on 
naïve cells, but may not affect or may even activate effector cells. 
Four studies have recently shown that CD4CD25 cells can restore tolerance after 
disease has been established, i.e. they can act on effector cells in an inflammatory 
environment (121, 123, 153, 154). This project has additionally shown that 
regulatory T cells may act to mediate spontaneous resolution of autoimmune 
inflammation without a requirement for infusion of high numbers of CD4CD25 
cells or the requirement for the use of cells from TCR transgenic mice. The 
importance of IL-10 production by B cells in models of inflammation, including 
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ENE, must not be forgotten. Determining the most effective methods of enhancing 
physiological regulatory mechanisms, under conditions similar to those present in 
patients with active disease, may lead to the establishment of long-term tolerance to 
specific antigens without the current requirement for general immunosuppression. 
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No. of no. of +ve +ve +ve +ve No. 
Source of 
cells/ initial clones clones clones clones clones 
cells 
well wells I week 2 wks 4 wks 5 mths tested 
LN CD4+ 
30 96 10 2 1 0 0 
CD25+ ______ 
LN CD4+ 
100 96 22 8 5 0 0 
CD25+  
CNS CD4+ 30 96 23 11 11 3 3 












sc30-1 Yes No High None 
sc30-2 Yes No High High 
sc30-5 No No High None 
sclOO-1 Yes No High Intermediate 
scbOO-2 Yes No Intermediate Intermediate 
sclOO-3 Yes No High Intermediate 
sclOO-4 No No None None 
scl00-10 Yes No High Low 
sclOO-13 Yes No High None 
scbOO-20 Yes No High None 
sclOO-21 I 	No No None None 
Table Al: Summary of cloning attempt I Table A shows source and number 
of clones scored positive at different timepoints. B shows results of testing of 
clones for levels of lFNy, IL-10 and proliferative responses to MOG(35-55). 
No. of no. of +ve +ve +ve 
Source of 
cells/ initial clones clones clones 
cells 
well wells I week 6 wks 9 wks 
LNCD4+ 
50-100 235 46 .13 13 
CD25+ 
Table A-2: Summary of cloning attempt 2 Purified CD4+CD25+ cells initially 
cultured with 5x10 5 APC, 10mM MOG(35-55), 50U/ml IL-2, 200pg/ml IL-10  
and bOng/mI IL-15, and positive wells restimulated weekly. After the first 
stimulation the concentration of MOG(35-55) was decreased to 4mM. After the 
first two rounds of stimulation IL-10 was no longer included. After 9 weeks the 
positive wells still did not appear to be expanding significantly. The 
concentration of IL-2 was increased to 500U/ml in an attempt to boost 













—*— CD25+:CD25- 0.1:1 
—0— CD25- alone 
10 	10.2 	10_ 1 	10 0 	101 
Anti-CD3 (tg/ml) 
Figure A-I: Titration of anti-CD3 for suppression assays 
2x104 MACS-sorted CD4+CD25- cells were cultured with CD4+CD25+ cells 
at the ratios indicated in graph key. 5x10 4 irradiated splenocytes were 
added as APC. Cultures were stimulated with the indicated concentrations 














0 	 1 	 2 
No. CD25 cells/CD25 cell 
Figure A-2: Testing different APC numbers in suppression assay 
2x1 04  MACS-sorted CD4CD25 cells were cultured with the indicated number 
of CD4CD25 cells and APC per well. Two sources of irradiated APC were 
used: whole splenocytes or splenocytes that had been depleted of T cells using 
Thyl -microbeads (Miltenyi Biotec). Cultures were stimulated with 0.5g/mI anti-
CD3 for 72 hours, with tritiated thymidine added for the last 6 hours of culture. 
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